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Bifidobacteria are prominent members of the human gastrointestinal tract, 
particularly in early life. Their presence is generally linked to health, as reduced 
abundance of bifidobacteria is linked to a range of diseases including, Inflammatory 
Bowel Disease (IBD). However, how these beneficial microbes modulate host health 
is currently unclear. The intestinal epithelium barrier is essential for gut health, and 
previous studies have suggested that Bifidobacterium breve UCC2003 protects 
intestinal epithelial cells (IECs) from experimental pathological epithelial cell 
shedding. Thus, I hypothesised that B. breve directly modulates IECs, which is 
essential for maintaining homeostasis. 
Initial studies, probing the role of the mechanosensitive ion channel Piezo1, 
indicated that this protein may not play a central role within the intestine (utilising 
zebrafish, and mouse models, and IBD patient biopsies), as had previously been 
described for the dermis. Furthermore, B. breve did not appear to modulate 
transcription or translation of Piezo1, suggesting other mechanisms may be involved 
in IEC regulation.  Therefore, I next assessed the global IEC transcriptome (via 
RNA-seq), and determined that UCC2003 induced distinct responses in neonatal 
IECs including, TLR2, TLR9, IL-17C, and integrin signalling upregulation, which 
correlates with this microbe’s ability to protect the epithelial barrier. Furthermore, 
analysis of the B. breve transcriptome in vivo (both in germ-free, and wild-type 
mice) highlighted host, and microbial community adaption responses including, bile 
acid resistance, iron scavenging, and differential nutrient metabolism.  
In summary, B. breve UCC2003 induces specific modulation of the IEC 
transcriptome during homeostatic conditions, which reveals targets for potential 
disease intervention. Furthermore, distinct B. breve transcription profiles in vivo, also 
indicate promising microbial factors that may have host/microbiota modulatory 
effects, that could be targeted for development of new ‘probiotics’. This work 
contributes novel insight into how bifidobacteria modulate intestinal responses, and 
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1 General introduction 
1.1 The human intestinal tract in health and homeostasis 
1.1.1 Macroanatomy 
The human gastrointestinal (GI) tract is an organ system forming a canal from the 
mouth to the anus, and is composed of the oral cavity, oesophagus, stomach, small 
intestine (SI, duodenum, jejunum, and ileum) and the large intestine ([LI], caecum, 
colon and rectum) (Figure 1-1.A). Additional organs directly associated with the GI 
tract include the liver, gall bladder and pancreas [1]. 
Research presented in this PhD thesis concentrates on the gastrointestinal (GI) tract 
including the small and large intestine, which directly connects to the stomach, and 
transports the chyme (partially digested food) towards the anus, while continuing 
enzymatic and mechanical digestion of food, absorbing nutrients and fluids. Each 
section of the GI tract has distinct physiological functions, and a specialised 
microscopic structure, essential for these processes (Figure 1-1.B) [2, 3]. The GI tract 
also harbours the intestinal microbiota (discussed in 1.3.2). 
 
Figure 1-1 Macro- and microanatomy of the human gastrointestinal tract. 
A Overview of the GI tract connecting the mouth to the anus via the oral cavity, pharynx, larynx, 
oesophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, appendix, 
colon, rectum and anal canal), accessory organs: bile produced in the liver is stored within the gallbladder 
and flows into the duodenum via the major duodenal papilla, the digestive juice produced by the pancreas 
enters the duodenum via the ducts of Wirsung (duct of Santorini) (figure adapted from Thibodea & Patton 





tissue, peritoneum, connects to mesentery), muscularis, submucosa, mucosa details and differences 
between large and small intestine highlighted in text (figure adapted from Reed & Wickam, 2007 [4]) 
1.1.2 Microanatomy 
The overall microscopic structure of the GI tract, shared with minor differences between 
the small and LI, is a hollow tube with the wall made up of four layers: mucosa, 
submucosa, muscularis and serosa (luminal to distal) (Figure 1-1.B). The serosa is made 
up of connective tissue forming a bag that contains the intestine and allows for free 
movement. The muscularis transports intestinal contents by muscular contraction, a 
process called peristaltic, and is structured in circular and longitudinal layers of smooth 
muscle cells. Connective tissue, blood and lymph vessels, glands and the Meissner’s 
plexus (innervating muscle fibres in muscularis) make up the submucosa, which are in 
direct contact with the mucosa, allowing for exchange of materials such as nutrients, 
fluids, electrolytes and bacterial compounds [5]. 
The mucosa is made up of the intestinal epithelium (IE, described in more detail in 
section 1.1.5), the underlying lamina propria (LP), and muscularis mucosae (luminal to 
distal). The separation of submucosa and mucosa is defined by the muscularis mucosa 
which is made up smooth muscles cells and in addition contains intestinal cells of Cajal, 
which control GI motility and sense extension [6]. The LP is rich in elastic fibres, which 
provide structural support for the epithelium during contractions of the muscle ring. 
Blood vessels transport nutrients absorbed from the intestinal lumen supply the IE and 
circulate hormones produced by intestinal endocrine cells. The LP also contains 
lymphatic structures which are part of the GALT (gut-associated lymphatic tissue). The 
GALT can contain up to 70% of all body immune cells, and is made up of isolated and 
aggregated lymph follicles [7, 8]. Peyer’s Patches (PP) are specialised lymph nodes 
covered in follicle-associated epithelium which allows interaction of the host immune 
system with luminal antigens (Figure 1-2.A) [8, 9]. PP and their role in intestinal 
immunity will be expanded upon below. 
The luminal surface of the mucosa is covered by a continues cell monolayer called the 
IE. This structure forms a selective, physical and biochemical barrier between the host 
and the intestinal lumen. The surface area available for contact and absorption is greatly 
increased by circular folds of the mucosa and formation of villi and crypts. In the small 





are present (Figure 1-2.) [10]. Additionally, intestinal epithelial cell membranes form 
microvilli towards the lumen, which increases the surface area by a further 20-fold. In 
total, the GI tract represents the largest surface area of the human body; > 400 m2 
(equivalent of two tennis courts). The IE in direct contact and key sight of interaction 
with luminal intestinal contents (including the gut microbiota), and contains a variety of 
specialised cell types, which will be listed below [11]. 
 
Figure 1-2 Overview of intestinal epithelial structure and cell types. 
Localisation of different cell types in intestinal epithelium: stem cells – crypt base, Paneth cells – crypt 
base, transit amplifying cells – from end of base to neck of crypt, differentiated cells located from crypt 
neck to top of villus (enterocytes, goblet cells, tuft cells (not shown), enteroendocrine cells); structure 
similar in colon without villus, Paneth cells, differing enteroendocrine cell type; intestinal stem cells can 
differentiate into four cell types of the intestinal epithelium: enterocytes or absorptive cells with luminal 
microvilli brush boarder to increase absorption area and three secretory cell types: Goblet cells secrete 
mucus which is stored in apical cytoplasmic granules, enteroendocrine cells secreting various hormones 
stored in smaller granules, and Paneth cells secreting antimicrobial peptides again stored in apical 






1.1.3 Physiological function 
Historically, the main physiological function of the intestinal tract has been digestion, 
and nutrient absorption. Mechanical and chemical breakdown of food nutrients starts in 
the oral cavity and stomach, after which the chyme enters the intestine. In the SI, bile 
and pancreatic juice continue nutrient breakdown into amino and fatty acids, and simple 
sugars, which are then absorbed by the epithelium. This process is completed when the 
digestive mass enters the colon where water and electrolyte retention occurs during 
transversion, which turns the chyme into solid faeces when it reaches the anus [2, 12]. 
The human gut microbiota colonises the whole GI tract, but composition, bacterial load 
and host effects differ between sections. This will be discussed in more detail later in 
section 1.3.2. 
1.1.3.1 The intestinal epithelium 
The IE is a single layer of intestinal epithelial cells (IECs) that line the GI tract, and is 
the first contact point of the intestinal environment with the host. The IE provides a 
critical function; it forms a selective, mechanical, and biochemical barrier that controls 
exchange between host and lumen, including micro and macro-molecule such as 
nutrients, and bacteria [10]. The IE also performs immune surveillance, including 
initiation of immune responses to pathogenic bacterial invasion, and maintenance of 
homeostatic responses with respect to resident gut microbiota. This essential barrier 
consists of four main cell types: enterocytes, goblet cells, Paneth and stem cells (Figure 







1.1.4 Intestinal epithelial cells interact with intestinal microbes 
The IE is in constant contact with luminal bacteria, with these interactions essential for 
intestinal homeostasis, and tolerance to commensal bacteria. In the following section, 
the mechanisms most relavant to this study will be highlighted.  
IECs are in direct contact with luminal bacteria and express receptors that allow them to 
sense the microbiota community, and steer the innate and adaptive immune response. 
This allows IECs to control homeostasis and immune tolerance in response to presence 
of commensal bacteria, and induce inflammatory responses in reaction to pathogens 
[10]. These pattern recognition receptors (PPRs) belong to the Toll-like receptors 
(TLRs), nucleotide-binding oligomerisation domain-like (NODs), and RIG-I-like 
family. The importance of this in intestinal homeostasis has been demonstrated in TLR-
2, TRL-4, and adapter protein Myd88 KO mice, which all present with increased death 
from dextran sodium sulphate (DSS)-induced colitis [14]. To note, Inflammatory Bowel 
Disease (IBD) pathology can involve TLR1,2 and 6 polymorphisms, with a TLR-2 KO 
mouse presenting with decreased trefoil factor 3 secretion, and increased susceptibility 
to DSS [15]. 
When TLRs recognise conserved microbial molecular motifs (MAMPs), or pathogen-
associated molecular patterns, they recruit signalling adapter Myd88, and TIR-domain-
containing adaptor protein, which induces interferon-β, via nuclear NF-kB [16]. The 
importance of NF-κB signalling in IECs was demonstrated in studies with KO models 
of components involved in activation (NEMO NF-κB essential modulator, IKK 
inhibitor of NF-κB kinase), which induced increased susceptibility to DSS colitis, or 
resulted in spontaneous colitis [17, 18]. 
As the intestine is not sterile, and commensal bacteria are present, it is important that 
IECs can differentiate between pathogenic and symbiotic signals. Interestingly PRRs 
can either be present in the apical or basolateral membrane of IECs and this could help 
discriminate between commensal and pathogen microbial signals (pathogen – basal, 
commensal – luminal). It is important to note that the differentiation of commensal and 
pathogen signals allows IECs to process this information. As an example, signalling 
through surface TLR9, who recognises bacterial and viral DNA rich in unmethylated 
CpG-DNA, at the apical side promotes inhibition of NF-κB signalling, whereas TLR 





1.1.5 The intestinal epithelial barrier; the molecules involved 
The selective, mechanical barrier formed by the IE is conferred by intercellular 
junctions between adjacent epithelial cells [21]. These complexes have both apical and 
basal elements. The apical part consists of adherence and tight junctions (TJ), while the 
basal segments include desmosomes and gap junctions. Together, these complexes are 
the main effectors of the mechanical barrier, with adherence junctions being responsible 
for cell-cell adhesion, and TJ control intercellular flux of micro- and macromolecules 
across the IE. TJ are made up of over 50 components including claudins and occludins, 
two families of membrane spanning proteins, which directly modulate movement across 
the epithelium [21, 22]. These two proteins are connected to intracellular acto-myosin 
rings, part of the cytoskeleton, through plaques formed by zone occludens 1 (ZO-1, 
Figure 1-3.A) [22]. 
 
Figure 1-3 Small intestinal homeostatic epithelial cell shedding occurs predominantly at the 
villus tip. 
A Intestinal epithelial cell junctional complexes. Individual intestinal epithelial cells joined to neighbours 
by continuous belt of tight junctions around the upper portion of the cell, TJs are responsible for 
gut/epithelial barrier function of macro and micro-molecules as well as member of the microbiota B 
Overview of small intestinal epithelium with extruded cell highlighted at tip of villus (figure and legend 






1.1.5.1 Renewal of epithelium involves cell shedding, which retains barrier 
function 
The IE undergoes constant self-renewal due to its exposure to microbial antigens and 
stress factors. Cell renewal in the IE is considered the most dynamic in the human body, 
with a complete turnover every 2-6 days [24]. The process starts with the previously 
mentioned stem cell expansion, at the bottom of intestinal crypts, followed by migration 
of progeny cells up the crypt-villus axis [25, 26]. Factors influencing this movement 
includes pressure generated through stem cell expansion, and villus contraction and 
elongation [27]. When SI cells reach the villus tip, they are shed into the intestinal 
lumen via a controlled mechanism (Figure 1-3.B).  
The process of cell shedding presents a considerable challenge to the host as it is 
essential to retain the barrier function of the IE, while continuously single cells are lost 
from the epithelial monolayer (approximately 1400 cells lost from single villi in 24 
hours) [28]. TJ reorganisation maintains barrier function during cell shedding as during 
cell extrusion, a complex expansion of the intercellular junction complex ensures that 
the gap left by the extruded cell is sealed and the barrier maintained [29, 30]. 
The expansion process follows a specific pattern and is initiated by TJ reorganisation 
involving redistribution of ZO-1 to the basal surface of the shedding cell [31]. This is 
followed by movement of occludin to the basal membrane, which forms a funnel that 
marks the site of shedding and retains barrier function. Other junctional proteins, 
including claudins and E-cadherin, are recruited into the structure [32]. Members of the 
cytoskeleton, in particular, F-actin, myosin II, Rho-associated and myosin light chain 
kinases and microtubules join the shedding funnel, and allow the complex to contract 
[33]. This movement expels the cell from the epithelial monolayer into the lumen 
accompanied by contraction of the intracellular actin ring that closes the gap in the 
monolayer [32]. Surrounding cells move into the gap and the shedding funnel is 
resolved through reestablishment of the intercellular junctional complex. This whole 







Figure 1-4 Intestinal epithelial homeostatic cell shedding retains barrier function by tight 
junction rearrangement. 
Illustration of “zipper” or purse string effect of epithelial cell shedding. Detachment from basement 
membrane as initiating process still being investigated, rearrangement of tight junctions form funnel that 
seals gap left by shedding cell, neighbouring cells move in to close gap by advancement of lamellipodia 






Under physiological conditions, rates of cell division and shedding are in a fine 
homeostatic balance to maintain equal number of IEC’s and therefore an intact 
epithelial monolayer [25]. The underlying mechanism that balances these two processes 
have not yet been identified, and factors controlling cell shedding and expansion are 
still being investigated [34].  
When enterocytes are extruded, they can be identified with markers of cell death, i.e. 
apoptosis, such as caspase-3 [35]. It is still unclear whether IECs undergo apoptosis 
while still being part of the epithelial monolayer marking them for shedding, or whether 
cell death is initiated after loss of contact with the epithelium through anoikis [36]. The 
investigation is difficult due to the temporarily and spatial closeness of these two 
processes. It has also been suggested that live cell shedding (followed by anoikis), and 
apoptotic cell shedding could exist as distinct pathways, initiated by different triggers, 
thus being involved in different processes, termed homeostatic and pathological 
shedding respectively (discussed in more detail in 4.1.1) [37]. Regulators of 
homoeostatic cell shedding are being heavily investigated. Recently, epithelial-
associated villin has emerged as a potential regulator as it can be found in two forms 
within intestinal epithelial cells. In its full-length form is has an anti-apoptotic role to 
maintain mitochondrial integrity regulating caspase-3 and caspase-9 pathways, while 
cleavage induces apoptosis [34]. Cleavage of the protein occurs during migration of 
enterocytes along the crypt villus axis and has pro-apoptotic effect as well as causing 
actin formational changes, which is essential for shedding funnel formation [38]. 
Another specific candidate, mechano-receptive ion channel Piezo1, will be discussed 
and investigated further in chapter 4. 
In contrast to homeostatic shedding events and levels retaining the epithelial barrier in 
health, pathological cell extrusion and elevated rates lead to loss of several 
neighbouring cells leading to a gap in the epithelial monolayer too large to be sealed by 
TJ expansion [39]. This results in breakdown of the IE integrity and uncontrolled 
exchange of matter between the host and the intestinal lumen. In vivo studies have 
shown tumour necrosis factor α (TNF-α) as an inducer of apoptosis and pathological 
cell shedding, leading to loss of epithelial cells at higher rates at the tip of small 
intestinal villi, and caused a decrease in intestinal permeability [40, 41].  
Increased intestinal epithelial permeability is one of the hall marks of IBD pathology 





disease (discussed in 1.2.2) [42, 43]. These two observations logically suggest a link to 
TNF-α induction of pathological cell shedding and the resulting effect on epithelial 
barrier integrity. A study of shedding rates in IBD patients in remission by confocal 
endoscopy showed individuals with higher cell extrusion rates to be more likely to 
relapse which draws a causative link between inflammatory response and intestinal 
epithelial barrier impairment by increased shedding rates (Figure 1-5) [44]. 
 
Figure 1-5 Loss of intestinal barrier function at sights of cell shedding in patients with IBD 
correlates with increased disease relapse. 
Intestinal confocal endomicroscopy following intravenous administration of fluorescein contrast agent of 
A intact barrier function with no escape of fluorescein into gut lumen (arrow) and B multiple sites of 
efflux of fluorescein through the epithelium into gut lumen (arrows), note increased fluorescence in the 
gut lumen, C Prediction of relapse of inflammatory bowel disease (IBD) based on Watson grade of cell 
shedding and local barrier dysfunction shows correlation of higher relapse events in patients with 
increased levels of cell shedding (grade I: physiologically normal, grade II: functional defects, grade III: 
structural defects) (adapted from Kiesslich et al., 2011 [39]) 
Therefore, it has been hypothesised that cell shedding, elevated by inflammation, causes 
barrier breakdown, which in return perpetuates the pro-inflammatory state observed in 
IBD, due to uncontrolled interactions of the luminal microbiota with the host immune 
system and results in a positive feedback loop. It remains to be determined whether the 
inflammatory stimuli initially cause barrier breakdown or vice versa [36]. 
The underlying mechanisms of pathological cell shedding (in addition to TNF-α) are 
still unclear and being actively investigated. A recent model showed that systemic LPS 
administration in mice increased apoptotic shedding. LPS activates TLR4 receptors on 
macrophages, which signals via Myd88 adapter protein and NF-κB in turn to increase 





IECs induces apoptosis (Figure 1-6) [45]. This rapid model of inflammatory, elevated 
cell shedding in the SI has been proposed as a consistent and robust system for studying 
increased shedding events with respect to intestinal pathologies such as IBD, due to the 
similarities in observed gaps within the IE, and elevated extrusion rates induced by 
inflammation.  
Recently, the commensal bacterium B. breve UCC2003, which has been shown to 
confer health beneficial effects for the host in several models of intestinal pathologies, 
offered protection from LPS induced elevated shedding (reviewed in 5.1.1) [46].  
 
Figure 1-6 Systemic LPS administration induces apoptotic cell shedding in small intestinal 
epithelial cells. 
Systemically delivered LPS is recognized by tissue resident TLR4-expressing mononuclear cells 
(monocytes/macrophages/dendritic cells), which produce TNF. TNF is released into the systemic 





dominates, or cell survival if NFκB1 signalling dominates (figure and legend adapted from Williams et 





1.1.6 Scientific methods and models utilised to study intestinal responses 
Historically, experimental investigation of human physiology has been aided by in vitro 
and in vivo models. The human intestinal tract is a complex system, and below I discuss 
the advantages and caveats of commonly applied scientific models.  
1.1.6.1 In vitro and ex vivo models 
In vitro models, have proved to be a useful tool for understanding intestinal responses, 
in part due to their simplicity and control over experimental conditions, which allows 
for measurements of single readouts without interfering background events.  
Traditional 2D cell culture of single epithelial monolayers grown on solid supports or 
permeable filters have been utilised and expanded by the use of Ussing Chamber, 
separating basal and luminal compartment allowing for exposure of basolateral and 
apical side of cell monolayers to different conditions to more closely simulates in vivo 
conditions [47]. Several immortalised intestinal cell lines have been developed over the 
years, with Caco-2 (human colon adenocarcinoma), HT-29 (human colon 
adenocarcinoma) and Intestine 407 (human small intestine/HeLa) being the most 
commonly used ones, and therefore best characterised. [48, 49] 
The development of 3D organoid cultures allows for a near physiological emulation of 
intestinal structure with primary cells, or stem cells self-organising into tissue structures 
resembling in vivo architecture including crypt and villi [50, 51]. However, organoid 
culture is still attached to significant costs, due to price of culture reagents, as well as 
the labour intensive nature of the work, which are factors to consider [52]. 
The described in vitro models are useful for studying various factors, but are still 
relatively simple models which seek to emulate the processes observed in vivo.  
1.1.6.2 In vivo models 
The use of laboratory mice as in vivo models of the IE, and its role in tissue homeostasis 
and host interaction with the environment, has proven significantly beneficial, due to 
the model’s complexity and similarity to its human counterpart [53]. Other advantages 
include low genetic variability, due to inbred mice strains, and the possibility to 
generate knockout strains. For IBD, more than 74 genetically altered mouse strains have 





IBD in adults and children, KO mice develop spontaneous colitis when conventionally 
raised, while being physiologically normal under GF conditions [54]. Hence, the model 
has been used in several studies investigating host-microbe interactions in IBD [55]. 
Chemically induced mouse colitis models have also been developed with DSS 
application in drinking water being widely used. The administration leads to colonic 
colitis by epithelial barrier disruption, due to loss of TJ protein ZO-1 [56, 57]. 
The overall intestinal tract anatomy and physiology is conserved between mouse and 
human. However, there are distinct difference, such as a shorter SI, but longer caecum 
in mice [58]. This has been attributed to differences in diet, with mice consuming a 
larger amount of complex carbohydrate non-digestible by the host, which requires 
fermentation by the gut microbiota in the caecum. Fittingly, these fermentation 
processes occur in humans predominantly in the colon, which is sub-compartmentalised 
into pouches, while the mouse LI is smooth. As the fermentation of plant derived 
carbohydrates is associated with short chain fatty acid (SCFA) production, which have 
health beneficial effects on the host, these differences in ecological niches should be 
taken into account when using mice in microbiota research [58].  
Due to the importance of gut microbes for intestinal physiology and pathologies, it 
should be mentioned that the human and mouse microbiota are similar at phyla level, 
but 85% of genera found in mice are not present in humans. This together with 
implications for research will be discussed in section 6.1.2 [59]. 
A benefit of mouse models in microbiota research is the similarity between biological 
repeats due to co-housing effects, and control over diet, which generates reproducibility, 
which is often lacking in human samples [60]. GF mice are a powerful tool for studying 
interactions and effects of single or combinations of microbes on the host and even 
allow for colonisation so mice with human microbiota grafts. Humanised mice fed with 
high fat diets showed a decrease in Bacteroides/Firmicutes ratio, which emulates 
microbiota profiles in humans, with diets high in animal facts increasing Bacteroides 





1.2 Inflammatory Bowel Disease 
Inflammatory bowel diseases are a heterogeneous, complex group of diseases 
involving chronic, intestinal, immune system mediated intestinal inflammation. The 
disease mechanisms are not completely understood, but are suggested to involve; 
multifactorial pathology, with dysregulated immune responses in genetically 
susceptible individuals to commensal intestinal bacteria, with environmental factors 
influencing onset and relapse of disease [63, 64]. Crucially, the IEC represents a 
major GI-associated cell type, with respect to disease pathophysiology, and is 
located at the interface between the host immune system, luminal microbes, and 
environmental factors (Figure 1-7). 
 
Figure 1-7 IBD pathogenesis is multifactorial with involvement of immune system and 
intestinal barrier in genetically predisposed individuals to gut microbes and 
environmental factors. 
Venn diagram overlapping role of gut microbiome, host and environmental factors in the 
aetiopathogenesis of inflammatory bowel disease. Dysbiotic changes in gut microbiome may be 
influenced by diet and other environmental factors and predispose to inflammatory bowel disease 





23 receptor, intestinal epithelium is located at interface between host and environment including gut 
microbiota (figure and legend adapted from Hold et al., 2014 [63]) 
In the UK, more than 620,000 patients (0.5-1% of population), suffer from IBD, with 
a prevalence of 243 per 100,000 individuals for Ulcerative Colitis (UC), and 144 for 
Crohn’s Disease (CD) [65-67]. IBD poses a heavy financial burden on health care 
systems of developed countries, with an estimated cost of at least €4.6 billion in the 
European Union in 2013. In the UK, treatment costs range from £1,693 to £10,760 
per annum/patient, depending on disease type and severity [65, 67].  
The incidence of IBD is influenced by geographical location, with the highest 
number of cases found in westernised countries. Notably, there is an increase in 
‘newly’ westernised countries in Eastern Europe, and Asia, which highlights a 
potential link to socioeconomic development, and development of disease [66, 68]. 
1.2.1 IBD can be subdivided into Ulcerative colitis and Crohn’s 
disease 
IBD is an umbrella term for a diverse range of intestinal pathologies, which can be 
further subdivided into the two major forms UC and CD. This is an important 
clinical distinction, as therapy strategies between the two pathologies differ. Not all 
intestinal inflammation related to IBD can be definitively categorised as either UC or 
CD (non-classical forms), and diagnostic standards are still being improved [69].  
UC is characterised by intestinal inflammation, and morphological changes limited 
to the colon, with the rectum being affected in many cases too. Inflammation is 
continuing and confined to mucosa. Patients present with bloody diarrhoea, weight 
loss and pain in the lower left abdomen. Figure 1-8 indicates the key 






Figure 1-8 Comparison of colonic mucosa of healthy, Crohn’s and ulcerative colitis 
patients. 
Top – schematic overview, centre – histological comparison, bottom - endoscopic appearance (figure 
and legend adapted from John Hopkins Hospital Gastroenterology and Hepatology Division [70]) 
In comparison, CD-associated inflammation can affect any section of the GI tract, 
but is most commonly found in the distal ileum and colon. The affected areas can be 
discontinuous, and histologically the inflammation is transmural, and often includes 
the serosa. Clinical symptoms can be subtler, and are dependent on localisation of 
inflammation along the GI tract. Patients suffer from abdominal pain, cramps, and in 
certain cases also have bloody diarrhoea, which may make it difficult to differentiate 
from UC. Figure 1-8 displays the key intestinal pathological characteristics of CD 
[71].   
Both diseases are chronic and can be lifelong, and drastically impact on quality of 
life for patients. They can also lead to life-threatening complications, including 
higher risk for development of colorectal cancer [72, 73]. IBD predominantly affects 
the GI system, but is associated with other non-intestinal manifestations including, 






1.2.2 The aetiology of IBD 
IBD is a multifactorial disease involving deregulated immune responses in 
genetically susceptible individuals, to the intestinal microbiota, with the intestinal 
barrier showing increased permeability. The pathology can be imagined as a cycle 
between intestinal inflammation, leading to epithelial barrier breakdown, causing 
further uncontrolled exposure of the host to microbial antigens, which in turn further 
drives inflammation [75]. It is still to be determined if the initial stimulus is 
generated by the immune system, or a leaky intestinal barrier [76]. However, 
evidence has emerged of increased permeability potentially being the initiating 
factor, as paracellular permeability of the IE of UC and CD patients was decreased 
during active and quiescent disease, compared to control (measured in biopsies in 
Ussing chambers culture, with FITC-dextran) [77]. Effects of low grade background 
inflammation in this study cannot be discounted, but further support is provided by 
IL-10 KO mice. This cytokine has anti-inflammatory effects and protects the IE by 
counteracting TNF-α and interferon γ (IFN-γ) effects [78]. KO mice develop 
spontaneous colitis, and increased intestinal permeability was detected early in life 
(starting at 2 weeks), before the on-set of inflammation (at 17 weeks) [79]. This is an 
interesting result particularly with paediatric IBD incidence having increased 
significantly over the last 15 years; in the USA at least 20% of all new cases being 
diagnosed in children [80, 81].  
The scope of this studies lies on the pivitol role of the intestinal epithelium in human 
helath and disease and the following section will dicuss the IE and its barrier 
function in IBD as well as highlighting relevant aspects of genetics and the immune. 
Environmental factors such as smoking, diet (including vitamin D), and stress are 
also influencing factors, but the major extrinsic factor involved in IBD pathogenesis 
is the microbiota, which will be covered in detail in the microbiota section (chapter 
1.3.5).  
1.2.3 The intestinal epithelium plays a critical role in IBD 
The intestinal epithelial barrier forms a distinct border between the luminal contents 





Hence, it is not surprising that it plays a pivotal role in IBD, with its breakdown 
contributing to the increased inflammatory response of immune cells. Several 
aspects of the epithelial barrier are affected in IBD, which will be described below, 
with a schematic overview shown in Figure 1-9. 
As previously mentioned (section 1.1.5), TJs are integral to the epithelial barrier, and 
IBD patients present with modulated junction composition, which is linked to barrier 
dysfunction [82]. In CD, biopsies collected from patients with active disease, had 
reduced intestinal resistance, which was related to reduced and abnormal TJs. The TJ 
proteins occludin, claudin 5 and 8 were decreased in expression, and not integrated 
in the junction, while claudin 2 (forms pores within TJ allowing for ion passage) 
expression was increased. In addition, claudin 2 expression was inducible by TNF-α 
in HT-29 cells, which agrees with observations that TNF-α decreases epithelial 
barrier function in vitro, and can also induce apoptosis in IECs, as observed in a 
mouse model of CD [83-85]. Another pro-inflammatory cytokine involved in IBD is 
IFN-γ, which had previously been linked to reduced epithelial disruption, as IFN-γ 
KO mice had normal barrier histology, when compared to control mice [86]. A 
previous GWAS study linked a transcription factor of TJ proteins, hepatocyte 
nuclear factor 4 α (HNF4A), to UC susceptibility [87]. Correspondingly, HNF4A 
expression was decreased in UC and CD patients, and mice with an intestinal 
conditional KO, presented with increased intestinal permeability, and reduced mucus 







Figure 1-9 Overview over intestinal mechanisms involved in IBD pathology. 
Under healthy conditions (left panel), pathogens are suppressed by beneficial commensal bacteria 
through the induction of antimicrobial proteins, such as IL-10 and REG3γ, thus maintaining 
homeostasis. In IBD (right panel), a combination of genetic factors and environmental factors (such as 
stress, diet, and antibiotic) lead to microbial dysbiosis, which in turn affects barrier integrity, innate, 
and adaptive immunity, resulting in uncontrolled chronic inflammation and hyper-activation of T 
helper 1 (Th1) and Th17 cells, increase in tight junction permeability, reduction in regulatory T (Treg) 
cells, and decrease in REG3γ and IL-10. ATG16L, autophagy-related 16-like; CARD9, caspase 
recruitment domain family member 9; FUT2, fucosyltransferase 2; IBD, inflammatory bowel disease; 
IL-10, interleukin 10; IRGM, immunity-related GTPase M; NOD2, nucleotide-binding 
oligomerization domain-containing protein 2; REG3γ, C-type lectin regenerating islet-derived protein 
3γ (Figure and legend adapted from Zhan et al., 2017 [89]) 
The importance of homeostatic cell shedding, and the increase in apoptotic, 
pathological cell shedding in IBD has been described in 1.1.5.1. Furthermore, UC 
patients have higher overall levels of apoptotic IECs, and numbers correlate with 
individuals eventually requiring surgery. In biopsies from CD patients, an increase in 
apoptotic IECs was localised to areas of active inflammation [90]. Notably, tumour 





TNF-α, inhibits IEC apoptosis, and previous GWAS studies have identified SNPs in 
this signalling molecule [91]. In vitro, TNFAIP3 has been shown to be critical for 
IEC tolerance to LPS, and in vitro an intestinal epithelial specific KO model showed 
increased susceptibility to DSS colitis and enterocytes hypersensitive to TNF-α [92, 
93]. However, it is not yet known in which way the polymorphism associated with 
IBD affects gene function. Further support for the role of TNF-α, is provided by 
findings that TNF-α overexpressing mice show ileal and colonic inflammation 
(including villus shortening, similar to that observed in the SI of  LPS challenge 
mice with elevated IEC apoptosis), and is comparable to CD patient histology [94]. 
In summary, these results agree with the hypothesis that inflammation drives IEC 
cell death and shedding, which in turn causes epithelial barrier breakdown, and 
further inflammation due to microbial exposure, thus perpetuating this vicious cycle.  
Importantly, loss or impairment of epithelial integrity, is a hallmark of IBD as it 
directly causes the continuous exposure of microbial antigens to the mucosal 
immune system, and increased intestinal permeability can be used as a predictive 
measurement for relapse in patients with inactive disease. The role of the microbiota 
in IBD will be discussed in more detail in subchapter 1.3.5. 
1.2.4 Scientific models of IBD 
Animal models of intestinal inflammation have contributed greatly to our 
understanding of IBD pathogenesis, and are essential for pre-clinical drug testing. 
A widely used experimental model of colitis, involves oral consumption of DSS 
dissolved in drinking water. This has been shown to induce both acute and chronic 
colitis in rodents, by inducing inflammation and recruitment of immune cells, and 
their subsequent activation directly through epithelial cell damage within the colon. 
This particular model has been found to resemble human UC in both clinical and 
histopathological findings. Indeed, DSS colitis is particularly useful to study innate 
immune mechanisms, including epithelial responses, of colitis during acute phases, 
whereas at later chronic stages it provides an opportunity to study the role that the 





Another chemical model of colitis utilises TNBS, which is suggested to more closely 
recapitulate CD-associated pathology. TNBS administered (in tandem with ethanol) 
rectally to rats induces potent inflammatory responses, including marked epithelial 
destruction, which is associated with weight loss [96]. 
In this PhD thesis, a small intestinal model of epithelial barrier breakdown, induced 
by systemic LPS administration, is utilised. It induces apoptotic cell shedding, in a 
time, and dose dependent manner, and allows assessment of involved processes 
directly, and short term, without excessive off target effects. It has been described in 
more detail in subchapter 1.1.5.1.  
Combination of transgenic mice, with microbiota modulation, can be a powerful tool 
to investigate microbiota involvement in IBD. Previous studies have shown that TNF 
overproducing mice (TNFdeltaARE) develop CD-like intestinal inflammation, with 
strong ileal involvement. These mice do not develop colitis or ileitis under GF 
conditions, with antibiotic treatment in conventionally raised mice, resulting in 
reduced ileum inflammation. The associated loss of antimicrobial defence 
mechanisms, due to failure of Paneth cells function (crytidin-2 and lysozyme), 
induced microbiota taxonomic and functional changes, which reproduced symptoms 
in GF TNFdeltaARE mice after faecal transplantation, with no effects after transfer of 
faeces from healthy animals. This provides further evidence for the casual role of the 
microbiota in ileal CD, and the associated microbiota modulation [97]. 
Adoptive transfer of naive T cells (CD4+ CD45RBhigh), into mice deficient of T and 
B cells, and hence immunodeficient (SCID or RAG2 KO) induces colonic 
inflammation 5 to 10 weeks post administration.  While transfer of mature T cells 
(CD4+ CD45RBlow) by themselves, or in  combination with naïve T cells, does not 
lead to colitis, due to the anti-inflammatory properties of Treg cells and IL-10 [98]. 
Hence, it is not surprising that IL-10 deficient mice develop spontaneous colitis after 
weaning, which is histologically similar to human IBD. Extensive studies, indicate a 
multi-hit pathology during IL-10 KO colitis, as an interplay of loss of homeostasis, 
and suppression of innate (DC, macrophages), and adaptive immune response 
(Th1/Th17), and microbiota dysbiosis, or pathogen invasion, results in excessive pro-





1.2.5 Current treatment options for IBD 
Anti-inflammatory drugs, 5-Aminosalicylates, are frequently used for treatment, and 
induction, or remission in UC, and may potentially prevent onset in high risk 
patients, however, they show very little effect in CD [100, 101]. Immunosuppressive 
agents can induce, and maintain remission in CD and UC [102]. Furthermore, two 
biologic agents have been introduced to clinical practice in the last decade, anti-TNF 
and anti-integrin agents [103]. Anti-TNF treatment with infliximab has 
revolutionised IBD treatment, and induces and maintains remission in both CD and 
UC [104, 105]. Anti-integrin therapy blocks activated T-cell homing to the intestine 
in response to inflammatory stimuli, reducing the exacerbated host response [102]. 
Several other new drugs are currently being developed and tested, including cytokine 
blockers, and inhibitors of cytokine gene expression [102] 
Despite a plethora of new drugs, many patients do not respond to drug therapy (30-
50% for anti-TNF therapy), and 30-40% of CD, and 20-30% of UC patients undergo 
surgery at some point in their life time, due to severity and progression of the 
diseases, with surgery associated post-operative complications [106]. 
Great progress has been made in IBD therapy, aided by large scale human genomic 
studies, complimented by mechanistic investigations, which often use IBD mouse 
models. Ultimately, the aim of IBD treatment is to induce remission and prevent 
induction in high risk individuals. There remains a large unmet need for novel 
therapeutics to achieve these aims. Probiotic intervention has been shown beneficial 
responses in IBD, and other related intestinal pathologies, which will be discussed 
further in general in section 1.3.5.3, as well as bifidobacteria specific in 1.4.6. 
Further investigation of involved mechanisms, could lead to the discovery, and 





1.3 The intestinal microbiota and its symbiotic relationship with the 
human host 
All surfaces of the human body, including the skin, oral cavity, and intestinal tract, 
are colonised by a complex microbial community called the microbiota [107]. The 
gut microbiota is the densest, with more than 1014 microorganisms, and includes 
bacteria, archaea, viruses, fungi and parasites. Members of the microbiota are being 
heavily investigated as their physiological role is essential for host health [108]. Here 
I will focus on the bacterial components of the microbiota. 
Until the advent of next generation sequencing (NGS), the traditional method for 
studying the gut microbiota has been selective culturing [109]. Due to the 
complexity of the microbial community and their ecological niches, it has been 
suggested that the majority of organisms within the intestinal microbiota are un-
cultivable, when comparing identified species by traditional in vitro growth to 
bioinformatic results (described below) [109, 110]. However, recent developments 
have increased the percentage of culturable bacterial species from intestinal samples, 
which has given rise to a field coined ‘culturomics’ (Lagier et al. [111], Lau et al. 
[112], Browne et al. [113]). The drawbacks of bacterial identification and isolation 
by culturing, are the time and labour requirements, however it is critically important 
to also perform phenotypic and functional analysis, particularly for development of 
therapeutics, hence a combined approach of sequencing identification and 
culturomics is warranted. 
1.3.1.1 Application of next generation sequencing in microbiota studies 
NGS is an umbrella term for technologies that determine the nucleotide sequence of 
millions of DNA or RNA fragments in parallel [114]. There are several differing 
technology platforms, and in general these can be separated into those that perform 
short or long read sequencing.  
Short read length sequencing is very high throughput, cost efficient, and time 
requirements have improved significantly in the last years, making it a viable 
approach for large scale population analysis, and even clinical applications. This 





the utilised platform. This technology performs sequencing by synthesis, which 
involves a priming adapter sequence binding to the sample DNA, and sequencing the 
complementary strand, nucleotide by nucleotide. The binding of fluorescent 
nucleotides to sample DNA allows for sequence detection, and is carried out in 
single base pair steps [115]. Long read length technology (utilised by Pacific 
Biosciences and Oxford Nanopore Technologies) is also constantly evolving, with 
improvements in cost and output, but has historically been applied more to de novo 
genome assembly [116, 117]. 
With cost of NGS decreasing, and output increasing, this has allowed the technique 
to be applied to the investigation of the human microbiota, which has corresponded 
with an explosion of research in this field.  
The microbiome can be analysed/profiled in a variety of ways; metataxonomic, 
metagenomic, metatranscriptomics, metabolomics, and metaproteomics. Each of 
these techniques provides different levels of information about microbial 
communities, and each has certain advantages and disadvantages, and these will be 
discussed more fully below.  
1.3.1.2 Taxonomic profiling by metagenomic 16S rRNA sequencing 
To assess taxonomic composition of a microbiota sample, 16S rRNA sequencing is a 
powerful tool, due to its low costs, and high throughput analysis [118]. It based on 
sequencing of the bacterial ribosomal subunit 16S, but due to the total length of the 
gene (i.e. 1400 bp) being outside parameters of short read length platforms, amplicon 
sequencing of hypervariable regions (V1-V9) is used [118, 119]. The process 
involves binding of universal primers to stable regions adjacent to the hypervariable 
areas, amplification by PCR, followed by sequencing, and analysis; either directly 
(via BLAST) to reference taxa, or more commonly grouping of reads into 
operational taxonomic units (OTUs, based on 97% sequence identify) [120]. 
Importantly, the PCR amplification step can introduce bias between different taxa, 
which may be due to differing GC content between bacterial 16S sequences, thus 
affecting universal primer binding [121, 122]. Therefore, studies suggest that 
hypervariable region amplification should be chosen based on predicted microbiota 





protocol and analysis improvements, 16S rRNA sequencing resolution has increased 
to genus level, and it is possible to quantify bacterial abundance relative to overall 
16S rRNA transcripts [123].  
Benefits of 16S metataxonomic profiling include, relatively low cost, the high 
throughput nature, and the identification of bacteria from theoretically single DNA 
copies by PCR amplification, hence increasing resolution of analysis greatly, 
particularly in low biomass samples. In addition, DNA can be extracted from dead 
cells without the need for live bacteria, in contrast to culturing, which broadens the 
variety of samples types capable of being studied [124-126].  
1.3.1.3 Investigating the active functional profile of microbiota by 
metatranscriptomics and metabolomics 
There has been a shift in the microbiota field from determining ‘who is there’ to 
‘what are they doing’. WGS allows the determination of potential functionality, 
based on genes present. This is generated by either mapping of raw reads to 
databases of reference genes, and their biological function, or by assembly into 
contigs, with the resulting predicted protein sequences being matched with similar 
functional databases. This has been used, for example, to assess changes occurring 
during IBD, with mouse models showing the acquisition of LPS secretion system 
during active disease [127, 128]. The fundamental limitations of this approach 
though are that the presence of a gene, and its associated biological function 
conferring functional potential, does not mean is it transcriptionally active. 
This can be assessed by metatranscriptome sequencing, which analyses a snapshot of 
the transcriptional activity of a microbiota at a given time, via shotgun sequencing of 
the total RNA population [129]. Analysis of the generated data involves either 
mapping to reference genomes or de novo assembly into contigs prior to mapping 
[124]. The second approach is usually applied to samples, which do not have well 
characterised bacterial members.  
The importance of analysing the transcriptional landscape is highlighted by findings 
from the gut microbiota, that transcription was more individualised between subjects 
than metagenomic functional profiles (but also less variable than taxonomy) [130]. 





transcripts, in relation to the abundance of their corresponding genes within the 
population (with 41% showing no differential regulation). Another example 
highlighting the importance of assessing transcription changes was observed in a 
gnotobiotic mouse model colonised by a model human gut microbiota. The 
administration of bifidobacteria and Lactobacillus, in fermented milk products, did 
not change the overall taxonomy or metagenomic composition. However, 
transcriptional analysis revealed an upregulation of genes related to carbohydrate 
metabolism, and in particular oligosaccharide fermentation by B. animalis subsp. 
lactis [131]. As carbohydrate metabolism is involved in bacterial cross feeding, and 
the resulting changes and products have been shown to affect the host (in particular 
butyrate production), this highlights the power of using transcriptional analysis to 
understand microbiome functions at a microbial community level, and how these 
genes may be involved in host crosstalk [132]. Furthermore, the correlation of 
bacterial transcription, with host effects, by dual transcriptomics (i.e. RNA 
sequencing, RNA-seq, of host and microbes), will further aid in understanding host-
bacterial interactions. The iHMP with its paired sampling of host and microbiota 
aims to integrate these data [133]. 
Gene transcription is a proximity measurement of protein expression, but 
posttranscriptional modification, and translation rates can influence protein levels 
and functions [124]. Hence, the proteomic profile of microbiota communities is a 
more direct assessment of functional activity [134]. As not utilised in this study, it 
will not be detailed further. 
Lastly, metabolomics can be used to identify and quantify metabolites, and other 
small molecules, in microbiota samples, and is considered a direct assessment of 
biological processes within a system [110, 135]. Metabolomics is based on analysis 
of compounds by high-performance liquid chromatography (HPLC) and mass 
spectrometry (MS), and/or nuclear magnetic resonance (NMR), but the 
heterogeneous nature of microbiome samples leads to difficulties in sample 
processing and analysis, due to wide range of products (e.g. carbohydrates, lipids, 
small molecules), and their dynamic concentration range [136]. Following data 
generation, pre-processing by peak picking, and deionisation, is followed by 





are identified by matching peak patterns to spectral databases, including machine 
learning for pattern recognition [137]. In IBD, metabolomics analysis showed a 
decrease of nicotinic acid in stool samples from CD patients [138]. Nicotinic acid is 
a bacterial product that signals via the same receptor as anti-inflammatory butyrate 
(GPR109A). Signalling through this receptor exerts anti-inflammatory effects on 
colonic macrophages and DCs, which in turn stimulate differentiation of Treg cells, 
and IL-10, while colonocytes are stimulated to produce IL-18. [139].  
With omics studies becoming more and more common, the next logical step is 
integration of different data types, to generate a holistic, dynamic network of 
biological function within the microbiota, and with the host [110]. Pathway analysis, 
based on taxonomic, genomic, transcriptional, proteomic and metabolomic 
databases, can aid in this process, giving deeper biological insights. This analysis 
could aid in hypothesis generation, associating distinct data types, and filling 
mechanistic gaps, as well as increase confidence in observations if several different 
data types arrive at the same conclusion [124]. Indeed, a recent publication utilised 
the previously mentioned dual RNA-seq method in a mouse colitis model, and 
showed a link between macrophage and granulocyte presence in the gut lumen, with 
bacterial upregulation of oxidative stress responses, implicating this in microbiota 






1.3.2 The human gut microbiota 
The healthy adult gut is colonised with a bacterial community consisting of between 
100 to 1000 unique bacterial species, with 160 commonly shared between 
individuals, and a total of 1014 microorganisms [141, 142]. The most abundant phyla 
are Bacteroidetes and Firmicutes, which contribute 80-90% of the total community, 
with the predominant classes in Firmicutes phylum being Clostridia and Bacilli, 
while the most abundant class in Bacteroidetes is Bacteroides [143]. In the 
following, I will described the overall gut microbiota composition in more detail, 
together with changes during the human life time, and highlight dysbiosis during 
IBD. 
1.3.2.1 Microbiota composition in the gastrointestinal tract 
In the GI tract, the composition and density of microbe colonisation increases 
longitudinally, and across the lumen, due to differences in the environment, and is 
summarised in Figure 1-10.A. In the stomach, 102 microorganisms per g of content 
can be found, which increases in the SI, and reaches 1012 per g within colonic 
content, which is the densest ecosystem, and contributes 70% of the total number of 
microbes found in association with the human body [143, 144]. In the stomach, and 
SI, a lower pH environment, caused by gastric acid, and digestive enzymes (e.g. bile 
acids), and higher levels of oxygen, create a harsher environment for bacterial 
growth, while in the LI, which has a lower pH, an anaerobic environment, and an 
array of complex carbohydrates, favours dense microbiota colonisation [145].  
Colonisation of microbes within the intestine cross-section differs; with complex 
microbial populations found in the lumen, and outer mucus layer (Figure 1-10.B). 
Levels in these regions are higher in the LI, due to the higher density, and thicker 
outer mucus layer, compared to the SI. The inner mucus layer is largely devoid of 
microbes [146]. Differing species can be observed by fluorescent in situ 
hybridisation (FISH) in the mucus layer, compared to intestinal contents, with 
Bacteroides, Bifidobacterium, Streptococcus, Enterobacteriacae and Ruminococcus 
preferentially found in luminal samples, while Akkermansia is more prevalent within 






Figure 1-10 Longitudinal and transverse distribution and composition of bacteria in the 
gastrointestinal tract. 
A Overview of composition and quantity of interinal microbiota along gastrointestinal tract. (figure 
and legend adapted from Konturek et al., 2015 [148]). B Mucus layer morphology and colonisation 
by bacteria along intesitnal tract (figure and legend adapted from Macpherson & McCoy, 2013 [146]).  
In the upper GI tract, Lactobacillus is the dominant genus. Within the LI, Firmicutes 
and Bacteroidetes are the predominant phyla, as well as Fusobacteria, Actinobacteria 
(which includes the beneficial member Bifidobacterium, which will be discussed in 
more detail in subsequent sections), Proteobacteria and Verrucomicrobia being 
represented in lower numbers (Figure 1-11.A) [147, 149]. The abundance ratio of 
these main components and their species composition can differ greatly across 
individuals. So far, the identification of “core” species in the adult intestinal 
microbiota has been difficult due to variation across life stages (discussed below), 
and between samples cohorts, especially comparing westernised and developing 
countries [147, 150]. Based on 16S rRNA sequencing of 17 faecal samples, and the 
requirement to be present in at least 50% of individuals, Faecalibacterium 
prausnitzii, Bacteroides vulgatus, Roseburia intestinalis, Ruminoccous bromii, 
Eubacterium rectale, Copronacillus sp. and Bifidobacterium longum was identified 
as potential core species [151]. Other studies identified differing shared members, 
and it has been hypothesised that the concept of core species is unlikely [141, 152].  
In contrast to finding common taxonomic composition, the result that inter-





the gut microbiota, as observed in 18 faecal samples from monozygotic twins, is 
intriguing (Figure 1-11.B). The analysed microbiota shared > 90% of gene functions, 
suggesting core functional groups, which are involved in housekeeping processes, 
such as transcription and translation, and also  carbohydrate metabolism of substrates 
found in the human GI tract (e.g. N-glycan degradation, fructose/mannose 
metabolism) [153]. These conserved functions are suggested to play an important 
role for the host, and will be discussed in detail further down below [142].  
 
Figure 1-11 Diversity of human microbiota at different phylogenetic scales and functional 
redundancy of differing compositions. 
A 16S rRNA sequence data of four adults from the United States, high diversity and variability 
among individuals, taxonomic grouping at high levels can mask this diversity is shown. Phylum level 
diversity can have marked variation even across healthy adults in the same population, tree depicts 
phylogenetic relationships between species-level phylotypes in most diverse phyla (Firmicutes) in 
individuals B and C, Branches specific to individual B are red; branches specific to individual C are 
blue; shared branches are purple. B Functional redundancy in microbial ecosystems may mirror that 
in macroecosystems, HMP data set, oral communities (top panels) and faecal communities (bottom 





on right) have remarkably similar functional profiles. (figures and legend adapted from Lozupone et 
al., 2012 [152]) 
1.3.2.2 Microbiota composition during human life time 
The colonisation of the human body starts at birth, and continues throughout the life 
course (Figure 1-12). The development of the human gut microbiota has recently 
been reviewed by Thursby & Juge, 2017 [154].  
Recent findings suggest that embryos in utero could be exposed to bacteria, as low 
richness, low diversity profiles were found (with Proteobacteria being the 
predominant member), in placenta, amniotic fluid and meconium samples from a 
study of 15 mother-infant pairs [155]. However, this in utero ‘seeding’ is still 
controversial, but represents an interesting area for further research, particularly the 
impact this may have on immune system development. 
It is certain that the first major exposure of the human body to microbes occurs 
during birth [156]. Naturally born babies present with an intestinal microbiota rich in 
Lactobacilli, which is a prominent member of the vaginal microbiome, and hence 
birth canal [157]. In early life, the intestinal microbiota is characterised by low 
diversity and complexity, with Actinobacteria, Proteobacteria and Firmicutes 
representing the main phyla, and B. longum, B breve and B. bifidum, the most 
abundant species [156, 158, 159]. 
The early life microbiota is in constant flux, and diversity and richness increases 
over time until at 2-3 years of age an adult ‘climax’ community develops. 
Contributing factors to this change are diet, exposure to environmental microbes, and 
immune development [154]. The trend of increased diversity continues until 
adulthood, at which richness reaches its peak [142]. The adult microbiota 
composition (as described above) remains mostly constant from then onwards, and 
the described high inter-individual variability could be attributed to factors discussed 
below (diet, genetics, antibiotics). 
Old age, defined as a decrease in physiological functions in advanced age, negatively 
affects gut microbiota diversity, but the specific effects are unclear [160]. It is 





differences have been observed, with Bacteroides abundance ranging from 92 to 3%, 
and Firmicutes from 94 to 7% in a 16S rRNA study of 161 seniors [161]. 
Interestingly, an increase in opportunistic pathogens (Campylobacter, Helicobacter, 
Fusobacterium) has been detected in faeces of elderly individuals [162].  
 
Figure 1-12 Composition of the human gut microbiota across life stages 
Global overview of relative abundance of key phyla of human microbiota composition in different 
stages of life. Measured by either 16S RNA or metagenomic approaches (Figure and legend amended 





1.3.3 Function of the gut microbiota for the host 
The co-evolution of human host and gut microbiota has led to a symbiotic 
relationship, which under homeostatic conditions, allows the microbiota to perform 
beneficial functions, and in turn the host provides nutrient resources, and niches for 
their survival [143]. These functions are encoded in the microbiome (total genetic 
information of the microbiota), which is at least 100-fold larger than the human 
genome, and sometimes referred to as the second genome [142, 163]. At a top level, 
commensal bacteria participate in nutrient metabolism, immune- and intestinal 
barrier modulation, and colonisation resistance from pathogens (Figure 1-13) [164]. 
In the following sections I will give details for each functional category. 
 
Figure 1-13 Overview of microbiota functions for the host in gastrointestinal tract 






1.3.3.1 Digestions of dietary components by the gut microbiota 
The human gut microbiota utilises both dietary, and host derived substrates for 
growth and replication.   
Simple carbohydrates are absorbed in the upper GI tract by the host, and the residing 
microbes, while non-digestible, complex carbohydrates such as resistant starches, 
plant cell wall polysaccharides, inulin and oligosaccharides reach the LI [166, 167]. 
The colonic microbiota harbours an extensive genetic repertoire for fermentation of 
these substrates [167]. Bifidobacteria play a significant role in this process and can 
cross-feed with other microbiota members, which will be discussed in more detail in 
section 6.1.1.  
Besides bifidobacteria, Bacteroides are associated with plant polysaccharide 
degradation, with B. ovatus, B. thetaiotaomicron, and B. uniformis have a 
particularly wide substrate range, which is suggested to be responsible, at least in 
part, for their high abundance in the adult GI tract [168, 169]. Bacteroides spp., are 
also believed to be cellulytic, but so far only B. cellulosilyticus has been shown to 
degrade cellulose [170]. In contrast, hemi-cellulose like xylans, mannans and 
galactomannans can be utilised by B. ovatus, B. thetaiotamicron, and B. xylanisovens 
[171-173].  
Degradation of these complex carbohydrates leads to the production of SCFAs; 
butyrate, propionate and acetate. They are present in a 1:1:3 ratio in the human gut, 
and several bacteria have been shown to produce SFCAs, with butyrate production 
mainly associated with Firmicutes, and propionate with Bacteroides [174, 175]. 
Acetate is generated by most microbes found in the intestine, including 
bifidobacteria [174]. SCFA production can contribute to social interactions, based on 
cross-feeding, which has been shown to increase e.g. butyrate levels, which will be 
discussed in the bifidobacteria section.  
SCFAs have many health beneficial effects on the host. All three are absorbed by 
IECs, and acetate is gluconeogenic, while propionate is lipogenic in the liver. In this 
regard, acetate has been shown to reduce serum insulin levels, and supress adipocyte 





Butyrate is the best studied SCFA. It has far reaching effects; acting as an energy 
source for colonocytes, affecting epithelial barrier integrity (via mucus and TJ 
proteins), as well as modulating epithelial turnover and the immune system [154, 
177].  
Folate production appears to be restricted to bifidobacteria, with certain strains (e.g. 
B. bifidum, B. longum subsp. infantis) characterised as high-level producers, and 
others (e.g. B. breve, B. longum subsp. longum, B. adolescentis) as low level 
producers in vitro [178]. The administration of B. adolescentis and B. 
pseudocatenulatum, together with prebiotic oligofructose, to rats resulted in an 
increase in systemic and liver folate concentrations [179]. Interestingly, folate serum 
levels are significantly lower UC patients compared to control [180]. The intestinal 
effects of folate are still being investigated, however apoptosis of IECs is increased 
with folate deficiency, suggesting that folate is important in physiological IEC cell 
turnover [181].  
The intestinal microbiota also participates in bile acid conjugation, and regulates 







1.3.3.2 Colonisation resistance and antimicrobial production by the 
microbiota. 
The healthy gut microbiota plays an important role in protection against pathogen 
infection, which has been shown in GF mice being more susceptible to C. rodentium 
infection, while the presence of a complete microbiota eradicated the pathogen 
within 21 days [182]. Supportive of this finding, are observations that antibiotic 
treatment increases susceptibility to infections in humans and mouse models, as 
shown with Clostridium difficile infection. The exposure to antibiotics reduces 
microbiota diversity and induces C. difficile overgrowth in mice [183]. Similarly, the 
pathogen does not colonise the human intestinal tract unless the normal microbiota 
has been disturbed (commonly after antibiotic treatment), and is the main cause of 
hospital-associated infectious diarrhoea [184]. 
The mechanisms by which the gut microbiota confers colonisation resistance can be 
subdivided into direct; i.e. competition for niches and nutrients, and anti-microbial 
production, and in-direct; i.e. enhancement of innate and adaptive immunity, and 
strengthening of the epithelial barrier.  
As nutrients are limited within the intestinal tract, niche competition is fierce in 
individuals with a healthy, complete microbiota. Hence, it is not surprising that 
resident bacteria with similar metabolic requirements as invading pathogens will 
‘contest’ their colonisation. This has been shown in a mouse model of 
enterohemorrhagic E. coli, simulated by C. rodentium infection. GF mice colonised 
by the pathogen were gavaged with an intestinal commensal E. coli from SPF mice 
causing a 200-fold reduction in C. rodentium faecal cfu within 3 days, and complete 
clearance within 14 days.  
The gut microbiota modulates the host immune system, which has been shown to aid 
in fighting pathogen infection. Commensal microbes induce IL-22 production in 
innate lymphocytes, which signals to IECs, causing increased mucus production, TJ 
protein expression, and antimicrobial production (RegIIIγ, β-defensins) [185]. This 
is supported by GF mice having lower levels of IL-22, and mice genetically modified 





187]. This strongly suggests that commensal bacteria regulate IL-22 production, and 
via this mechanism offer protection against pathogen colonisation. 
1.3.4 Interaction of the microbiota with the intestinal epithelium 
The intestinal microbiota has a profound effect on the IE, as observed in GF animals, 
and SPF mice treated with antibiotics, as they show decreased epithelial turnover, 
measured by reduced crypt proliferation, and migration of enterocytes up the crypt 
villus axis. Interestingly, oral administration of SCFAs (i.e. acetate, propionate, 
butyrate) restored turnover in antibiotic treated SPF mice, suggesting these microbial 
products mediate this effect [188].  
A summary of microbiota interact with the IE is given in Figure 1-14 and specific 
mechanism will be discussed below. 
Butyrate can influence both IEC proliferation and apoptosis, in what has been 
labelled the “butyrate paradox”. Butyrate concentrations are highest in the lumen at 5 
mM, with the mucus barrier causing a gradient, leading to reduced concentrations 
along the crypt villus axis, which reaches its lowest point (50-800 uM) at the crypt 
bottom [189, 190]. Butyrate influences histone acetylation in colonocytes in a dose 
dependent manner, with lower concentrations, as found in the crypts, being 
completely metabolised by the IECs, which increase acetyl-CoA a co-factor for 
histone acetyl transferases, causing histone acetylation. When colonocytes are 
exposed to higher levels (at the villus tip), not all butyrate can be metabolised, which 
accumulates in the nucleus where it acts as a histone deacetylase inhibitor. These two 
processes cause upregulation of differing gene expression profiles, and lead to a 
stimulation of growth in the crypts, while IECs at the tip have reduced proliferation, 
and undergo apoptosis [191]. This has been suggested to be protective from 
development of colorectal cancer. 
Regarding barrier integrity, butyrate appears to potentially be the most potent of the 
intestinal SCFAs, as shown in vitro; butyrate increased barrier reestablishment 
following breakdown, and increased overall barrier integrity by increasing claudin-1 
expression, and redistribution of ZO-1 and occludin to the TJ complex [192]. In a 
mouse model of hepatic ischemia, causing intestinal epithelial damage and bacterial 





endotoxin translocation, by increasing ZO-1 expression, as well as reducing liver 
macrophage activation, and neutrophil infiltration, linked to a reduction in serum 
TNF-α and IL-6 levels [193]. These data suggest a combinatory effect of butyrate, by 
increasing epithelial barrier integrity, and excreting anti-inflammatory modulation, 
that could play an important role in host homeostasis.  
Commensal bacteria also appear to facilitate epithelial repair, as shown by L. 
rhamnosus GG in a DSS mouse model. L. rhamnosus gavage for a single day was 
shown to enhance recovery from DSS damage, measured by a decrease of systemic 
and local inflammatory markers, and increased barrier function (FITC-dextran 
permeability). This effect was related to production of reactive oxygen species in 
vivo, which resulted in increased focal adhesion (FA) formation, and IEC migration 
(via increased focal adhesion kinase phosphorylation). FA are essential in repairing 
the IE, as they facilitate cell migration, thus these results suggest a health beneficial 
effect of L. rhamnosus by facilitating epithelial wound healing and restoring barrier 
integrity [194].  
 
Figure 1-14 Intestinal epithelial responses to gut microbes in IBD 
Several immune mechanisms work in concert to the intestinal microbiota and contribute to intestinal 
homeostasis. Goblet cells secret mucin glycoproteins, plasma cells secret IgA, and epithelial cells 
secrete antimicrobial proteins through toll-like receptors (TLRs), or nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2)-dependent mechanisms. (figure and legend 










The mucus barrier is an important host defence mechanism. A role for the microbiota 
in mucus production is also suggested, as GF mice present with decreased mucus 
thickness, and this can be restored by administration of LPS and peptidoglycan [195, 
196]. Furthermore, certain microbiota members can influence mucus production and 
glycosylation. B. thetaiotaomicron can digest host derived glycans, and when 
administered to GF mice increased goblet cells numbers, mucus production, and 
modulated glycosylation profile in the colon, 2 days following gavage [197]. Glycan 
modification can also confer health beneficial effects. L. casei and B. 
thetaiotaomicron can modify the cell-surface glycans of HT29-MTX cells in vitro, 
which blocks rotavirus infection.  
The antimicrobial function of RegIIIγ has been mentioned (1.1.4), together with 
induction of its release from Paneth cells by the commensal B. breve in GF mice. 
This suggests a role of the microbiota in stimulating the intestinal barrier via 
antimicrobial secretion and is hypothesised to be depend on Myd88-dependent TLR 
sensing. This is supported by Myd88 IEC specific KO mice showing impaired 
RegIIIγ secretion [198]. Furthermore, RegIIIγ and RegIIIβ impaired mice are more 
susceptible to infection of several gut pathogens, including L. monocytogenes and S. 
enterica subsp. enterica [199, 200].  
Lastly, strengthening of the epithelial barrier and protection from pathological IEC 
apoptosis via TRL2 signalling of the microbiota has previously been shown. In vitro, 
activation of TLR2 by a synthetic lipopolypeptide preserved TJ integrity and barrier 
function, and decreased apoptosis in Caco-2, IEC-6 and ex vivo murine small 
intestinal epithelial cells. Furthermore, in vivo, during DSS-induced colitis the 
activation of TLR2 restored TJ integrity, and reduced apoptosis in epithelial cells 
which resulted in reduced inflammatory responses [201]. Hence, it is suggested that 
the recognition of bacterial cell wall peptidoglycans by TLR2 is important for 






1.3.5 Dysbiosis of the gut microbiota 
1.3.5.1 Influencing factors potentially causing dysbiosis 
The human gut microbiota can be influenced by a variety of environmental, and host 
derived factors. The most significant and far reaching is thought to be exposure to 
antibiotics. One human study observed that a seven-day course of clindamycin 
induced significant disturbances of the gut microbiota, with a sharp decline in 
Bacteroides, which did not recover fully during the two year observation period 
[202]. As discussed in the section about colonisation resistance, decreases in 
microbiota diversity, by antibiotic treatment, reduces colonisation resistance and 
increases susceptibly to various pathogens, including C. difficile [203].  
As the first major exposure of the human body to microbes occurs during birth,  
mode of delivery has a strong effect on the composition of the seeding microbiota 
[156]. Infants born via C-section show reduced diversity lasting for 2 years, lower 
abundance and diversity of Bacteroides, high incidence of Staphylococcus and 
Acinetobacter, and overall stronger similarities with the composition of the skin- and 
hospital-associated bacteria [204]. As the early life microbiota confers important 
functions for the host (immune modulation, pathogen resistance, etc.), these 
differences may result in negative effects for the host, such as increased risk of 
developing of necrotising enterocolitis (NEC) [205]. 
Diet can significantly shape the human gut microbiota in early life as well as in 
adulthood. Strong differences have been observed between breast and formula fed 
infants, with bifidobacteria being the predominant coloniser in response to breast 
feeding. Bottle feeding supports Bacteroides growth, with reduction of bifidobacteria 
abundance [206, 207]. Further studies have indicated a more complex 
Bifidobacterium microbiota is associated with breast feeding, and that specific 
strains (e.g. B. longum ssp. infantis) typically associates with breast feeding [208, 
209]. This is particularly important as bifidobacteria have many health beneficial 






Dietary changes in adulthood can significantly modulate the intesitnal microbiota but 
is not the focus of this study, hence will not be described in great detail. Diet-
induced changes can be rapid, as a recent human trial showed that within five days, 
the intestinal bacterial composition was altered by dietary intervention, with greater 
effects than inter-individual differences. The effect of fibres was observed in a 
human study involving 14 overweight men. The diet was either high in resistant 
starch, or contained no starch polysaccharides, and was consumed for 3 weeks. Great 
inter-individual differences to diet modulation were observed, but time course 
analysis by 16S rRNA revealed distinct changes, which were reversed by the 
opposing diet regime [169]. 
Lastly, host genetics can shape the microbiota. This has been extensively studied in 
IBD, and large cohort GWAS studies showed a consistent microbial profile for 
certain shared SNPs, such as NOD2, across individuals [210]. Another example is a 
mutation in IL-10, or its receptor, which has been linked to very early onset IBD 
[211]. As described, IL-10 deficient mice suffer from spontaneous colitis shortly 
after weaning [212]. No comparison between modulation of the microbiota in IL-10 
KO mice and patients carrying the SNPs have been made, but it could be 
hypothesised that this genetic alteration influences the profile, as the model 






1.3.5.2 Diseases associated with dysbiosis 
These modulating factors can alter the human microbiota, which when associated 
with disease, is termed dysbiosis. Many studies have observed a decrease in diversity 
associated with disease states, as well as shifts in overall composition, but for 
multifactorial pathologies no single disease-causing microbiota member has been 
identified. 
Human studies have shown that a low diversity of the intestinal microbiota precedes 
asthma onset at school age [213]. Further studies showed a decrease in relative 
abundance of genera Lachnospira, Veillonella, Faecalibacterium and Rothis in a 
study of 319 infants at risk of asthma. The underlying mechanism is not yet 
understood, but is suggested to potentially involve invariant natural killer cells, 
which are elevated in the lung and the intestine in GF mice, increasing morbidity to 
ovalbumin driven allergic asthma, and oxazolone-induced colitis [214].  
A role of the gut microbiota in obesity was first discovered when the transfer of 
microbiota from obese mice into GF mice resulted in a weight gain of the recipients 
[215]. Since then, several studies have investigated the difference between the 
microbiota of normal vs obese state, and have identified a decrease in Bacteroides, 
both in humans, as well as mice [59, 216]. Interestingly, diversity is decreased with 
weight, when comparing lean with obese twins, while weight loss increases richness 
[217].  
Large parts of the investigations profiling microbiota dysbiosis in IBD have 
concentrated on analysing differences in composition, between disease samples and 
healthy controls. Recently, some promising functional association have emerged, and 
I will give an overview over both below.  
In general, CD and UC microbiota profiles are lower in diversity compared to the 
general population, and seem to harbour distinctly different communities compared 
to each other [143]. Figure 1-15 shows relative abundance of statistically significant 
altered intestinal microbiota families in UC and CD patients, compared to controls 
from a recent human study, including 313 IBD patients and 512 healthy volunteers 





In CD, a study of 6 patients and 6 controls by 16S rRNA microarray hybridisation, 
showed a decrease in Firmicutes, attributed to several species including F. 
prausnitzii, R. albus, and B. fragilis, while C. difficile, Shigella flexneri and Listeria 
spp. were present in higher abundance [219]. A different study of 40 twins, either 
concordant or discordant for CD, utilising 454 pyrotag sequencing, observed a 
difference between CD patients and healthy controls. Overall, colonic CD presented 
with increased Firmicutes abundance compared to control levels, while ileum CD 
had decreased abundance including F. prausnitzii [220].  
The same twin study did not observe a clear separation in microbiota profiles 
between CD patients and healthy controls [220]. In contrast, phylogenetic analysis of 
15 UC patients during remission and active disease, and 15 controls, found the UC 
microbiota to be stable and similar between patients across age, gender, and location. 
Diversity was reduced compared to controls, and significant decreases in abundance 
was observed for Clostridium cluster IV members, as well as butyrate and propionate 
producing bacteria (including R. bromii and Eubacterium rectale). Opportunistic 
pathogens including Fusobacterium spp., Helicobacter spp., and Campylobacter 
spp., were increased [221]. The authors hypothesised that reduced SCFAs with their 
anti-inflammatory and barrier strengthening effects, could be involved.  
Overall, it has been suggested that IBD patients harbour reduced anti-inflammatory 
bacteria within the gut microbiota (e.g. F. prausnitzii and B. adolescentis), while 
being enriched for members with potentially pro-inflammatory properties, such as R. 
gnavus [89, 222]. However, studies have observed inconsistent results, most likely 
due to the diversity of the human microbiota, and the fact that IBD is a multifactorial 
disease, with phylogenetic differences being caused by an interplay of host genetic, 






Figure 1-15 Changes to abundance of bacterial families in patients with UC and CD 
patients versus healthy controls. 
(data shown as log2 fold change compared to healthy controls, false discovery rate<0.05, adapted 
from Imhann et al., 2016 [218]) 
IBD dysbiosis is often characterised by a shift in abundance from obligate anaerobes 
to facultative anaerobic bacteria. As the intestinal inflammatory response in IBD 
produces nitric oxide and reactive oxygen species these could be utilised by 
facultative anaerobes such as Enterobacteriaceae [225]. This increase has also been 
observed in an immune compromised colitis mouse model, and adherent invasive E. 
coli can induce colitis in WT recipient mice [226]. Using a culture dependent 
approach, E. coli abundance was associated with the mucosa (isolation from lesions), 
was increased in CD patients (30%), compared to UC (6%) and healthy controls 
(5%) [227]. Adherent invasive E. coli can invade IECs, and survive in macrophages, 
and the preferential growth of these pro-inflammatory bacteria could potentially 
increase intestinal inflammation, which in turn could increase the aerobic 






1.3.5.3 Restoring the healthy gut microbiota 
With identification of microbiota dysbiosis in several human disease pathologies, 
modulation of the microbiota has become an interesting target for intervention and 
treatment. 
Faecal matter transplant (FMT) is a radical approach, aiming to ‘re-set the system’, 
in regard to intestinal microbiota composition. It involves transfer of a microbiota 
sample from a ‘healthy’ donor to a patient, via most commonly, enema or 
colonoscopy. FMT has shown very promising results for treatment of CDI with a 
recent metareview of 684 patients across 23 studies finding a resolution rate of 
90.4% [229]. Minimal adverse effects were reported, and it was suggested as a safe 
and efficient alternative treatment of CDI, and is now on NHS NICE (National 
Institute for Health and Care excellence) guidelines in the UK [230].  
Regarding treatment of IBD, a systematic review reported 18 studies with 122 
patients in total (79 UC, 39 CD, 3 unclassified), and a clinical remission rate of 45%, 
but a low rate of randomised control trials requires further investigation [231]. As 
IBD is a multifactorial disease, including genetic susceptibility, these results should 
not detract from the potential health benefits of FMT. Further investigations should 
be conducted to observe effects of status of disease (active vs remission), similarity 
of donor and recipient microbiota profile, and differences in pathogenic factors 
(genetics, environment, drugs, etc.) on successfulness of FMT, as all these can 
potentially influence the outcome [231].  
A more targeted approach for treatment of microbiota dysbiosis involves the 
administration of probiotics. Probiotics are defined by the World Health 
Organisation in 2001 as “live organisms which, when administered in adequate 
amounts, confer a health benefit on the host” [232]. These effects can either be 
direct, or by modulating the overall microbiota profile, to be more similar to a 
‘healthy’ state. 
Probiotics have historically been isolated from humans and been used successfully in 
treatment of different pathologies [89]. Regarding IBD, particularly Lactobacillus 
and Bifidobacterium species have shown health beneficial effects, with the latter 





supplementation in UC patients undergoing ileal pouch-anal anastomosis (39 
treatment vs 78 control),  significantly reduced progression of UC (measured by 
frequency of pouchitis episodes following surgery), with cumulative risk at 3 years 
being 7% in treatment group, and 29% in control individuals [233]. The probiotics 
mechanism could involve a heat and acid stable, low molecular peptide, produced by 
L. rhamnosus GG, which induces heat shock protein 25 and 75 expression in IECs 
via mitogen activated protein kinases (MAPKs). This protected IECs from oxidative 
stress, potentially by modulating cytoskeletal integrity [234]. Oxidative stress is one 
of the main contributing factors in IBD, produced by macrophages and neutrophils 






1.4 Bifidobacteria are an important member of the human intestinal 
microbiota 
Bifidobacteria are one of the first colonisers of the human intestine, and persists into 
old age [236]. Notably, presence of bifidobacteria in the gut has been correlated with 
improved health, and this genus has also been used for many years as an active food 
ingredient, and probiotic. In the section below I will give an overview about the 
genus Bifidobacterium; including their abundance across the life course, 
fermentation of substrates, and colonisation factors, and relate these to modulatory 
effects on the wider microbiota, as well as the host (e.g. IECs) [236, 237]. 
1.4.1 Bifidobacteria is part of the healthy microbiota across the 
human life time 
In section 1.3.2, the healthy human adult microbiota was described, and below I 
detail bifidobacterial abundance across the human life time; they are one of the 
earliest colonisers after birth, and they persist into old age Figure 1-16. 
There is strong evidence of vertical transmission of bifidobacteria strains between 
mother and child. Analysis of 25 mother-infant samples by internal transcribed 
spacer approach (identification via sequencing of hypervariable regions), revealed 
seeding of the GI tract of neonates by bifidobacteria found within the GI and vaginal 
tract of the mother [238]. In addition, transmission was observed via breast milk of 
bifidobacteria strains B. longum spp., B. bifidum 1887B and B. breve. This 
transmission may explain why natural birth appears to transfer a higher level of 
bifidobacteria to the gut, in comparison to C-section, as exposure to GI and vaginal 






Figure 1-16 Bifidobacteria colonised human intestinal tract at birth and remain part of the 
microbiota until old age 
Bifidobacteria colonised the intestinal tract at birth and are present at highest levels (60-70%) in early 
life, levels decrease in childhood and reach a plateau in adulthood at 30-40%, decreases in old age is 
still controversial, and dependent on geographic localisation of cohort samples, as well as use of 
antibiotics (Figure adapted from Arboleya et al., 2016 [156]) 
Components in breast milk (e.g. human milk oligosaccharides, HMOs) have been 
shown to preferentially feed bifidobacteria (which will be discussed in more detail 
below), and therefore mode of feeding can also shape the infant microbiota. 
Interestingly, a difference in species can be found between breast and formula fed 
infants with B. longum spp. longum associated with formula, and B. longum spp. 
infantis and B. bifidum found more predominantly in breast fed babies [209].  
At 6 months, the intestinal microbiota shifts, and diversity increases due to changes 
in diet (milk to solid foods), and continuing exposure to environmental bacteria. At 
this point in time, bifidobacteria abundance decreases to 40%, with the number 
further decreasing to 2-14% in adulthood [156, 239]. Due to the changing nutritional 
environment, there is a switch in bifidobacteria species, from the HMO degrading 





have investigated the human adult bifidobacteria population, with slight differences 
in most abundance species; ranging from B. longum to B. adolescentis and B. 
cetanulatum [240]. 
Abundance of bifidobacteria stays stable for the remainder of adulthood, but when 
old age is reached, abundance appears to decrease further to 0-5% [241, 242]. Here, 
it should be mentioned that environmental and extrinsic factors can have a large 
impact on bifidobacteria intestinal abundance, with antibiotics and their high use in 
the elderly potentially playing a role in the observed decrease in bifidobacteria [243]. 
This is particularly important as higher levels of bifidobacteria have been associated 
with good health, while other studies did not observe a difference in frailty between 
elderly that had high or low bifidobacteria levels [244, 245].  
Notably, many studies have determined that reduced levels of bifidobacteria, at all 
stages of life, correlates with various pathologies including allergy, metabolic 
syndrome, and chronic inflammatory conditions, and this will be discussed in more 






1.4.2 Genomic overview of the genus Bifidobacterium  
Bifidobacteria were first isolated from faeces of breast fed infants in 1899, and have 
since then been extensively studied [246]. They are non-motile, non-spore forming, 
non-gas producing, anaerobic, gram positive bacteria with a Y-shape under stress 
free conditions (Figure 1-17) [247]. 
 
Figure 1-17 B. breve UCC2003 in vitro with characteristic Y-rod shape. 
B. breve UCC2003 cultured in MRS and visualised by scanning electron microscopy, image courtesy 
of Jennifer Ketskemety and Kathryn Cross (QIB).  
The first complete genome sequence of a Bifidobacterium spp. strain was published 
in 2002, and since then the total number of publicly available sequences has 
increased to 661 (December 2017, according to NCBI) [248]. There are 55 identified 
species and subspecies with an average genome size of 2.2 Mb (average gene 
number 1825) and a high G+C content (52.29% B. aquikefiri LMG28769 to 65.53% 





associated with the human GI tract, including the oral cavity, SI and LI, but also the 
GI tract of other mammals, reptiles, insects, and in sewage [237, 250]. The 
composition and abundance of bifidobacteria in the human intestine has been 
reviewed in 1.4.1. 
Analysis of bifidobacterial genomes has revealed a variety of ecological adaptations, 
including mechanisms for colonisation of the human GI tract, which have also been 
experimentally investigated, and which will be described below (1.4.3). 
1.4.3 Bifidobacteria can ferment of wide range of carbohydrates, 
which in turn cross-feed other microbiota members 
The gut microbiota utilises both diet- and host-derived sources for growth, and 
bifidobacteria encode a range of genomic adaptions to reside within the GI tract.  
While simple sugars like lactose and sucrose are absorbed by the host in the upper 
part of the intestinal tract, as well as utilised by other bacteria such as lactobacilli 
residing in these niches, complex poly-carbohydrates, including cellulose, xylans and 
pectin, cannot be digested by the host due to their limited arsenal of glycosyl 
hydrolases (GH) [251-254]. These enzymes catalyse the breakdown of longer 
carbohydrates into smaller fragments [255]. Human encoded GH are not capable of 
digesting fructose-, glucose-, xylose-oligosaccharides, inulin or arabinoxylan, which 
therefore reach the LI [256]. Notably this is the main GI tract niche of 
Bifidobacterium spp, which encode transport systems and enzymes for efficient 
metabolism of these complex dietary substrates; 12% of the bifidobacteria genome 
encodes proteins involved in carbohydrate metabolism, with 5.5% of the core 
genome attributed to this function [257, 258]. Further specialised enzymes encoded 
in certain species of Bifidobacterium (e.g. B. bifidum and B. longum subsp infantis), 
also  allow bifidobacteria to digest HMOs, which are found in breast milk [259].  
Different Bifidobacterium strains have also been shown to cooperate, or cross-feed, 
via metabolism of complex carbohydrates. This includes the interaction of B. breve 
UCC2003 with B. bifidum PRL2010 and digestion of host mucins [260]. Indeed, 
10% of all bifidobacterial GHs are secreted, which therefore make breakdown 





microbiota. B. magnum and B. cuniculi, which when grown together on starch, 
synergistically used their extracellular enzymes, and internalised the breakdown 
products [258]. In vivo, this cross-feeding behaviour was investigated by 
supplementing mice with four bifidobacterial strain, and results indicated that 
introduction of two or more strains enhanced persistence and increased the 
modulatory effect on the caecal microbiota. This was attributed to an increase in the 
glycobiome, to include digestion of plant-derived carbohydrates, and host-derived 
glycans [261].  
Bifidobacteria can produce acetate, one of the three major SCFAs found in the GI 
tract, which also includes propionate and butyrate [262]. Acetate is produced as a by-
product of the hexose fermentation pathway, termed the ‘‘bifid shunt’’. The key 
enzyme is fructose-6-phosphoketolase, which is present in all members of the family 
of Bifidobacteriaceae, and is thus considered to be a taxonomic marker for members 
of this group. Interestingly, supplementation of the diet with complex carbohydrates, 
such as prebiotic inulin-type fructans or arabionoxylan oligosaccharides, 
preferentially feeds bifidobacteria (i.e. is bifidogenic), and also increases butyrate 
producing bacteria in the gut (butyrogenic) [263]. It has been shown that prebiotic 
supplementation increases acetate levels, which in turn is used by butyrate producing 
bacteria, which increases overall concentration of butyrate in the gut. Butyrate can be 
used an energy source by colonocytes, and can also modulated immune responses 
[264]. Butyrate has been shown to decrease NF-κB activation, stimulated by TNF-α 
in HT-29 cells [265]. In biopsies of CD patients, butyrate decreased TNF-α 
production, while decreasing LPS stimulated cytokine expression in peripheral blood 
mononuclear cells, by decreasing NF-κB activation [266]. It has also been shown to 
enhance the intestinal epithelial barrier measured by TEER in vitro, via increased 
expression of claudin-1 [192]. It also has effects on the immune system with 
induction of Treg cell differentiation [267].  
1.4.4 Bifidobacteria express specific factors for GI colonisation  
Bifidobacteria have evolved various adaptions to the GI environment that aid their 
colonisation (Figure 1-18). As previously discussed, bile acids are secreted by the 





They also confer antimicrobial activity via lysis of cell membranes and DNA 
damage [269, 270]. To circumvent these processes bifidobacteria employ several bile 
resistance mechanisms which includes bile-efflux systems, and bile-salt hydrolases 
(BSH). Preventing intracellular accumulation of bile salts to counteract toxicity is a 
common trait in Bifidobacterium spp, and transport systems involved in bile export 
have been described in several species (B. longum 702259T, B. longum NCC2705, 
B. breve UCC2003) [271-274]. Functional studies have shown that mutations of the 
gene Bbr_0838 in B. breve UCC2003, a membrane bound permease, results in 
decreased growth in colic acid. Bile salt hydrolases offer protection via 
deconjugation, and have been shown to be more active in bifidobacterial species 
relative to other intestinal microbes including members of the Lactobacillus genus 
[274, 275]. Several strains have been shown to have BSH in vitro activity including 
B. breve DSM 20091 and DSM 20456 [275, 276]. 
 
Figure 1-18 Overview of Bifidobacteria mechanisms aiding host intestinal colonisation 
Several bifidobacteria components are involved in interaction with intestinal epithelium and 





potentially cross feed other microbiota members with breakdown products, bile resistance by 
membrane transporters and hydrolases, Bile-AA (conjugated bile acids), bile-COO- (deconjugated 
bile acids), Tad (tight adherence), EPS (exopolysaccharides) HMO (human milk oligosaccharides), 
adapted from Grimm et al., 2014 [277]. 
Adhesion of bacteria to host structures (e.g. IECs and mucus) are a common 
colonisation and persistence trait, which also relates to colonisation resistance 
activities. The adherence to IECs by bifidobacterial strains has been studied 
extensively in vitro, for example B. bifidum MIMBb75 shows adherence to Caco-2 
and HT-29 cell lines, whilst in the presence of fructose and mannose further 
increases adherence, and which is regulated via BopA lipoprotein [278]. Other 
factors that are important for GI colonisation include pili, and previous studies in GF 
mice have shown that expression of these structures are critical for efficient 
colonisation [279]. The EPS capsule of B. breve UCC2003 has also been shown to 
facilitate persistence, but not initial colonisation of the murine GI tract, which may 
also be linked to its immune-modulatory properties, which will be discussed in the 
next section [280]. 
1.4.5 Bifidobacteria confers health beneficial effects on the intestinal 
epithelium 
The IE plays a central role on host-microbe interactions during homeostasis as well 
as diseases such as IBD, due to its role in barrier function and innate immunity.  
Several studies have shown that bifidobacterial species can increase barrier integrity 
in vitro. Particularly, B. bifidum and B. longum were able to increase TEER as a 
measurement of epithelial barrier function in Caco-2 cells, in addition to preventing 
TNF-α induced barrier breakdown. This effect was related, at least in part, to 
production of acetate, as addition of this SCFA to Caco-2 cells increased TEER in 
TNF-α treated cells [281]. Another study utilised B. infantis conditioned supernatant 
with T84 human epithelial cells, which increased TEER, and was associated with 
increased expression of TJ proteins ZO-1 and occludin. Further in vivo studies, using 
the IL-10 deficient colitis model, determined that administration of conditioned 





reduced inflammation and intestinal IFN-γ concentrations [282]. In another mouse 
model of colonic colitis, induced by DSS, a strain specific effect of B. longum ssp. 
longum CCDM 7952 was identified to involve an increase in intestinal epithelial 
barrier function (assessed by FITC-dextran permeability measurements), which was 
associated with retention of TJ protein expression. In vitro work revealed signalling 
that these responses were induced via TLR2 and NOD, and is in agreement with 
findings that TLR2 is essential to maintenance of epithelial barrier integrity via 
Myd88 dependent signalling cascade, with effects on TJ protein ZO-1 [201]. Further 
investigating the effect on IEC barrier function in vivo, a mouse model, inducing 
increased intestinal cell shedding by LPS administration, showed that B. breve 
UCC2003 reduced IEC apoptosis, which was via the bifidobacterial EPS capsule and 
host Myd88 (to be discussed further in chapter 4). In a NEC mouse model, B. 
infantis was shown to upregulate TJ proteins Claudin 4 and Occludin, and may link 
to the beneficial effects observed in infants supplemented with Bifidobacterium for 
prevention of NEC [283]. 
1.4.6 The role of bifidobacteria in IBD 
IBD pathology is associated with disturbances in the microbiota. Importantly, 
several studies have identified lower bifidobacteria levels in both CD and UC 
patients, relative to health controls. Furthermore, epithelium-associated 
bifidobacteria levels were lower in active and quiescent UC, compared to control 
samples, while in UC patients a 30-fold decrease in bifidobacteria when compared to 
healthy controls was observed [284, 285]. 
Many studies (which have been described previously) have shown supplementation 
of Bifidobacterium strains to mouse models, or addition to in vitro assays, provides 
beneficial effects. However, there are several clinical trials that also indicate that the 
‘re-introduction’ of bifidobacteria may provide beneficial effects to IBD patients. In 
a study with nine UC patients and 10 healthy controls, administration of B. longum, 
isolated from the intestine of a healthy volunteer, in combination with a prebiotic, 
lead to reduction in mucosal TNF-α and IL-1α levels, as well as improved clinical 
outcomes 1 month after the feeding trial [285]. A follow up study to the one 





which resulted in reductions in histological inflammation, and disease activity [286]. 
A double-blind placebo controlled intervention study in UC patients, with 
administration of B. infantis 35624 for 6-8 weeks lead to a reduction in c-reactive 
protein and IL-6.  Most recently, patients with mild to moderate UC were 
supplemented for 8 weeks with B. longum 536, which resulted in a significant 
decrease in disease activity, whereas significant reduction was not seen in the 
placebo group [287].  
Taken together, these results together suggest that Bifidobacterium supplementation 
in IBD patients may be a suitable therapy for reducing clinical systems, and 
inflammatory markers. However, limitations of these studies include, small samples 
size, short period of probiotic supplementation, in combination with no assessment 
of colonisation of the administered bifidobacteria strain, as well as effects on overall 
microbiota profile [246].  
In this chapter, I have highlighted the importance of bifidobacteria to human health, 
and described our current understanding on how this genus modulates immune 
modulation, and the IE. However, the exact mechanisms by which bifidobacteria 
protect the host from inflammation are still unclear and require further investigation. 
Due to the central role of the IE in this process, this study aims to understand the 
holistic effects of bifidobacteria colonisation on the IE in neonate, as well as adult 
stages, and to delineate how this microbiota member provides health beneficial 






2 Overarching and specific hypotheses 
2.1 Overarching hypothesis 
Bifidobacterium breve UCC2003 beneficially modulates IEC responses, during both 
early life and adulthood, via direct mechanisms, and via modulation of the wider 
microbiota. 
2.2 Specific hypotheses 
Chapter 4 - Investigating the role of mechano-receptor Piezo1 as a regulator of 
mammalian intestinal epithelial cell shedding in health and disease 
Piezo-1 regulates homeostatic and pathological mammalian epithelial 
cell shedding. 
 
Chapter 5 - B. breve UCC2003 induces distinct transcriptional responses in small 
intestinal epithelial cells of neonate mice under homeostatic condition 
Bifidobacteria can positively influence homeostatic intestinal health by 
specifically modulating the transcriptome of IECs. 
 
Chapter 6 - B. breve UC2003 transcription shows distinct modulation during 
colonisation of gnotobiotic and conventionally raised mice, and affects wider 
microbiota function  
B. breve transcriptional profiles differ in an in vivo environment, and in 
the presence of a diverse microbiota, which may link to modulation of 





3 Materials and Methods 
3.1 Materials 
3.1.1 General materials 
All general chemicals and reagents were obtained from Fisher Scientific or Sigma-
Aldrich unless otherwise indicated. Bacterial media was purchased from Oxoid. 
Water was deionised or where indicated ultrapure water by Mili-Q (Merck) was 
used. 
3.1.2 Oligonucleotide primers 
For quantitative PCR (qPCR) analysis of gene expression in host tissue, QuantiTect 
Primer Assays from Qiagen were used. A summary of primers can be found in Table 
3-1. 
Table 3-1 QuantiTect Primer assays used in this project 
 
Analysis of micro RNA 21 (miR-21) expression in mouse tissue was performed by 
qPCR with TaqMan MicroRNA assays (Applied Biosciences) with primer 
information listed in Table 3-2. 
Table 3-2 TaqMan MicroRNA primers used for miR21 qPCR 
 
Single stranded RNA was synthesised by Eurofins with specification shown in Table 
3-3. miR sequences were obtained from NCBI (hsa-miR-21-5p ID: 406991) and 










Table 3-3 miR mimetics used in study 
 
3.1.3 Antibodies and histological stains 
Antibodies used for histology and FACS are listed in Table 3-4. 
Table 3-4 Antibodies utilised for histology and FACS 
 
Histological stains applied in this study are summarised in Table 3-5. 
Table 3-5 List of histological stains 
 
3.1.4 Bacterial strains 
Bacterial strains utilised in this study are listed in Table 3-6. Bacteria were grown 
overnight in the appropriate media and growth conditions upon receipt and used to 
prepare stocks (15% glycerol added) followed by flash freezing and storage at -70 
°C. 






3.1.5 Cell lines 
Cell line IEC-6 (ATCC#CRL-1592), rat intestinal epithelial cells, was utilised for 
cell culture experiments. Upon on receipt of frozen stocks, the cell line was 
resuscitated by warming to room temperature (RT) and suspended in prewarmed 
Dulbecco’s modified Eagle’s medium (DMEM, Mediatech Inc.) with 10% foetal 
bovine serum and 4 mM L-glutamine. DMSO was removed by centrifugation at 100 
g for 15 min and resuspended in fresh media. Cell suspension was then transferred 
into 25 cm2 culture flasks (Corning) and grown to confluence at 37 °C and 5% CO2. 
Following trypsination (1% in media for 10 min), cell density was adjusted to 5x106 
cell/ml and 5% DMSO added before flash freezing 1 ml aliquots and banking in 
liquid nitrogen at -190 °C. For use of cells, aliquots were resuscitated and maintained 
as described and used within 10 passages. 
3.1.6 Zebrafish 
Adult, wild type zebrafish (90-120 days) were supplied by Ching-Ling Lien at the 
Children’s Hospital Los Angeles and maintained under standard conditions (14 h-
dark/10 h-light cycle at 28.5°C). Animal use was approved and monitored by the 
Children’s Hospital Los Angeles IACUC and designed to follow ARRIVE 
guidelines. 
3.1.7 Mice 
Conventionally raised (SPF: specific pathogen free), female C57 Bl/6 Jax mice 
(adult: 10-14 weeks, neonate: 2 weeks) were obtained from Charles River and 
housed within the Disease Modelling Unit (DMU) at the University of East Anglia 
(UEA) for at least 2 weeks for acclimatisation purposes prior to use. 
Gnotobiotic (GF: germ free), female C57 Bl/6 Jax mice (12 weeks) were generated 
by the Germ Free Facility (Quadram Institute Biosciences) at the DMU and housed 
under sterile conditions for the duration of the experiment. 
All experiments were performed under the UK Regulation of Animals (Scientific 





under which these studies were carried out was approved by the UK Home Office 
and the UEA Ethical Review Committee. 
3.2 Methods 
3.2.1 Methodology involving work with bacteria 
3.2.1.1 Bacterial growth conditions and gavage inoculum preparations 
B. breve UCC2003 was streaked from frozen glycerol stocks onto Reinforced 
Clostridial Agar plates (RCA, Oxoid) and incubated in an anaerobic chamber 
(miniMACS, Don Whitely Scientific, 5% CO2, 10% H2 and 85% N2) at 37 °C. 
Single colonies were picked for inoculation with prewarmed Reinforced Clostridia 
Medium (RCM, Oxoid).  
For preparation of gavage inoculums, 5 ml of inoculated RCM was incubated 
overnight followed by sub-culturing into 5 ml Man Rogorosa Sharpe (RCM, Oxoid) 
medium. After an additional overnight incubation, another sub-culture into 40 ml 
RCM was performed. Inoculums were prepared from cultures by 3 rounds of 
centrifugation at 3220 g for 10 min followed by 3 PBS washes before dilution in 
sterile PBS.  
For in vivo colonisation, the Bifidobacterial pellet was resuspended in 4 ml of PBS 
(adult mice) or 2 ml (neonate mice) and for in vitro co-culture in 4 ml of IVOC 
growth medium. Bacterial concentration of inoculum was enumerated by plating 
serial dilutions in sterile PBS on RCA plates and enumerating colonies following 2 
day incubation to calculate cfu/ml. 
Salmonella enterica subsp. enterica servora Typhimurium SL1344 frozen stocks 
were expanded on Luria broth (LB, Oxoid) agar plates and grown overnight at RT. 
Single colonies were used to inoculate prewarmed LB broth in conical flasks and 
incubated at 37 °C and 200 rpm. 
3.2.1.2 Method for isolating potential vesicle from bacterial conditioned 
media 
Overnight culture of B. breve UCC2003 was diluted in 2 l of prewarmed, prereduced 





conditions. Culture was then centrifuged at 3,000 g for 30 min at 4°C and 
supernatant cleared from remaining cells and debris by vacuum filtration through 
0.22 μm pore-size polyethersulfone membrane bottle top filter (Sartorius). 
Supernatant was concentrated to 20 ml by ultrafiltration through a Vivaflow 50 
filtration cassette (Satorius) with a 100 kDa molecular weight cut-off. The membrane 
retained any molecules above 100 kDa (including potential OMVs), whereas smaller 
molecules were removed together with the flow-through. Filtration was performed at 
speed setting 4 for 2 h and cassette and samples were placed on ice during the entire 
process. Afterwards, the filter was rinsed with 200 ml of ice cold PBS and 
ultrafiltration continued until total volume was reduced to 20 ml again. Following 
this, the sample was further concentrated to 10 ml using a Vivaspin 20 (Satorius) 
with 100 kDa molecular weight cut-off by centrifugation at 10,000 g for 30 min at 4 
°C. Flow through was transferred to a ultracentrifuge tube and spun at 150,000 g for 
2 h at 4 °C. Supernatant was removed and pellet resuspended in 30 µl ice cold PBS 
followed by sonication (10 s x 8) and a final filter-sterilisation (0.22μm). Cell lysate 
(5 µl) was mixed 1:2 with NuPage SDS running Buffer and heated at 70 °C for 10 
min. Protein separation was performed by SDS-page gel electrophoresis by loading 
10 µl of sample onto NuPage Novex Bis-Tris gel (10%) and run at 200 V for 1 h in 
NuPage running buffer. A negative control (10 µl sterile MRS media) was run 
alongside. Gel was then stored in 1% acetic acid at 4 °C until processing for protein 
analysis. 
3.2.1.3 Proteomic analysis of isolated potential bacterial vesicles 
Protein preparation was carried out together with Alfonsina D’Amato (QIB). 
Proteomic analysis by HPLC-MS was performed by Alfonsina D’Alomoto. 
Protein bands in SDS gel were cut and stored at -80 ˚C. Samples were defrosted on 
ice and washed 3 times with 100 µl of 50 mM NH4HCO3 in acetonitrile followed by 
200 µl 100% Acetonitrile for 3 min each. Afterwards, samples were incubated with 
100 µl 1.5 mg/ml DTT in 50 mM NH4HCO3 at for 20 min at 56 ˚C followed by an 
Acetonitrile wash. This was repeated 3 times. Following this, liquid was aspirated 
and 100 µl 10 mg/ml iodacetamide in 50 mM NH4HCO3 added for 30 min at RT in 





using a Speed Vac system at the Low Drying setting (no heat) on a Speed Vac 
SC110 (Savant). Samples were trypsin digested by adding 1 µg trypsin in 100 µl 25 
mM NH4HCO3 pH 8.5 at 4 ˚C for 10 min. Solution was removed and replaced with 
20 µl of 25 mM AMBIC and stored over night at 4 ˚C. The following day, samples 
were spun down and supernatant frozen on dry ice until analysis by Orbitrap.  
Prior to analysis, supernatant was defrosted and acidified by addition of 1 µl of 0.1% 
formic acid followed by vortexing for 20 sec and incubation at RT for 20 min. 
Samples were then transferred into a 0.2ml skirted 96-well PCR plate (Thermo AB-
800) and placed in autosampler of Orbitrap HPLC. Samples were analysed and data 
saved in Orbitrap RAW data file. Data was analysed using Mascot 2.4.1. 
3.2.1.4 Analysing effect of miR21 on bacterial growth kinetics 
Effect of host miR21 on bacterial growth was assessed by growth kinetics. Overnight 
cultures of B. breve UCC2003 in MRS and S. Typhimurium 1344 in LB were set up 
as described (3.1.4). Growth curves were performed by inoculating 200 ml of pre-
warmed, pre-reduced MRS media with B. breve UCC2003 overnight culture to an 
OD of 0.1, and incubated anaerobically at 37 ˚C.  For SL 1334, overnight culture 
was diluted 1:100 in 100 ml fresh pre-warmed LB broth and incubated aerobically at 
37 ˚C with shaking at 200 rpm.  
miR21 hsa-miR- 876-5p (Sequence: GUGUUCCGACGUAUCUAUUAAU), 
scrabbled control (both at 1.25 uM) or PBS (control) was added to cultures at point 
of inoculation. At the indicated time points, 1 ml of media was removed from the 
culture using aseptic techniques, serial diluted, plated on the MRA (UCC2003) or 
LB plates (SL1344) and incubated anaerobically (UCC2003) or aerobically (SL 
1344) for colony enumeration at 48 h (UCC2003) and 24 h (SL1344) post plating. 
3.2.2 In vitro cell culture methods 
3.2.2.1 Assessing cell shedding in vitro by staining shedding funnels in IEC-
6 monolayers 
IEC-6 cells were seeded onto chamber slides (Corning) at a density of 200,000 cells 
per chamber and grown under standard conditions until confluency was reached. 





gadolinium or PBS (control) was added. Slides were incubated for 30 min under 
standard conditions followed by removal of media, and fixing with 200 µl 4% 
neutral buffered formalin for 15 min. Cells were washed thrice with 200 µl ice cold 
PBS for 5 min each and stained with 20 µl (1 U) rhodamine-phalloidin in 200 µl 
PBS, and mounted using Prolonged Gold + DAPI (Thermo Fisher). Shedding was 
enumerated by counting actin rings surrounding shedding cells on a Leica DMI 6000 
microscope. Data presented as events per mm2 of a chamber. 
3.2.2.2 Quantifying cell shedding via enumeration of cell in supernatant of 
IEC-6 monolayers 
IEC-6 cells were seeded in 24-well cell culture plates (Corning) at a density of 
400,000 cells per well and grown under standard conditions. When confluency was 
reached, media was removed, wells washed with ice cold PBS, and 100 µl of media 
added with 1, 10 or 100 µM gadolinium or equivalent volume of PBS in media 
(control). Cells were incubated for 30 min, supernatant removed into a new 24 well 
plate and incubated with 1 µl of 1 mg/ml DAPI at under standard conditions. After 
10 min, cells were spun down at 500 g for 10 min and number of cells adhered to 
plate bottom counted with an Olympus BX60 microscope. Data displayed as events 
per mm2 of a well.  
3.2.3 Zebrafish in vivo methods 
3.2.3.1 Assessing effect of Piezo1 inhibition by gadolinium on zebrafish 
intestinal cell shedding 
Adult wildtype zebrafish, maintained under described conditions, were exposed to 10 
and 100 uM gadolinium in water or water without inhibitor (control group), and 
euthanised 4 h post exposure. Midguts were collected and processed in 0.5 ml 4% 
neutral buffer formalin for 2 h followed by storage at -80 ˚C. Cryo-sectioning (4 um) 
was performed and sections mounted on Superfrost slides, stained for F-actin with 
rhodamine-phalloidin (1:1000, Thermo Fisher) and mounted with Vector shield with 
DAPI (Vectorlabs). For each fish, 30 villi were imaged using a Leica DMI 6000, and 
actin rings forming around shedding cells were enumerated. Data are shown as 





3.2.4 Mouse in vivo methods 
3.2.4.1 Colonisation of intestinal tract with B. breve UCC2003 by oral 
gavage 
Adult mice were colonised with B. breve UCC2003 by oral gavage with bacterial 
inoculations of 100 µl every 24 h for 3 consecutive days. Neonate mice received 50 
µl of concentrated inoculum ensuring equal number of bacteria administered. 
Control mice received an oral gavage of sterile PBS. Colonisation was confirmed by 
collection of fresh faeces and homogenisation with 1 ml sterile PBS by shaking at 
200 rpm for 15 min followed by plating of serial dilutions in sterile PBS on RCA 
with 50 mg l-1 mupirocin and counting of colonies following 2 day incubation to 
calculate cfu/mg of faeces. 
3.2.4.2 Inducing colitis by DSS administration and assessment of severity 
Mice received 1.5% DSS (TdB Consulting) ad libitum in the drinking water for 7 
days inducing acute colitis, while control mice received drinking water only. Fresh 
DSS solution was prepared every 2 days. During DSS exposure, mice were assessed 
daily for disease activity index (DAI, Table 3-7) and body weight. Mice were 
euthanised on day 7 of DSS exposure, tissue collected, colon weight and length 
recorded as an assessment of severity of colitis [288]. 
Table 3-7 Disease Activity Index to assess severity of DSS induced colitis in mice 
 
3.2.4.3 Inducing intestinal cell shedding by LPS administration 
To induce small intestinal cell shedding, a systemic LPS model was used [289]. 
Mice received 200 µl intraperitoneal (IP) injection of 1.25mg/kg or 10mg/kg LPS in 





monitored and reaction to LPS challenge did not exceed limits set out in UK 
Regulation of Animals (Scientific Procedures) Act of 1986. Mice were euthanized at 
1.5 and 4 h post IP injection and tissue collected.  
3.2.4.4 Collection of mouse tissue 
Small and large intestinal tissue for formalin fixed paraffin embedded (FFPE) 
processing was collected in 5ml 10% neutral buffered formalin (NBF), fixed at RT 
for 24h, processed with an ASP300s tissue processor (2 h each in 70%, 80%, 90% 
and 100% ethanol followed by 2 consecutive baths in xylene for 2 h each and finally 
temporary storage in paraffin wax), and embedded in paraffin wax. For SEM, SI and 
LI tissue (0.6 cm in length) were collected, opened longitudinally and cut in 0.2 x 0.2 
cm squares with a razor blade. Tissue was fixed in 2.5% glutaraldehyde (Agar 
Scientific) in 0.1M PIPES buffer (pH 7.4) overnight. Intestinal contents were 
squeezed into sterile tubes and stored at 4 ˚C for bacterial enumeration or into Lysing 
Matrix E tubes (MP Biomedicals) and snap frozen in ethanol (EtOH) cooled with dry 
ice for molecular analysis. For transcriptional analysis, 0.5 cm sections of SI and LI 
were collected in 200 µl RNAlater (Qiagen) for 24 h at 4 ˚C, removed from 
RNAlater, blotted dry on filter paper and stored at -80 ˚C. For protein analysis 
(ELISA), SI and LI tissue was snap frozen in 100% EtOH cooled with dry ice, and 
stored at -80 ˚C. 
3.2.4.5 Isolating intestinal epithelial cells and assessing preparation purity 
For SI IEC isolations, an adapted Weisser method was applied [290] [46]. Sections 
(10cm) of SI were collected in ice cold PBS, dissected into 0.5 cm2 pieces and 
placed in 200 ml Duran bottles.  
Faecal matter was washed off by inverting 10 times in 0.154M NaCl and 1mM DTT. 
Liquid was drained and mucus layer removed through incubation of samples in 
1.5mM KCl, 96mM NaCl, 27mM Tri-sodium citrate, 8mM NaH2PO4 and 5.6mM 
Na2HPO4 for 15 min at 220 rpm and 37 ˚C. IECs were separated from basal 
membrane by incubation in 1.5mM EDTA and 0.5mM DTT for 15 min at 200 rpm 
and 37 °C followed by shaking vigorously 20 times. IECs were collected from 





cell pellet resuspended in 3 ml of ice cold PBS. Cell concentrations of isolated IEC 
samples calculated by labelling dead cell with trypan blue (Biological Industries) at a 
1:1 v/v ratio and enumeration of viable cells using a haemocytometer (Hawksley) on 
an inverted microscope (ID03, Zeiss). 
For protein extraction, volume containing 5x108 cells was spun down at 500 g for 10 
min at 4 ˚C and pellet resuspended in 700 µl CellLytic MT lysis buffer in Lysis 
Matrix E tubes, followed by 3 beat beating steps at speed setting 6 for 1 min each 
using a FastPrep Homogeniser (MP Bio). Samples were placed on ice between beat 
beating steps. Sample was cleared by centrifugation at 10,000 g for 15 min at 4 ˚C 
and supernatant removed into a fresh tube followed by storage at -80 ˚C. For RNA 
extraction, a volume containing 3x106 cells was processed as described in 1.2.8.3. 
Preparation purity of IEC isolations was assessed by Fluorescence-activated Cell 
Sorting (FACS) of collected cells and histological analysis of stripped tissue. For 
FACS analysis, volume of isolation containing 5x106 cells were added into 5 ml 
FACS tubes followed by centrifugation at 510 g for 3 min at 4 ˚C and removal of 
supernatant. Cells were stained with CD45-A700 (1:200) in 200 µl FACS buffer 
(Hank’s Balanced Salt Solution, 0.01 BSA, 2mM EDTA, 20mM HEPES, 0.01% 
NaN3) by vortexing for 20 sec and incubation on ice for 30 min. Two washes with 2 
ml FACS buffer followed and addition of 200 µl of propidium iodide (1:400) in 
FACS buffer. Blank samples were prepared for each isolation, substituting stains 
with equal volumes of FACS buffer. Samples were run on Sony FCS SH-800 and 
data analysed using FlowJo 7.2 (TreeStar). For histology, tissue samples were 
collected at end of each incubation step, FFPE processed as described in 1.2.4.4, 
sectioned (5 µm) and mounted on Superfrost slides. Samples were stained with 
Haematoxylin and Eosin (H&E) by removal of paraffin in xylene twice for 5 min, 
rehydration with 5 min consecutive baths in 100%, 90%, 80%, 70% EtOH followed 
by water, incubation with H&E stain for 4 min, differentiation with 1% acid in EtOH 
for 30 s, washing under running water, and bluing with 0.2% ammonia for 30 s 
followed by another wash under running water. Samples were dehydrated in 70%, 
90% and 100% EtOH baths for 5 min each followed by 2 x 5 min xylene baths and 
mounting with Hydromount (National Diagnostics). Slides were imaged suing a 





3.2.5 Histological methods 
3.2.5.1 Scanning electron microscopy of intestinal epithelium 
Scanning electron microscopy (SEM) was performed by Kathryn Cross (QIB).  
Tissue was collected and fixed as described in 1.2.4.4. Fixative was washed off with 
3 x 15 min baths in 0.1M PIPES buffer and tissue then dehydrated in EtOH (30, 50, 
70, 80, 90, 3x 100%) for 15 min each followed by drying in a Leica EM CPD300 
Critical Point Dryer using liquid carbon dioxide as transition fluid. Tissue was then 
mounted with quick drying conductive silver paint (Agar Scientific) on aluminium 
SEM stubs with intestinal epithelial layer oriented upwards. Samples were coated 
with gold in a high resolution sputter-coater apparatus (Agar Scientific). SEM 
performed on a Zeiss Supra 55 VP FEG SEM, operating at 3kV. 
3.2.5.2 Visualising shedding intestinal epithelial cells by caspase-3 staining 
FFPE fixed small intestinal tissue was sectioned at 5 um and mounted onto 
Superfrost slides. Tissue was de-paraffinised twice in Histoclear (National 
Diagnostics) for 5 min each, rehydrated in an ethanol series (100, 90, 80, 50% 
followed by water for 5 min each) and treated with 1% H2O2 in methanol for 12 min. 
Antigen retrieval was performed by boiling samples in 0.01M citrate acid buffer 9pH 
6) 3 times for 10 min in a microwave (800W) and section marked of on slide with 
wax pen. Tissue then incubated with rabbit anti-caspase-3 antibody (1:500, R&D 
systems) in 1% Tris-HCl with 1% BSA for 2 h at RT. Afterwards antibody solution 
as flicked off and slides incubated with peroxidase conjugated goat anti-rabbit 
secondary antibody (EnVision DAB kit) for 30 min at RT and developed with DAB 
substrate for peroxidase (Vector Laboratories) for 30 s. Lastly, slides were washed in 
water, counterstained with Harris Haematoxylin as described in 3.2.4.5, washed in 
running water, dehydrated in an ethanol series (50, 80, 90, 100% for 5 min each), 
sealed with Safemount (VWR chemicals), and dried overnight at RT. Slides were 
imaged with a Leica DMI 3000 B. 
Quantification of shedding events along crypt-villus axis was performed using 
caspase-3 stained tissue slides. Using full length, intact villi only, epithelial cells 





side of villus (epithelial cell at base of crypt – last cell position). While counting, cell 
with absent caspase-3 labelling and in contact with neighbouring cell and basal 
membrane recorded as “normal”. Cells with positive capspase-3 labelling and loss of 
contact recorded as “shed”. At least 15 villi in at least 6 separate intestinal sections 
counted per mouse. Data recorded using WinCrypts and analysed using PRISM. 
Imaging was performed using an Olympus BX60 microscope. 
3.2.5.3 Visualising Piezo1 within the intestine  
FFPE fixed samples were sectioned de-paraffinised, rehydrated and antigen retrieval 
performed as stated (3.2.5.2). Tissue then incubated with rabbit anti-mouse Piezo1 
(1:500, Novus Biologicals) in 1% BSA for 2 h at RT. Slides washed 3 times in PBS 
and incubated with goat anti-rabbit IgG antibody (1:1,000) in 1% BSA for 30 min at 
RT. Slides washed in PBS and mounted with Vector shield with DAPI (LifeTech) 
and imaged immediately using a Leica DMI 3000 B. For chromogenic staining, 
piezo1 antibody at 1:400 dilution was used following protocol in 1.2.4.5.  
3.2.5.4 Using RNAscope technology to visualise transcripts within intestinal 
tissue 
RNAscope was performed using a commercial kit from Advanced Cell Diagnostics 
as per the manufacturer’s instructions using Piezo1 and Bifidobacteria specific 
probes designed to bind to piezo1 RNA transcript and B. breve UCC2003 16S rRNA 
sequence respectively. Briefly, formalin fixed paraffin embedded tissue sections (5 
um) were mounted on Superfrost plus slides before baking in a dry oven at 60 °C for 
1 h. Slides were then deparaffinised with Xylene for 5 min and bathed in 100% 
ethanol for 5 min before applying Pre-treat solution 1 for 10 min at RT. Sections 
were washed in distilled water twice for 30 s before incubation in boiling Pretreat 2 
solution for 15 min. Following 3 further washes in water for 30 s each, Pretreat 3 
was applied in a humidified chamber at 40 oC for 30 min. After further 3 washes, 
Piezo1 specific, Bifidobacteria specific or Cyclophylin B control probe were 
hybridised to samples for 2 h at 40oC. Following washes in wash buffer, a series of 
amplification probes (AMP1 to AMP6) were sequentially bound to and washed off 





RT each for 30 min. Signal detection was achieved by adding DAB substrate to 
sections for 2 min followed by washing in running water. Counter stain with H&E 
was performed as described 3.2.4.5, tissue dehydrated and mounted for visualisation 
using a Leica DMI 3000 B microscope. A minimum of 12 villi per sample were 
observed for enumeration of Piezo1 transcripts per cell as described in 3.2.5.2. Data 
shown as means +/- SD of transcripts per cell along crypt-villus axis. 
3.2.6 Analysis of human biopsies and ex vivo culture 
3.2.6.1 Measuring transcription within colonic biopsies of UC patients 
Study was carried out, samples collected, RNA extracted and cDNA generated by 
Elizabeth Thursby (QIB). 
Study participants were recruited from patients undergoing colonoscopy in the 
gastroenterology department at the Norfolk and Norwich University Hospital 
(NNUH). Ethical approval was obtained through the Faculty of Medicine and Health 
Sciences Research Ethics Committee at the UEA (reference 2012GAST022).  
Colonic biopsies were obtained from patients being assessed for a suspected flare of 
UC or for investigation of another possible bowel condition (found macroscopically 
and microscopically normal, control group). Inflammation of each patient was 
categorised as normal or inflamed based on grading of separate clinical samples by a 
histologist at the NNUH. Additional information given in Supplementary Table 1. 
Pinch biopsy (5 mm) were collected from the ascending colon, immediately frozen 
on dry ice and stored at -80 ˚C. Frozen biopsies were placed in 200 µl RNAlater-ICE 
solution and stored at -20 overnight. Samples were then transferred into 350 µl RLT 
buffer (RNeasy Mini Kit, Qiagen) with 1% v/v β-mercaptoethanol and incubated for 
5 min at RT. Tissue was disrupted using a disposable, autoclaved pellet pestle and 
vortexing until fully lysed. RNA was extracted following RNeasy Mini Kit 
‘Purification of Total RNA from Animal Tissues’ protocol from step 5, performing 
steps D1-D4 in replacement of step 6, and at the end 2 elution steps with 30 μl 
RNase free water were carried out. Extracted RNA was banked at -80°C.  
For cDNA synthesis, sample RNA was thawed on ice and RNA integrity and 





manufacturer’s instructions. For each reverse transcription PCR (RT-PCR), 0.5 µg 
RNA per sample was used. Initially, gDNA was eliminated and RT-PCR performed 
using the Quantitect reverse transcription kit (Qiagen), according to the 
manufacturer’s instructions. qPCR analysis was performed as described (3.2.8.3) 
with QuantiTect primers assays specific for human transcripts. 
3.2.6.2 Assessing transcription in colonic biopsies of UC patients 
This study was carried out, and samples collected by Dr Johanna Brooks 
(QIB/NNUH). Co-culture was performed together with Johanna Brooks. 
Study participants were recruited from patients undergoing colonoscopy in the 
gastroenterology department at the Norfolk and Norwich University Hospital 
(NNUH). Ethical approval was obtained through the Faculty of Medicine and Health 
Sciences Research Ethics Committee at the UEA (20162017-28HT) and NHS 
research and development permission was granted from the NNUH (reference 19-10-
16). 
Colonic biopsies were obtained from patients undergoing routine check-ups for UC 
monitoring, for assessed of a suspected flare of UC or for investigation of another 
possible bowel condition (found macroscopically and microscopically normal, 
control group). Inflammation of each patient was categorised as normal (control 
group), UC in remission (UC-R) or inflamed (UC-I) based on grading of separate 
clinical samples by a histologist at the NNUH. 
Pinch biopsy (5 mm) were collected in quadruplets in close proximity from each 
other at transverse colon and stored in IVOC culture media (4.7 g/l NCTC 135 
medium, 1.1 g/l sodium bicarbonate, 5 g/l D-Mannose, 10% New-born Calf Serum, 
45% DMEM medium) at RT. One biopsy was frozen on dry ice and stored at -80 ˚C 
for baseline gene expression. RNA was extracted from frozen samples and 
transcriptional analysis performed as described in 3.2.8.3 using a human specific 





3.2.6.3 Co-culturing B. breve UCC2003 with colonic UC patient biopsies in 
pIVOC 
pIVOC was performed by cutting biopsy in half using a scalpel and sandwiching 
each half between two 12mm diameter Perspex disks (both with a 2 mm central 
aperture) on top of a cellulose nitrate filter (3 μm pore, Whatman) with the mucosal 
side upwards. Mounting was sealed with Histoacryl tissue glue (Braun Medical Ltd) 
to prevent leakage and mounted on Snapwell supports in 6 well culture plate 
(Croning). Basal compartment was filled with 3 ml IVOC culture media and apical 
compartment with 100 µl IVOC media (control) or media containing 107 cfu/ml B. 
breve UCC2003 and incubated at 37 °C and 5% CO2. At 2 h, 80 µl of the apical 
media was removed to improve biopsy survival. Removed media was stored at -80 
˚C and 10 µl plated on RCA + 50 mg l-1 mupirocin for enumeration of bacteria 
(cfu/ml). After 8h, biopsies were removed from sandwich, washed 3 times in ice cold 
PBS and stored at -80 ˚C for RNA extraction (3.2.8.3)  
3.2.7 Metabolomic analysis of intestinal contents 
Bile acid isolation and quantification in mouse intestinal contents was performed by 
Mark Philo (QIB).  
Intestinal content (25 mg) was added to tubes containing 6 ceramic beads, 1 ml of 
70% v/v methanol and 25µl of 40 µg/ml d4-DCA and homogenised for 30 s at 3.300 
g using a table shaker. Faecal slurry was then cleared by centrifugation at 800 g at 4 
°C and supernatant transferred to a new tube with the addition of 25 µl of 40 µg/ml 
d4-CDCA. Centrifugal evaporation at 50° for 70 min was carried out until sample 
was almost dry and then made up to 1 ml volume with 5% v/v methanol with the 
addition of 25 µl of 40 µg/ml d4-CA. Reconstituted sample was passed through 
hydrophilic-lipophilic balance clean-up cartridge (Waters Oasis Prime HLB, 1cc, 
30mg), washed with 1 ml of 5% methanol and eluted in 500 µl methanol with the 
addition of 25 µl of 40 µg/ml d4-GCA (primary reference internal standard) and d4-
LCA. Sample was then submitted for analysis by HPLC/MS operated in multiple 
reaction monitoring (MRM) mode using Agilent 1260 binary HPLC coupled to an 
AB Sciex 4000 QTrap triple quadrupole mass spectrometer. HPLC was run using 





and solvent B (Methanol + 5mM Ammonium Ac + 0.012% Formic acid) at a 
constant flow rate of 600 µl/min. Separation was made using Supelco Ascentis 
Express C18 150 x 4.6, 2.7µm column maintained at 40°C.  Injection was made at 
50% B and held for 2 min, ramped to 95% B at 20 min and held until 24 min. 
Column was equilibrated to initial conditions for 5 min. Mass spectrometer was 
operated in electrospray negative mode with capillary voltage of -4500V at 550°C. 
Instrument specific gas flow rates were 25ml/min curtain gas, GS1: 40 ml/min and 
GS2: 50 ml/min. Data was collected and quantification achieved using Analyst 1.6.2 
software to integrate detected peak areas relative to the deuterated internal standards. 
Metabolomic analysis of mouse intestinal contents was carried out by Gwenaelle Le 
Gall (QIB). 
Intestinal content (25 mg) was mixed with 1 ml 5% MeOH by vortexing. Samples 
were then loaded onto Waters OASIS PRIME HLB 1 30mg SPE cartridges and 
washed with 1 ml 5% MeOH. Flow through fraction was dried using a Speedvac® 
centrifugal evaporator and reconstituted with 600µL NMR buffer made up of 0.1 M 
phosphate buffer (0.51 g Na2HPO4, 2.82 g K2HPO4, 100 mg sodium azide and 34.5 
mg sodium 3-(Trimethylsilyl)-propionate-d4 (1 mM) in 200 mL deuterium oxide). 
Supernatant was transferred into 5-mm NMR tube for NMR recording. High 
resolution 1H NMR spectra were recorded on 600MHz Bruker Avance spectrometer 
fitted with a 5 mm TCI cryoprobe. Sample temperature was controlled at 300 K. 
Each spectrum consisted of 512 scans of 65,536 complex data points with a spectral 
width of 12.5 ppm (acquisition time 2.67 s). The “noesypr1d” pre-saturation 
sequence was used to suppress the residual water signal with a low-power selective 
irradiation at the water frequency during the recycle delay and a mixing time of 10 
ms. Spectra were transformed with 0.3 Hz line broadening and zero filling, manually 
phased, and baseline corrected using the TOPSPIN 2.0 software. Spectra were 
transferred into AMIX ® software for bucketing. Metabolites were identified using 
Human Metabolome Database, (http://www.hmdb.ca/) and 2D-NMR methods 
(COSY, HSQC, and HMBC). Multivariate statistical analyses (Principal Component 
Analysis) were carried out using the PLS Toolbox v5.5 (Eigenvector Research Inc.) 
running within Matlab, v7.6 (The MathWorks Inc.). Graphs of metabolite signal 





3.2.8 Molecular techniques 
3.2.8.1 Analysing intestinal epithelial cell expression using qPCR arrays 
Analysis of gene expression using Real-Time Ready Custom Panel 480–96 PCR 
arrays (Roche) was carried out by Kevin Hughes (QIB). In brief, whole small 
intestinal mouse tissue was collected and RNA extracted (3.2.8.3). Reverse 
transcription was performed, using Transcriptor First Strand cDNA Synthesis Kit 
(Roche) following manufacturer’s instructions. qPCR was performed using 
LightCycler 480 Probes Master Mix and Real-rime ready Custom Panel 480–96 PCR 
arrays on a LightCycler II (Roche) as per manufactures instructions. CT values of 
target genes were normalized to expression of housekeeping genes and fold change 
versus control samples calculated using the ∆∆CT method. 
3.2.8.2 Extracting DNA from faeces 
DNA was extracted from faecal samples using with the FastDNA SPIN Kit for Soil 
(MP Biomedicals) following the manufacturer’s instructions with elongation of 
bead-beading time to 3 min. In brief, a minimum of 50 mg of faeces was added to 
Lysis matrix E tubes prepared with 980µl Sodium Phosphate Buffer. To sample, 120 
µl MT Buffer was added and sample homogenize 3 times in the FastPrep instrument 
for 1 min each at a speed setting of 6. In-between beat-beating, samples were placed 
on ice for 5 min. Tubes were centrifuge at 14,000 g for 15 min. Supernatant was 
transferred to a tube containing 250µl PPS. Sample was mixed by inverting 10 times 
and centrifugation at 14,000 g for 10 min to pellet precipitate. Supernatant was 
transferred to a 15 ml tube containing 1 ml of resuspended Binding Matrix and 
inverted for 2 min to allowed binding of DNA to Binding matrix. Following a 3 min 
incubation at RT to allow matrix to settle, 500µl of supernatant was removed without 
disturbing settled matrix. Binding Matrix was resuspended in remaining supernatant 
and 700µl transferred to SPIN filter. The filter was then centrifuged at 14,000 g for 1 
min, catch tube emptied follow by transfer of remaining resuspended matrix to filter 
and an additional centrifugation at 14,000 g for 1 min. After catch tube was emptied, 
500 µl SEWS-M was added and pellet resuspended. Filter was then centrifuged at 





Catch tube was replaced by Eppendorf tube and sample air dried 10 min at RT 
followed by 5 min at 37 ˚C. Afterwards, 65 µl DES was added to the Binding 
Matrix, incubated at RT for 5 min, centrifuged at 14,000 g for 1 min to elute DNA 
into Eppendorf tube. DNA was then stored at -20˚C. 
3.2.8.3 Analysing transcription in mouse tissue by qPCR 
Tissue was removed from -80 ˚C on dry ice. Using a scalpel, 10 mg section were cut 
off and placed in 600 µl RLT buffer (RNAeasy plus mini kit, Qiagen) in Lysis 
Matrix E tube. Sample was homogenised using a FastPrep 24 homogeniser (MP Bio) 
thrice for 1 min at speed setting 6 followed by centrifugation at 10,000 g for 15 min 
at +4˚C. In-between beat-beating, samples were placed on ice. Supernatant was used 
for downstream RNA isolation. 
RNA was extracted from IEC isolations by adding a volume containing 2x106 cells 
in PBS to Qiashredder spin columns (Qiagen) followed by centrifugation at 9.300 g 
for 1 min. Follow-through was mixed with 600 µl RLT lysis buffer and used for 
subsequent RNA isolation. 
Homogenised sample in RLT buffer from both tissue and IEC isolations were 
processed by adding 700 µl of 70% ethanol and mixing by pipetting. Into RNeasy 
spin column, 700 µl of sample was added and spun at 8,000 g for 15 sec. Flow 
through was discarded and process repeated until all of sample was filtered through 
column. Then 700 µl of buffer RW1 was added to column and centrifuge at 8,000 g 
for 30 s. Again, flow through was discarded and filter placed in a new collection 
tube. To the filter, 500 µl RPE was added and spun at 8,000 g for 30 s followed by 
discarding of flow through. An additional 500 µl RPE was pipetted into column and 
centrifuged at 8,000 g for 2 min. Spin column was then placed in a new collection 
tube and centrifuged at 8,000 g for 2 min. Columns were transferred to a RNA low-
bind Eppendorf tube and 30 µl of RNase free water added to directly to the filter. 
After an incubation of 1 min at RT, sample was centrifuged at 8,000 g for 1 min and 
flow through containing RNA stored at -80 ˚C. RNA was quantified and quality 





Reverse transcription PCR (RT-PCR) was performed with the Quantitect Reverse 
Transcription Kit (Qiagen) following manufacturer’s instructions. In brief, reagents 
and RNA samples were thawed on ice. RNA template (500 ng) was mixed with 2 µl 
of gDNA Wipeout buffer and made up to 14 µl with RNase free water on ice. 
Reaction was incubated at 42 ˚C for 2 min and immediately placed in ice. To sample, 
14 µl reverse transcriptase and 1 µl of primer mix were added and incubated at 42 ˚C 
for 15 min followed by 3 min at 95. Afterwards, samples were stored at -20 until 
analysis by qPCR. 
To analyse gene expression, qPCR of cDNA was performed using a LightCycler 480 
II (Roche) with Quantifast SYBR Green PCR Kit (Qiagen) and Quantitect primer 
assays (Qiagen) following manufacturer’s instructions. In brief, samples and 
reagents were thawed on ice and reaction mix (Table 3-8) set up in 384 well plates. 
Cycling was performed as detailed in Table 3-9. Expression levels of gene of interest 
were calculated using ∆∆CT method normalised against expression of housekeeper 
gene. Data shown as fold changes in expression compared to levels in control 
groups. 
Table 3-8 qPCR reaction mix 
 
Table 3-9 PCR conditions for qPCR on cDNA generated from isolated host RNA 
 
3.2.8.4 ELISA on Piezo1 protein in intestinal tissue 
Whole tissue (10 mg) and IEC preparations (volume with 5x108 cells) were 





Matrix E tubes and Fastprep 24 following protocol (3.2.8.3). Lysate was cleared by 
centrifugation and protein concentration analysed using Qubit 2.0 (Invitrogen) 
followed by storage at -20 ˚C. 
Lysate was analysed using ELISA for mouse Piezo1 (Cusabio BioTech) following 
manufacturer’s instructions. In brief, samples were diluted 1:1 in sample diluent and 
100 µl added to wells on ELISA plate together with serial dilutions of Piezo1 
standard. Plate was incubated at 37 ˚C for 2 h. Liquid was removed from wells and 
100 µl of Biotin labelled Piezo1 antibody added. After incubation at 37 ˚C for 2 h, 
liquid was aspirated and wells washed 5 times with wash buffer followed by tapping 
plate dry on paper towels. To each well, 100 µl of HRP-avidin was added and 
incubated in the dark for 1 h at 37 ˚C. Again, plate was washed 5 times but without 
drying 90 µl of TMB substrate was added and incubated at 37 ˚C for 30 min in the 
dark. Immediately after adding 50 µl of stop solution, absorbance of wells at 450 nm 
was measured on a Fluostar Optima plate reader (BMG Labtech). Blank 
measurements were subtracted and Piezo1 protein concentration calculated using 
standard curve generated from absorbance of serial diluted Piezo1 standards. Data is 
presented as Piezo1 protein level fold changes in comparison to control mouse SI. 
3.2.8.5 Measuring expression of miR21 in mouse intestinal samples 
Extraction of RNA including miRNAs from mouse intestinal tissue was performed 
by TriZOL method [291]. Snap frozen samples stored at -80 ˚C were removed from 
the freezer on dry ice. Using a scalpel, 10 mg section was cut off and placed in 1 ml 
TRIzol (Thermo Fisher) in Lysis Matrix E Tubes and incubated at RT for 5 min. 
After the addition of 200 µl of chloroform, tissue was disrupted by beat beating on a 
FastPrep 24 for thrice 1 min at speed setting 6. Samples placed on ice between 
beating steps. This was followed by another incubation for 3 min at RT. Samples 
were then centrifuged at 12,000 g at 4 ˚C for 15 min. Aqueous phase was transferred 
to a fresh tube and 1 µl Glycoblue added. Mixing by inversion was performed and 
500 µl isopropanol added to each tube followed by additional mixing by pipetting up 
and down. Samples were then incubated at -80 ˚C for 1 h and immediately without 
thawing centrifuged at 12,000 g for 20 min at 4 ˚C. The supernatant was removed 





cold 100% EtOH and centrifuging at 7,400 g in a 4 ˚C for 5 min. EtOH was 
completely removed and samples air dried on bench for 30 min. Pellet was then 
resuspended in 25 µl nuclease-free water and RNA quantified by Nanodrop 2000 
Spectrophotometer (Thermo Fisher) followed by storage at -80 ˚C.  
Generation of miRNA specific cDNA by RT-PCR was carried out using miRNA 21 
and endogenous control U6 snRNA specific Taqman probes and assays (Applied 
Biosystems) following manufacturer’s instructions. In brief, Reagents and samples 
were defrosted on ice and reverse transcription reaction prepared on ice in PCR tubes 
as indicated in Table 3-10. Two RT-PCR reaction were performed for each sample 
with either miR21 or u6 snRNA primer added for transcript specific cDNA 
generation. After gently mixing by inversion, PCR was run with parameters listed in 
Table 3-11. on a thermocycler. PCR product was stored at -20 ˚C until use for miR 
expression analysis by qPCR.  
Table 3-10 Reaction mix for miR specific RT-PCR reaction 
 
Table 3-11 miR specific RT-PCR conditions 
 
miR quantification was achieved by qPCR. cDNA and reagents were thawed on ice 
and reaction prepared in 384 well plates as indicated in Table 3-12. Plates were 





Table 3-13. Expression levels of miR21 calculated using ∆∆CT method normalised 
against expression of U6 snRNA control. Data shown as fold changes in expression 
compared to levels in control groups.  








Table 3-13 qPCR conditions using TaqMan Small RNA Assay 
 
3.2.9 Sequencing and bioinformatics 
3.2.9.1 Sequencing of mouse and bacterial RNA 
Extracted RNA (mouse and bacterial) was quantified and quality controlled using 
RNA 6000 Nano kit on a 2100 Bioanalyser (Agilent). Only samples with RIN values 
above 8 were sequenced. RNA was transferred to 96 well plate and shipped on dry 
ice 
RNA-seq was performed at the Welcome Trust Sanger Institute. Isolated RNA was 
processed by poly-A selection and/or Ribo-depletion. Sample specific information 
regarding library preparation and sequencing technology platforms are shown in 
Supplementary Table 2 and Supplementary Table 3. All samples were sequenced 
using non-stranded, paired end protocol. 
3.2.9.2 Bioinformatic analysis of mouse RNAseq data 
Analysis was performed with the support of Shabhonam Caim (QIB). 
Initial processing was performed at Welcome Trust Sanger Institute as follows. Data 
demultiplexed and adapter removed. Raw reads quality controlled using FastQC 
(0.11.3, [292]) and trimmed (phred score < 30) using FASTX (0.1.5, [293]). This 
was followed by read alignment to mouse reference genome (NCBI Mus musculus 
GRCm38) using Tophat (2.1.1, [294]) using maximum intron size 500.000 bp and 
default settings. Aligned transcripts were assembled and quantified using Cufflinks 





At QIB, read counts were extracted manually and differentially expressed genes 
(DEGs, cut-off’s: q-value<0.05, log2 fold change > +/-2.5) between sample groups 
calculated and visualised using DeSeq2 (3.5, [295]). DEGs were analysed using 
Ingenuity Pathway Analysis (Summer 2017 release, last accessed 19.12.17, Qiagen), 
InnateDB (last accessed: 12.12.2017, [296]) and Cytoscape (3.5.1, [297]).  
3.2.9.3 Bioinformatic analysis of bacterial RNAseq 
Analysis was performed with the support of Shabhonam Caim (QIB). 
Initial processing including demultiplexing, adapter removal and, quality control and 
trimming performed at Welcome Trust Sanger Institute as described above (3.2.9.2).  
At QIB, raw reads were aligned to B. breve UCC2003 genome (NCBI reference 
Sequence NC_020517.1) with Bowtie2 (2.3.2, [298]) using standard parameters and 
smallest intron setting (50 bp). Counts were generated with HTseq (0.8.0, [299]) 
using standard parameters with smallest gap skip and differential gene expression 
calculated and visualised with Deseq2 (setting as described in 3.2.9.2). 
For metatranscriptome analysis, raw read files were analysing with SUPER-FOCUS 
(0.27, [300]) for microbiota taxonomic profiles and functional subset binning 
referencing SEED database (last accessed 14.11.2017, [301]). Taxonomic profiles 
were visualised with Prism as abundance of mapped reads relative to total reads. 
Functional profiles visualised and statistical significance analysed with Prism. 
3.2.9.4 Profiling the gut microbiota using 16S rRNA sequencing 
PCR amplification of 16S rRNA gene was carried out with the help of Charlotte 
Leclaire (QIB). 
Concentration of DNA isolated from mouse faeces was quantified by Qubit (Fisher 
Scientific) and normalised to 5 ng/ml. DNA then used as a template for PCR 
amplification of V1-V2 region of the 16S rRNA gene. Primers were sourced from 






Table 3-14 Primer sequence used for amplification of 16S rRNA gene 
 
To allow multiplexing of samples, primer pairs with unique barcodes were used for 
PCR amplification and 3 reactions were performed for each sample to ensure 
amplification of sufficient materials for sequencing. Samples and reagents (New 
England biolabs) were defrosted and kept on ice. Reaction was set up as indicated in 
Table 3-15 in 96 well plates on ice.  
Table 3-15 PCR reaction components for 16s rRNA amplification 
 
PCR conditions are listed in Table 3-16. Samples and reagents were defrosted on ice 
and PCR reaction set up in 96 well plates. PCR was then performed on a Thermal 
Cycler PCR machine (Applied Biosystems) and product stored -20 until further 
processing. 
Table 3-16 Cycling conditions for 16s rRNA PCR 
 
Following PCR amplification, samples were cleaned up using Agencourt AMPure 





and beads were brought to RT. Triplicate repeats PCR amplification reaction were 
combined in new 96 well plate. Beads were then vortexed for 30 sec and 75 µl added 
to wells and mixed by gentle pipetting. After incubation at RT for 5 min, plate was 
placed on magnetic stand for 2 min to trap beads. Supernatant was removed and 
discarded. Wells containing beads were washed twice by adding 200 µl 80% EtOH 
for 30 sec. Afterwards, plate was left to air dry at RT for 15 min followed by 
removal from magnetic stand. Following the addition of 52.5 µl of 10 mM Tris pH 
8.5, samples were incubated for 2 min after which the plate was returned to the 
magnetic stand. Supernatant was transferred to new 96 well plate and quantified 
using Qubit. RT-PCR product concertation was equalised and prepared for sending 
on dry ice in 96 well plates. Sequencing of 16S rRNA gene libraries was carried out 
at Welcome Trust Sanger Institute on Illumina MiSeq platform with 300 bp paired 
end reads. 
3.2.9.5 16S rRNA gene sequencing analysis 
Analysis was performed with the support of Shabhonam Caim (QIB). 
Raw data generated from sequencing of 16S RNA gene libraries were analysed using 
an in-house paired end protocol. Quality of raw paired reads was classified using 
FASTX-Toolkit (minimum quality threshold = 33, < 50% of reads per sample above 
threshold, 0.11.3). Quality controlled reads for each pair separately, were aligned 
against SILVA database (SILVA_119_SSURef_tax_silva) using BLASTN (2.2.25+; 
Max e-value 10-3, [302]). Output files of aligned paired read sequences were 
annotated for taxonomic assignment using MEGAN 6 paired end protocol (threshold 
setting: Min Score = 50, Top Percent = 10, reads without assignment classed as “No 
Hit”, [303]) Data was then analysed and visualised within MEGAN 6 [303]. 
3.2.9.6 Predicting miR21 binding sites in bacterial genomes  
Analysis was performed with support by Padhmanand Sudhakar (EI). 
Sequence of mature miR21 (NCBI gene ID: 406991) was used to predict potential 
binding site in B. breve UCC2003 (NCBI reference Sequence NC_020517.1) and S. 





alignment using MiRbase (accessed: 12.4.2017, [304]). Entropy cut off <-16 was 
applied to filter results. 
3.2.10 Statistical analysis 
Statistical analysis performed using Prism 6, R (3.4.1), MEGAN 6 [303] and 
DESeq2 (3.5, [295]). Applied statistical tests within Prism include Mann-Whitney U 
test (comparing 2 sample groups), Kruskal-Wallis one-way test with Dunn’s multiple 
comparison test (comparing more than 2 groups) and two ANOVA (compare 
difference between 2 groups with several observations). Data presented as mean +/- 






4 Investigating the role of mechano-receptor Piezo1 as a regulator 
of mammalian intestinal epithelial cell shedding in health and 
disease 
4.1 Introduction 
The single cell layer formed by the IE is essential for health; controlling contact and 
exchange between the host and the luminal contents of the intestine [305, 306]. 
Constant renewal of the IE poses a significant challenge for maintenance of an intact 
barrier, as single cells are lost at the tip of intestinal villi [40, 306]. This renewal 
process has to be tightly controlled, as elevated shedding levels and resulting gaps 
are involved in intestinal disease aetiology, including IBD [305, 307]. However, the 
processes governing epithelial cell extrusion remain incompletely understood, and 
due to its integral role in human health, I sought to investigate the potential role of a 
newly discovered ion channel Piezo1 in this process. 
4.1.1 Ion channel Piezo1 as a potential regulator of intestinal 
epithelial shedding and turnover by sensing cell crowding and 
stretching 
Piezo1 belongs to a novel protein family including only one other member, Piezo2, 
with which it shares 47% sequence homology [308]. The proteins are over 2000 
amino acids in length and predicted to from 24 to 40 transmembrane structures 
(Figure 4-1.A). The membrane bound ion channel can conduct K+, Na+ and Ca+ and 
is activated by distortion of the cell membrane and converts mechanical force into 
biological signals, so called mechanosensation (Figure 4-1.B) [309]. This process is 
important in physiological nociception, in hearing, in sensing shear stress (vascular 
and muscular tension), as well as embryonic development. Therefore, expression 
levels are high in tissues constantly exposed to stretch such as lung, bladder, and 






Figure 4-1 Structure and functional mechanism of membrane bound, mechanoreceptive ion 
channel Piezo1 
A Piezo1 (Uniprot Q92508) transmembrane structure with 24-40 domains generated with Swiss-Prot 
tools, predicted to be one of the largest membrane spanning proteins, forms homotetramer 
configurations but total number of pores still unknown (figure adapted from Bagriantsev et al., 2014 
[309]) B Mechanical perturbations of the lipid bilayer alone are sufficient to activate Piezo channels, 
illustrating their innate ability as molecular force transducers ( adapted from Seyda et al., 2016 [311]) 
Recently, Eisenhoffer et al.[37], suggested that the stretch-sensitive ion channel 
Piezo1 is also important for sensing cell density and causing live cell extrusion in the 
zebrafish fin and cell culture epithelial monolayers and hypothesised its role in the 
intestine (Figure 4-3.A). The study presented evidence that physiological cell 
shedding occurs within areas of the epithelium in which cell density is highest. This 
was modelled using zebrafish fins, where IEC migration increases cell density at the 
fin tip, and Madin-Darby canine kidney (MDCK-II) monolayers grown on stretched 
elastic supports, where release of tension increased cell density. In both models, an 
increase in density caused an elevation in cell shedding, until physiological cell 
density was restored. By culturing extruded cells during homeostatic shedding, the 
authors showed that predominantly live cells were removed during this physiological 
cell shedding. In contrast, apoptotic stimuli (i.e. UV radiation), applied to in vitro 
cell lines, also elevated cell shedding, and was correlated to extruded cells 
undergoing cell death i.e. apoptosis. These data added to the body of evidence 





induced shedding, with physiological extrusion potentially governed by cell density 
(Figure 4-3.B).  
The authors proposed that the stretch activated channel Piezo1 may be involved in 
this cell shedding mechanism, and subsequently inhibited Piezo1, using gadolinium, 
in the zebrafish fin. Gadolinium is lanthanide frequently used as a contrast agent in 
magnetic resonance imaging [312, 313]. They observed decreased cell expulsion, 
and formation of cell masses, suggesting the ion channel as a main regulator of 
physiological shedding. To further probe Piezo1-induced mechanisms of cell 
shedding, the authors inhibited Piezo1 in MDCK-II monolayers, which were 
artificially stretched to induce cell crowding. Addition of gadolinium to inhibit 
Piezo1 reduced cell shedding, further supporting the role of Piezo1 in controlling this 
process. 
 
Figure 4-2 Piezo1 RNA expression levels in adult mouse tissues with differing mechanical 
activity 
mRNA expression profiles of Piezo1 determined by qPCR from various adult mouse tissues, GAPDH 





+/- SEM of two separate experiments, DRG: dorsal root ganglion (reproduced Coste et al., 2010 
[308]). 
Previous work by the same group had shown that shedding cells release sphingosine-
1-phosphatase (S1P, a bioactive lipid), which binds to S1P receptors on surrounding 
cells [314]. Binding of S1P induces formation of the shedding funnel, and Rho-
kinase (RHOK) mediated contraction of actin-myosin, leading to cell expulsion. S1P 
is released during both homeostatic and apoptotic shedding, with extrusion of dead 
cell being controlled by Bcl-2, a regulator of apoptosis. Building on these studies, 
Eisenhoffer et al., determined that selective inhibition of RHOK or S1P signalling 
significantly decreased both homeostatic and apoptotic cell shedding, indicating that 
S1P signalling via RHOK is required and that Piezo1 may act upstream of S1P, 
however this requires further mechanist work (Figure 4-3.B). 
 
Figure 4-3 Piezo1 senses cell crowding and induces homeostatic life cell shedding  
As investigated in zebrafish dermis and cell culture by Eisenhoffer et al, A Suggested role of Piezo1 
in sensing cell density triggering homeostatic cell shedding in human colon epithelium, zebra fish fin 
tip and cell culture monolayers, cell movement pictured as black arrows, at top of colon epithelium, 
tip of fins and middle of monolayers, cell density is highest due to cell movement leading to shedding. 
Inhibition of Piezo1 using gadolinium or knockdown of the protein causes formation of cells masses 
in the zebrafish fin model caused by decreased cell shedding (not shown) B Model of induced versus 










More recently, Gudipaty et al. [315] published a follow-on study describing the 
involvement of Piezo1 in controlling mitosis by sensing mechanical stretch. In 
MDCK-II monolayers, grown on elastic supports, stretching decreased cell density, 
which in turn increased stretching forces in the cell membrane, and was associated 
with increased cell division to return cell density to normal levels. In a pathological 
stretch-induced injury MDCK-II model, wounds or gaps in the epithelium were also 
closed through increased mitosis. Inhibition of Piezo1 with gadolinium or knock 
down by short interfering RNA (siRNA) was shown to inhibit this response, leading 
to a reduction in mitosis, and reduced wound closure, increasing the time required to 
return cell density to pre-stretch levels. In the zebrafish fin, knock down by 
CRISPR/Cas9 (Clustered Regularly Interspaced Short PalindromicRepeats/Cas 9 
nuclease complex) reduced mitosis events and slowed cell turnover. Furthermore, the 
authors were able to correlate the cellular location of Piezo1 with function. They 
showed that when Piezo1 localises to the cell membrane, this correlates with sensing 
stretching forces, which in turn influences mitosis, whilst when located within the 
nuclear envelope, Piezo1 senses cell crowding, and induces live cell extrusion. The 
pathway through which Piezo1 links to mitosis was identified as phosphorylation of 
extracellular signalling kinase 1/2 (ERK1/2), by selective ERK inhibition with 
inhibitor U0126, and assessing the effect of stretching on mitosis. ERK activation 
was shown to induce activation of cycling B transcription, which in turn drives cell 
division.  
Through these studies, the authors have proposed Piezo1 is essential for sensing cell 
crowding at the tip of the zebrafish fin and induction of cell extrusion to maintain 
homeostatic cell numbers. Although the authors did not perform any experiments 
using intestinal systems, they further propose that Piezo1 may also be the main 
regulator of homeostatic cell extrusion within the IE, however the role of Piezo1 
within the intestine has yet to be determined. As Piezo1 has this potential dual role, 
this ion channel may link balanced cell division in intestinal crypts to cell shedding 
at the villus tip, and hence is an interesting candidate for further investigation (Figure 
4-4). Current studies have only utilised models of the zebrafish dermis, and canine 
kidney epithelium as a basis to determine the role of Piezo1. However, investigating 





specific role. Concurrent studies to determine involvement of Piezo1 in pathological 
elevated cell shedding, utilising appropriate physiologically relevant models that 
mimic human intestinal diseases, alongside validation in patient intestinal biopsy 
samples is also required. Performing these studies will further our understanding of 
intestinal barrier integrity in health and disease, and may provide a platform for 
development and design of new therapies. 
 
 
Figure 4-4 Piezo1 suggested to control intestinal epithelial homeostasis by sensing stretch in 
intestinal crypts and inducing mitosis while reacting to crowding at villus tip by 
induction of cell extrusion 
A Theoretical graph of density-dependent Piezo1 function for cell division and cell death: Epithelia 
trend to a steady-state density, X. If density is reduced, stretching causes Piezo1 to activate cell 
division, if it increases, crowding causes Piezo1 to activate cells to extrude and die B Schematic 
showing how Piezo1 (green) localizes to plasma membrane in sub-regions of epithelia that are sparser 
and divide and accumulate into cytoplasmic aggregates in sub-regions that are crowded and extrude 






4.2 Hypothesis and aims 
4.2.1 Hypothesis 
Piezo-1 regulates homeostatic and pathological mammalian epithelial cell shedding. 
4.2.2 Aims 
1. Investigate effect of Piezo1 inhibition on homeostatic cell shedding in 
zebrafish intestinal epithelium and a mammalian intestinal epithelial cell line. 
2. Assess effects of increased, pathological shedding on Piezo1 transcription 
and translation using an in vivo mouse model  
3. Determine localisation of Piezo1 within mouse intestinal epithelial cells 
4. Measure Piezo1 transcription in biopsies of UC patients during active disease 
5. Determine role of the microbiota member B. breve UCC2003, on Piezo1 
translation and transcription  






4.3.1 Inhibition of Piezo1 in zebrafish intestine and mammalian 
intestinal cell culture models increases homeostatic cell 
shedding levels. 
Eisenhoffer et al. and Gudipaty et al. used zebrafish larvae fins (32 hours post 
fertilisation) as a model for homeostatic cell shedding, and showed reduced shedding 
rates when inhibiting Piezo1 using gadolinium at differing concentrations 
(Eisenhoffer et al. - 10 mM, Gudipaty et al. – 10 µm). As it remains unclear if 
Piezo1 inhibition has a similar effect on cell shedding within the intestine, I utilised 
the adult zebrafish mid gut (analogous to the mammalian LI) to investigate the effect 
of gadolinium, and thus Piezo1 inhibition, on intestinal homoeostatic cell extrusion.  
Preliminary experiments (data not shown) using the same concentration of 
gadolinium (10 mM) as Eisenhoffer et al. caused exposed adult fish to die after 2 h, 
suggesting a lower tolerance of adult zebrafish to gadolinium than embryos, as the 
authors were able to collect live embryos after 28h of exposure. When exposing fish 
to lower concentrations of 10 µM (same concentration used as Gudipaty et al.) or 
100 µM gadolinium, fish were alive after 4 h. Interestingly, at both concentrations of 
the inhibitor, an increase in cell shedding was observed within the intestine, in a dose 
dependent manner with a significantly elevated response (p<0.0001) for fish treated 
with 100 µM gadolinium as determined by histological analysis of F-actin formation 






Figure 4-5 Inhibition of Piezo1 in zebrafish intestine and mammalian intestinal cell culture 
models increases homeostatic cell shedding events 
A Zebrafish exposed to piezo1 inhibitor gadolinium at 10 and 100 µM for 4 h and intestinal cell 
shedding funnels enumerated by staining for F-Actin, data shown as funnels per micron of midgut 
epithelium, mean +/- SD (n=6), 30 villi per biological repeat counted, image shows representative 
zebrafish midgut villus stained with F-actin to visualize shedding funnels (white arrow). B Confluent 
IEC-6 monolayers grown on chamber slides were treated with 100 µM Gadolinium for 2 h followed 
by staining of F-actin to count cell ring formations around shedding events, data are shedding events 
per um2, mean +/- SD (n=9), three images per chamber enumerated, representative image shown with 
white arrow highlighting shedding funnel. C Cells shed into the supernatant were collected after 
exposure of confluent IEC-6 monolayers to 1, 10 and 100 µM gadolinium for 2h and visualized with 
DNA stain for quantification, data presented as shedding events per mm2 of confluent monolayer, 
means +/- SD (n=12), three images per well captured, representative image of shed cells collected by 





p<0.0001), data analysed with Mann Whitney U test (B) and Kruskal-Wallis and Dunn’s post hoc test 
(B,C). 
To further assess the role of Piezo1 inhibition within the intestine, I utilised the rat 
small intestinal epithelial cell line IEC-6. Both Eisenhoffer et al. and Gudipaty et al. 
utilised an in vitro cell line derived from canine kidney epithelium, rather than IE, 
and measured cell shedding by enumerating extruded cells. Cell shedding funnels 
can be quantified by exposing confluent IEC-6 monolayers grown on chamber slides 
to 100 µM gadolinium for 2 h; subsequent staining with phalloidin for F-actin can 
then be used as a measurement of cell extrusion. It was observed that under these 
homeostatic conditions, gadolinium caused a significant increase (p<0.05) in cell 
shedding as determined by funnel enumeration (Figure 4-5.B). A significant 
(p<0.0001), and dose dependent increase was also observed when quantifying the 
number of extruded cells in the supernatant at 2 h when exposed to 10 and 100 µM 
inhibitor (Figure 4-5.C).  
These data indicate that Piezo1 inhibition by gadolinium, under homeostatic 
shedding, resulted in increased cell extrusion, rather than a reduction as observed in 
the zebrafish dermis, suggesting a different role for Piezo1 within the IE of zebrafish 
and mammalian intestinal cell culture models. 
4.3.2 Piezo1 protein levels are not influenced by experimentally-
induced elevated cell shedding in mouse small intestine and 
large intestine. 
To further investigate the function of Piezo1 in a more translationally relevant 
mammalian intestinal model, I focused my next studies on the mouse intestine. 
Previous studies indicate that Piezo1 is highly expressed in tissues exposed to strong 
mechanical forces such as the bladder, lung, or endothelium [308]. Therefore, to 
compare expression levels in the mammalian gut, I analysed Piezo1 transcription in 
the small and LI, and compared it to the lung, to analyse organs with differing levels 
of stretch and crowding forces (Figure 4-6). Lung tissue was observed to have 
significantly higher (p<0.05) Piezo1 expression when compared to small intestinal 






Figure 4-6 Piezo1 expression is higher in mechanically more active lung tissue compared to 
small and large intestine 
Piezo1 expression measured under homeostatic conditions in mouse small intestine, large intestine, 
and lung by qPCR, mean +/- SD shown, n=3, statistical significance (*=p<0.05) analysed with 
Kruskal-Wallis and Dunn’s post hoc test, qPCR results normalized to house keeper and relative to 
small intestinal expression by deltadeltaCT method. 
Gadolinium is toxic to mice, causing lesions, leading to capillary embolism and liver 
and spleen necrosis 48 h after single intravenous injection of gadolinium III chloride 
[313, 316]. Hence, I was unable to utilise this Piezo1 inhibitor in my in vivo 
experiments due to animal welfare constrains, as well as potential off-target effects 
of toxicity on shedding. Hence, I applied an established model of pathologically 
elevated small intestinal cell shedding, induced by systemic administration of LPS 
[289] previously discussed (section 1.1.5.1). In brief, TLR4 presenting monocytes, 
including macrophages and dendritic cells, within intestinal tissue respond to 
systemic LPS and produce and release TNF-α, which in turn binds to TNF-R1 on 
intestinal epithelial cells. This causes cell extrusion, via apoptosis induced by 





between Piezo1 expression and increased sensing of shedding inducing events, as 
well as elevated signalling responses, causing higher levels of cell extrusion. 
 
Figure 4-7 Systemic LPS administration induced small intestine apoptotic cell shedding  
As shown by Williams et al. [317], A Schematic of LPS IP induced elevated SI cell shedding model 
in mice, mice injected IP with PBS (control) or 1.25 and 10 mg/kg LPS, tissue collection 90 min most 
administration and apoptotic shedding observed by caspase-3 standing of small intestinal sections B 
Histological images of small intestine 90 min post LPS injection stained for caspase-3, LPS induces 
strong apoptotic response in small intestine IECs, representative images shown, apoptotic shedding 
events return to normal levels at 4 h post injection (not shown). 
The applied model induces caspase-3 positive cell extrusion by intraperitoneal (IP) 
injection of LPS from the SI villus, in a dose and time dependent manner. At 90 min 
post injection, the strongest shedding response can be observed with shedding rates 
returning to physiological levels at 4 h post challenge. An injection of 10 mg/kg LPS 
is the highest dose possible to inject due to animal welfare constraints and induces 
the strongest response, whilst 1.25 mg/kg LPS is the lowest concentration at which 
an effect on shedding can be measured. 
To compliment analysis in whole tissue samples, and to correlate Piezo1 specifically 





method, the epithelial monolayer was stripped from the underlying stroma while 
leaving the LP intact. As systemic LPS challenge of mice causes acute inflammation, 
and destruction of the intestinal epithelial lining, as well as changes to the villus 
morphology, I tested the purity of IEC isolations using FACS staining for dead cells 
(PI) and a common leucocyte marker CD45+. The analysis showed preparations to be 
free of contaminating leukocytes, as well as a high percentage of viable IECs 
(Supplementary Figure 1). 
When analysing Piezo1 expression in whole SI, expression levels were significantly 
elevated at 1.5 h post IP injection, when compared to the control group (PBS 
injected), in both 1.25mg/kg (p<0.0001) and 10mg/kg LPS (p<0.005) challenged 
mice. However, at 4 h post challenge, expression was no longer significant compared 
to control. Notably, in isolated IECs, whilst Piezo1 expression was somewhat 
increased at 1.5 h post injection for both LPS concentrations, this was not 







Figure 4-8 Piezo1 protein levels are not influenced by experimentally induced elevated cell 
shedding in mouse small intestine 
A Piezo1 transcription during altered shedding rates was measured by qPCR in whole small intestine 
and IEC isolations comparing 1.25 and 10 mg/kg LPS administration at 1.5 and 4h post challenge 
(IECs collected at 1.5 h time point), qPCR results normalized to HPRT and relative to control 
(deltadetlaCT method), data shown as mean +/- SD, WSI n=9 IEC n=6 B Piezo1 protein content in 
WSI and IECs quantified by ELISA in paired samples from A, data are fractions of Piezo1 (pg) per 
whole SI (mg) or IEC protein (mg), statistical significance (*=p<0.05, ** p<0.005, *** p,0.0005, 
**** p<0.0001) analysed with Kruskal-Wallis and Dunn’s post hoc test . 
To validate the Piezo1 expression data, I also measured protein levels to determine if 
a greater number of ion channels correlated with apoptotic shedding levels. Paired 
samples used for qPCR analysis were analysed for protein concentration by ELISA 
(Figure 4-8.B). Notably, WSI Piezo1 protein levels showed no significant difference 
during elevated cell shedding induced by 1.25 mg/kg LPS at 1.5 and 4 h post 
injection, compared to the control group. However, a significant decrease (p<0.005); 
compared to control levels, of Piezo1 protein was observed at 1.5 h post 





but not significantly different, increase of Piezo1 protein during LPS challenge in 
both treatment groups.  
The small and LI differ in physiology and histology, with cell shedding being 
investigated by application of different models. To explore the possible role of 
Piezo1 in colonic cell extrusion I applied a mouse model of acute colonic colitis by 
DSS in drinking water [288]. As expected I observed acute inflammation and 
hyperplasia and elevated disease activity index and colonic weight (p<0.05,  
Supplementary Figure 2). However, inflammation of the LI did not affect Piezo1 
expression, as shown by a non-significant change in transcription compared to 
healthy control tissue (Figure 4-9). 
 
Figure 4-9 DSS induced colitis does not influence piezo1 transcription in large intestinal 
tissue 
Large intestinal tissue analysed by qPCR for Piezo1 expression in mice with acute colonic colitis 
induced by administration of dextran sodium sulphate (DSS) in drinking water for 7 days, results 
normalized to HPRT and relative to control (deltadetlaCT method), data analysed with Mann Whitney 





Taken together, my results indicate that whilst Piezo1 transcription in whole SI 
tissue is modulated during small intestinal inflammation, this did not correlate with 
isolated IEC samples, or Piezo1 protein expression, indicating Piezo1 may play a 
somewhat different role in this system. 
4.3.3 Piezo1 RNA and protein in IECs is located in the cytoplasm at 
the villus tip and membrane associated in the crypt. 
As localisation of the protein appears to be linked to its functional effect; Gudipaty et 
al. showed Piezo1 to be localised to the cell membrane or in nuclear aggregates in 
zebrafish or in vitro, I investigated the location of Piezo1 RNA and protein in the 
mammalian gut. With RNAscope, an immunofluorescent in situ hybridisation 
method allowing for visualisation of transcripts by bright field microscopy, I 
observed localisation of Piezo1 within small intestinal epithelial cell crypts, with 
fewer to no transcripts in IECs at the top of villi (Figure 4-10.A). The intracellular 
position in the control group is basolateral, and interestingly Piezo1 transcription 
also appeared to occur in cells present in the villus stroma. In contrast, in LPS 
challenged mice, greater Piezo1 staining was observed in epithelial cells overall, 
with a more pronounced increase observed in crypts (as well as villus stroma). 
Quantification of transcripts per IEC supports this qualitative observation as 
transcripts were present in significantly higher numbers (p<0.05) overall along the 
crypt-villsu axis in LPS challenged SI compared to control, with greater differences 
towards the villus crypt (Figure 4-10.B). Intracellular localisation appears unaltered, 







Figure 4-10 Piezo1 transcripts is increased by LPS induced cell shedding with more 
pronounced effects in intestinal crypts 
A Piezo1 transcripts visualised by RNAscope in the small intestine under physiological conditions 
(control group) and during elevated cell shedding (“10 mg/kg LPS” IP injection, collection 1.5 h 
post), representative bright field microscopy images, brown spots: Piezo1 transcripts, counter stained 





control and LPS injected groups, n=5 (12 villi per sample counted), data shown as mean +/- SD, 
statistical analysis by two-way ANOVA (* p<0.05). 
To investigate the intracellular protein position of Piezo1, immunofluorescent 
staining of small intestinal cryosections was performed. In agreement with the 
transcript localisation, during homeostasis Piezo1 staining was more pronounced in 
the crypt compared to the villus tip (Figure 4-11). In crypt luminal cells, the protein 
was directly associated with the cell membrane while localised more nuclear in IECs 
at the villus tip with this pattern was also observed in LPS challenged mice. 
However, Piezo1 was not localised to the cell membrane at the villus tip IECs, but as 
previously indicated for RNAscope, LPS-induced epithelial destruction made 
accurate observations difficult. 
 
Figure 4-11 Piezo1 protein in small intestinal epithelial cells is located in the cytoplasm at the 
villus tip and to the luminal cell membrane in crypts 
Localisation of Piezo1 protein at villus tip and crypt base in mouse small intestine in control mice 
(homeostasis) and LPS injected mice (increased cell shedding) visualised by IF staining. 
Representative images shown, green: Piezo1, blue: nuclei (DAPI), LPS administration at 10 mg/kg 





In summary, this suggests cell membrane villus crypt, and cytoplasmic villus tip 





4.3.4 Altered mouse intestinal microbiota does not influence Piezo1 
protein expression during physiological and elevated cell 
shedding rates.  
The gut microbiota plays an essential role in regulating intestinal homeostasis, and it 
has been recently reported to influence IEC gene expression and function [318]. 
Therefore, the microbiota may be expected to play a role in Piezo1 function, with 
respect to epithelial physiology. Hence, I investigated this by comparing Piezo1 
transcription levels in WSI and WLI of conventionally raised and GF mice. GF mice 
were raised and housed in a sterile environment and gnotobiotic status verified by 
culture independent (faecal cytox stain, Supplementary Figure 3) and dependent 
methods (faecal expansion culture, Supplementary Table 4). Notably, there was no 
significant difference in Piezo1 expression observed in the SI and LI when GF mice 
and conventionally raised animals were compared (Figure 4-12), indicating that the 
gut microbiota does not appear to play a role in Piezo1 expression. 
 
Figure 4-12 Intestinal Piezo1 expression is not influenced by microbiota colonisation status of 
mice 
Piezo1 expression in mouse small (A) and large intestine (B) of conventionally raised (SPF) and germ 
free (GF) mice, quantified by qPCR, data normalized by deltadetlaCT method to housekeeper and 






GF mice are underdeveloped in terms of epithelial and immune physiology and 
therefore may not represent the best model for determining impact of the microbiota 
in Piezo1 on cell shedding. I also determined that GF mice show a slightly decreased 
proliferation of intestinal epithelial cells, when compared to SPF controls, by 
quantification of Ki 67 positive cells (marker of proliferation), which agrees with 
previous studies (Supplementary Figure 4) [319, 320]. Importantly, more specific 
changes in microbiota composition, including reduction in overall diversity, have 
been correlated with pathologies. Especially gut inflammatory pathologies, including 
UC, are associated with a significant reduction in particular species including the 
microbiota member Bifidobacterium (reviewed in 1.4.6) [321]. Notably, 
administration of Bifidobacterium longum to patients suffering from UC has been 
associated with a reduction in relapse frequency [322, 323]. 
 
Figure 4-13 B. breve UCC2003 colonisation protects small intestinal epithelial cells from LPS 
induced apoptotic cell shedding  
As shown by Hughes et al., 2017 [46], schematic of protective effect of B. breve from LPS induced 
elevated SI cell shedding, mice gavaged with 109 cfu B. breve on three consecutive days prior to 1.25 
mg/kg LPS IP injection, tissue collected 90 min post, cells being shed from small intestinal epithelium 
visualised with caspase-3 stain, strong reduction of shedding event in B. breve colonised mice, 






Recently, it has been shown that B. breve UCC2003 reduces pathological intestinal 
epithelial cell shedding in the LPS mouse model, as utilised in my previous 
experiments [46]. Mice pre-colonised with B. breve, have reduced numbers of 
caspase-3 positive cells and epithelial destruction which will be further discussed in 
section 5.1.1 (Figure 4-13). As previously mentioned (1.1.5.1), systemic LPS 
administrations induces cell shedding via release of TNF-α from macrophages, 
which induces apoptosis in IECs via binding to TLR-4. However, the protective 
effect of B. breve appears to be independent of TNF-α production by mononuclear 
cells, but rather via signalling through epithelial-specific Myd88 and the 
bifidobacterial EPS capsule. I hypothesised that B. breve may impact Piezo1, which 
in turn could play a partial role in modulating cell shedding. Mice were gavaged with 
B. breve UCC2003 for three consecutive days leading up to LPS challenge, with 
colonisation levels up to 108 cfu/mg at time of tissue collection, while no 
bifidobacteria could be cultured from control group (i.e. PBS) faeces (Figure 5-4 and 







Figure 4-14 Colonisation by B. breve UCC2003 does not influence Piezo1 protein expression 
during physiological and elevated cell shedding rates 
SPF mice gavaged with PBS (control) or B. breve UCC2003 (UCC2003 group) for 3 days prior to IP 
administration of LPS (UCC2003 group), tissue collected 1.5 h post administration A Piezo1 
expression in whole small intestine (WSI) and small intestinal epithelial cell isolations (IEC) 
measured by qPCR, data analysed by deltadeltaCT method normalized to housekeeper and relative to 
control B Piezo1 protein quantified by ELISA in paired samples from A, data shown as fraction of 
Piezo1 (pg) per whole SI (mg) or IEC protein (mg), statistical significance (*=p<0.05) analysed with 
Kruskal-Wallis and Dunn’s post hoc test, data shown as mean +/- SD, n=5. 
When analysing intestinal Piezo1 transcription in this model, I observed no 
significant differences in B. breve colonised mice in whole intestinal samples, when 
compared to control mice during homeostatic conditions at 1.5 h post challenge 
when the cell shedding protective effect is demonstrated. Analysing intestinal 
epithelial transcription, Piezo1 expression was elevated in LPS samples compared to 





was observed between control group and B. breve colonisation either during 
homeostasis or during elevated shedding (Figure 4-14.A).  
When measuring Piezo1 protein ratios, Piezo1 levels appeared unaffected by B. 
breve colonisation during homeostasis, as well as during LPS-induced elevated 
shedding, in both WSI and IEC isolation when compared to non-colonised mice 
(Figure 4-14.B). No difference between control and LPS treated samples in Piezo1 
protein expression was observed. 
In summary, these data indicate that the strong protective effect from pathological 
cell shedding by B. breve colonisation is not conferred by Piezo1. 
4.3.5 Piezo1 expression in not altered in Ulcerative Colitis human 
colonic tissue. 
As previously highlighted, intestinal epithelial cell shedding is important for gut 
homeostasis and elevated or pathological shedding plays a key role in the aetiology 
of intestinal pathologies such as UC [27, 32, 39]. To address the translational aspect 
of a potential involvement of Piezo1 in controlling intestinal shedding in human 
patients, I investigated transcription levels in human colonic biopsies, comparing 
expression rates in healthy colonic tissue, to patients suffering from acute inflamed 
UC (Figure 4-15.A). However, I did not observe a significant change in expression 
and additionally the level of inflammation did not appear to be an influencing factor, 
as biopsies from UC patients with mild (UC-R), versus severe inflammation (UC-I), 
both present with no significant changes to Piezo1 expression (Figure 4-15.B).As 
mentioned above, B. breve provides protection from inflammation-induced cell 
shedding in vivo, and reduced levels of bifidobacteria have been observed in patients 
suffering from UC. Thus, I also investigated the effect of Bifidobacterium on Piezo1 
transcription in the human colon. Colonic biopsies from healthy volunteers and 
patients with mild (UC-R) and severe (UC-I) UC inflammation were co-cultured 
with 107 cfu/ml B. breve UCC2003 (UCC2003) or sterile media (Control) in pIVOC 
for 8 h followed by Piezo1 RNA measured by qPCR (Figure 4-15.C). No significant 
change in transcription was observed in all three patient groups comparing 






Figure 4-15 Piezo1 expression in human colonic tissue is not altered by active inflammation 
induced by Ulcerative Colitis 
A Colonic biopsies collected from healthy volunteers (control) and patients suffering from Ulcerative 
Colitis with active inflammation, piezo1 transcription quantified by qPCR, n=3 B PIEZO1 expression 
in human colonic tissue of healthy volunteers and Ulcerative Colitis patients in remission (UC-R) and 
active inflammation (UC-I) assessed by qPCR, n=3 C Human biopsy samples paired with B co-
incubated with apical Bifidobacterium breve UCC2003 in pIVOC (polarised in vitro organ culture) 
for 8 h, control group incubated with no bacteria, PIEZO1 transcription quantified by qPCR, n=3, 
statistical significance analysed with Mann Whitney U test (A, C) and Kruskal-Wallis and Dunn’s 
post hoc test (B), data are mean +/- SD, qPCR results analysed by deltadeltaCT method (normalized 
to housekeeper, relative to control/healthy group expression). 
Taking together, these results suggest that Piezo1 expression in the human colon is 








The control of epithelial cell shedding from the tip of intestinal villi is essential the 
intestinal physiological homoeostasis [27, 31]. Dysregulation of this process can 
cause epithelial barrier breakdown and is involved in pathologies such as UC [307]. 
Hence, understanding the underlying mechanisms of cell shedding is of great 
importance 
Recent publications by Eisenhoffer et al. [37] and Gudipaty et al. [315] have 
identified the mechano-sensitive Piezo1 as a main regulator of cell shedding and 
division. The authors used the fin of zebrafish embryos and canine kidney cell lines 
as study models, and were able to show that Piezo1 senses cell crowding at the tip of 
the fin and induces cell extrusion to maintain homeostatic cell numbers. The authors 
proposed the channel may also be the missing link between cell shedding and 
expansion, as they observed increased mitosis in areas of decreased cell density 
causing membrane stretch. However, these functions of Piezo1 have not been 
investigated within the intestine and I applied in vivo zebrafish and mouse models as 
well as in vitro cell culture and ex vivo human biopsy models to understand the role 
of Piezo1 in cell shedding in the mammalian IE. 
Previously, the role of Piezo1 in the zebrafish fin was investigated via inhibition of 
the channel with gadolinium or knockdown via CRISPR, with subsequent 
assessment of effects on homeostatic shedding and mitosis [37, 315]. To further 
probe the role of Piezo1 in cell turnover in the IE, I also inhibited Peizo1 with 
gadolinium and assessed cell shedding in the zebrafish intestine. Surprisingly, when 
inhibiting Piezo1 in the zebrafish intestine, the published experimental dose of 
gadolinium by Eisenhoffer et al. led to early death in adult fish, indicating a stronger 
toxicological effect of the compound in adult zebrafish than in its progeny. Exposure 
to gadolinium, at similar concentration used by Gudipaty et al., did not cause 
reduced cell shedding, but rather induced cell shedding in a dose dependent manner, 
indicating a different role for Piezo1 within the adult zebrafish intestine compared to 
the fin. It is possible the gadolinium has an additional toxic effect on the adult 
zebrafish (differing from the zebrafish larvae in effect inhibitor concentration), 
which may impact the apoptotic cell shedding response, which could be further 





extruded cells [324]. With the recently described role of Piezo1 in influencing 
mitosis as a response to cell stretching, it may be that inhibition of the channel in the 
gut prevents a reduction of cell division in the intestinal crypts, and hence increases 
overall cell numbers within the epithelial monolayer, counterbalanced by increased 
shedding. A potential link between cell shedding and expansion has been heavily 
investigated, as reduced cell division could lead to reduced extrusion based on fewer 
numbers of enterocytes moving up the villus and hence reduced crowding at the tip 
[34]. Although stem cell expansion is the driving force of enterocyte migration 
towards the villus; whether rate of cell loss from the villus impacts expansion rates is 
still unclear [25], however ongoing studies in chronic inflammation models have 
indicated that SI villus damage, and cell death, does not correlate with increased 
crypt proliferation (Parker et al., unpublished data). In contrast, acute injury of the 
colonic epithelium induces increased proliferation of stem cells in neighbouring 
crypts leading to wound closure. This process is delayed compared to the epidermis 
where proliferation occurs at time of injury, while in the colon expansion takes place 
at later phases of wound healing; highlighting the differences in homeostasis and 
response to injury based on tissue types [325]. Although, Piezo1 knockdown in 
zebrafish fins appears to reduce mitosis and extrusion, suggesting a role in dermis 
homeostasis, our contradictory intestinal findings, of increased shedding rates after 
Piezo1 inhibition, indicate that other factors may play a role in the more 
physiologically developed adult zebrafish intestine.  
To further probe the impact of Piezo1 with respect to the IE, I also examined a 
mammalian cell culture system; IEC-6 monolayers, a rodent intestinal cell line, 
which was exposed to gadolinium at concentrations identical to the ones used by 
Eisenhoffer et al. and Gudipaty et al. (these authors used MDCK-II canine kidney 
cells). Contrary to previous studies, I observed that Piezo1 inhibition resulted in 
increased cell shedding during homeostatic conditions with no forces applied. 
However, Eisenhoffer et al. crowded and Gudipaty et al. stretched, and additionally 
performed a wound healing assay on the epithelium (MDCK-II cells). I sought to 
mimic physiological extrusion levels, rather than using external mechanical forces, 
and would therefore expect Piezo1 inhibition to reduce cell extrusion and division, 





may correlate to the different cell lines used (intestinal vs kidney), and methods of 
shedding quantification as I both reproduced the method applied by Eisenhoffer et 
al. (enumerating cells extruded into supernatant), and in addition quantified 
formation of shedding rings within epithelial monolayers, which could be a more 
direct measurement of shedding events. It should also be mentioned that mechanical 
forces acting on the dermis, kidney and IE differ greatly [326]. The epidermis is 
under constant stretch and crowding, with epithelial turnover being constant due to 
injury and exposure to the external environment [327]. Therefore, the dermis does 
share some similarities with the IE (i.e. exposure to substances passing through the 
GI tract), however the strength of applied forces is significantly less pronounced in 
the IE [328, 329]. In addition, the zebrafish fin is a specific epidermis structure with 
its overall macroscopic structure being like the intestinal villus, but differing at the 
microscopic level, with the fin epithelium being layered and without directional cell 
movement. Regarding cell culture models, the IEC-6 cell line is widely used in 
investigating intestinal mechanisms, while MDCK-II cell were generated from 
kidney epithelial cells, which are thought to not proliferate in vivo unless injured 
[330, 331]. Further investigation, especially observing the effect of cell crowding 
and stretching in an intestinal cell line would offer further insights into the role of 
Piezo1 in IE homeostasis. This could be particularly interesting as the wound healing 
assay performed by Gudipaty et al. mimics not only cell sparsity in the intestinal 
crypt, inducing mitosis, but also potentially decreases cell density (causing 
membrane stretch), when single cells are extruded at the villus tip. Hence, Piezo1 
could be involved in homeostatic cell shedding, as well as pathological extrusion 
(more cells lost = more membrane stretch), and may be important for epithelial 
repair. Furthermore, previous studies have determined that overcrowding is sensed 
by Piezo1, which sets in motion a downstream cascade involving S1P signalling and 
RHOK activation, followed by myosin contraction and cell expulsion. More 
recently, Gudipaty et al. connected Piezo1 sensing of cell density to cell division via 
phosphorylation of ERK1/2 leading to activation of cycling B transcription which in 
turn drives mitosis. However, a possible connection between cell cycle control to cell 





Whilst cell lines as model systems are useful to probe potential mammalian Piezo1 
mechanisms, it is significantly worthwhile to also examine the role of Piezo1 in 
more complex and translationally relevant preclinical models. As an ion channel, the 
control of ion flux by Piezo1 across the cell membrane is essential for its 
physiological effect, therefore the use of gadolinium as an inhibitor in mammalian 
systems, including the mouse, is not possible due to its toxicity, which will be 
discussed in the future work section of this chapter [309, 316]. Recently, GsMTx4, 
another mechanosensitive ion channel selective blocker isolated from Grammostola 
rosea spider venom, has been successfully used in ex vivo mouse tissues and in vivo 
pig models, and thus may represent a tool for studying Piezo1 in mouse models 
(toxicity and dose-effect to be measured) [332, 333]. Eisenhoffer et al. and Gudipaty 
et al. knocked down Piezo1 in cell culture models and zebrafish via CRISPR and 
with translation-blocking morpholino. However, both methods are difficult to apply 
consistently in vivo particularly when targeting the IE, due to problematic delivery 
orally through the stomach or the rectum, and Piezo1 knock out mice die at mid-
gestation due to defects in vascular remodelling [334]. Therefore, I decided to 
analyse Piezo1 transcription and translation as measurements correlated to intestinal 
epithelial turn over, however I acknowledge changes in levels may not be fully 
required for modulation of cell shedding-associated signalling events. 
I chose to utilise the LPS in vivo model as it correlates with human UC patient 
pathological shedding, and it provides a rapid and increased rate of shedding, 
expected to mimic high epithelial cell turnover, and thus relevant for studying the 
role of Piezo1. Interestingly, when I profiled Piezo1 expression in different mouse 
tissues (during homeostasis), there was a strong link with increased expression in 
organs undergoing constant mechanical movement such as the lung, whereas the 
small and LI had lower transcription [335]. This may be since, whilst the intestine is 
macroscopically exposed to peristaltic movement, and microscopically to 
lengthening and shortening of villi, this is relatively low mechanical induction, when 
compared to high mechanical forces at work within the lung [336, 337]. 
Notably, whilst I observed an increase in Piezo1 expression within whole SI 
homogenates during LPS induced pathological cell shedding, I did not observe any 





Piezo1 may also be localised to a different intestinal cell or tissue type. Notably, 
Piezo1 is highly expressed in blood vessel and lymphatic vasculature, and these 
structures could play a critical role in the shedding model, as inflammation is 
associated with increased vessel formation to allow trafficking of immune cells e.g. 
macrophages, which are involved with localised tissue injury and are required for 
TNF-α release and apoptotic cell shedding [338-340]. Therefore, these changes, 
correlated to elevated Piezo1 expression, which may indirectly influence the 
shedding phenotype. This potential role requires further investigation in this mouse 
model as well as patients suffering from IBD. 
As Piezo1 is a mechanosensitive ion channel protein, it is important to correlate 
transcription with protein. I observed increased WSI transcription during elevated 
shedding, which was not recapitulated by protein levels. To note, both transcription 
and protein levels were not statistically altered in IECs. The discrepancy between 
RNA and protein levels in the analysed paired samples could be due to rapid 
transcriptional responses, but delayed translation. It should also be mentioned that 
Piezo1 would not necessarily require changes in protein levels to increase signalling 
levels when inducing cell shedding. As an ion channel, even unchanged levels of 
Piezo1 could modulate and amplify signalling via ion flux across the cell membrane, 
and even slight alterations of ion channel numbers can potentially have great effects 
due to signal amplification [341]. This hypothesis would benefit from further 
investigation, and may be tested using GsMTx4 once this is validated in mouse 
models [333].  
To comprehensively cover the role of Piezo1 in the gut epithelium I also examined 
expression within the LI using DSS to induce large intestinal colitis (a well-
established model for UC [95]) and epithelial shedding, as the LPS mouse model 
induces cell shedding only within the SI. However, as observed in the SI, colonic 
inflammation and epithelial shedding did not affect Piezo1 transcription levels 
further suggesting that Piezo1 transcription does not play a role in mammalian 
pathological cell shedding, and other non-Piezo1 factors may be involved in this 
process. Interestingly, epithelial-associated villin is a potential candidate, which in 
its full-length form has anti-apoptotic functions, whilst cleavage induces apoptosis, 





enterocytes and binding to actin maintains mitochondria stability, which is essential 
for shedding funnel formation. Importantly, as the form of villin, and thus its 
function, is controlled by intracellular calcium concentrations, this suggest that 
Piezo1 is not involved in intestinal epithelial barrier homeostasis, as it appears to be 
calcium independent, and therefore villin may be an interesting candidate to focus on 
in future studies [38, 342].  
Previous studies have indicated that Piezo1 is localised to the cell membrane in 
regions of low cell density, and in nuclear aggregates at sites of epithelial crowding. 
It has been hypothesised that the separate functional effects of Piezo1 on mitosis and 
cell shedding, and sensing of cell crowding and sparsity, is influenced by its cellular 
location. Translating this to the intestinal villus, cell expansion in the crypt could 
lead to lower cell density due to cell migration up the villus, causing Piezo1 to 
localise to the cell membrane, whilst at the villus tip the cell would expected to be 
crowded and Piezo1 would be expected to localise more within the nucleus. Indeed, 
IF microscopy imaging indicated that Piezo1 was localised within the cell membrane 
of crypt cells, and more nuclear at the villus tip, which also agrees with the 
observations by Gudipaty et al. Furthermore, the localisation of Piezo1 transcripts 
presents more basolaterally, which could be explained by post translational 
trafficking of proteins. The increase in transcripts during elevated cell shedding, 
particularly in crypt cells, indicates increased cell division to replenish enterocytes 
lost at the villus tip. The qualitative observation of protein levels not changing 
during elevated cell extrusion mirrors the quantitative ELISA results, and could 
again be explained by delayed protein translation. Unfortunately, the LPS model 
does not allow for tissue collection after 4 h post injection due to ethical constraints 
with respect to mouse welfare. Notably, previous studies indicate that cell expansion 
actually increases forces in the crypt, when compared to pressure in the villus tip 
[343]. Furthermore, as pathological shedding rates leads to the extrusion of several 
cells from the villus tip, decreased cell density generates cell membrane stretch. 
Piezo1 has been shown to induce mitosis in response to stretch, however currently 
no studies have observed cell division outside of the stem cell compartment of the 





the crypt for induction of tissue repair after pathological cell shedding, which could 
be probed further to examine the role of specific Piezo1 localisation in this process.   
As previously mentioned (1.3.3, 1.3.4), the gut microbiota plays an integral part in 
maintaining gut homoeostasis, by interacting with the host immune system and 
IECs; a key crosstalk interface [344-346]. Therefore, I also sought to investigate the 
effect of the microbiota on Piezo1 transcription. Initially, I assessed this in GF mice 
as a completely ‘clean’ system, however, there were no differences in Piezo1 
expression in either the large or SI, when compared to SPF mice, which may 
correlate with the reduced IE proliferation observed in these mice. Recently our lab 
determined that B. breve UCC2003 was protective in the LPS-induced cell shedding 
mouse model, making this microbe an ideal candidate to observe the potential role of 
Piezo1 in this health beneficial effect [46]. Apoptotic cell shedding levels in mice 
colonised with B. breve correlated with increasing Piezo1 RNA levels in IECs, 
however this trend was not mirrored by Piezo1 protein content. As previously 
discussed () the ion channel might not be directly involved in cell extrusion, 
therefore future studies utilising Piezo1 knock out models, could investigate if B. 
breve confers its protective effect on the epithelial barrier integrity through Piezo1, 
via a yet to be identified pathway. Unfortunately, Piezo1 KO mouse models suffer 
from pre-weaning lethality, which does not allow us to further test the role of Piezo1 
in this model [334]. Conditional KO models may be useful for future studies, but the 
cell type involved would need to be identified as my studies indicate epithelium-
associated Piezo1 may not play a prominent role.  
Thus far, the role of Piezo1 in intestinal cell shedding has been tested using mouse 
models of acute intestinal inflammation. However, it may be that this protein 
regulates extrusion within the human intestine during more chronic inflammation, 
thus I investigated RNA levels in the human intestine from patients suffering from 
UC (mild, moderate and sever disease). If Piezo1 is involved in UC pathology I 
would expect a strong signature, particularly in the moderate and sever disease 
samples, as well as the ex vivo pIVOC samples tested, however I did not observe 
any differences in transcription levels, supporting my mouse model findings, and 
further emphasising that Piezo1 may not be involved in intestinal epithelial 





In summary, previous studies have utilised the zebrafish fin and canine kidney cells 
as models to understand the role of Piezo1 in controlling epithelial cell shedding and 
mitosis. These models are suitable for observing the function of Piezo1 within the 
dermis and the kidney epithelium, but as these tissues differ significantly in function 
and physiology from the IE, the key regulator position of Piezo1 in the gut, as 
proposed by the authors, has not been corroborated by sufficient experimental 
evidence. My in-depth research studies investigated Piezo1 in zebrafish, mice and 
human samples, and the data presented do not support a role for Piezo1 in intestinal 
cell shedding. More specifically, Piezo1 inhibition in the zebrafish intestine and 
mammalian intestine cell lines did not reduce cell shedding as expected but rather 
increased extrusion, strongly suggesting Piezo1 not to be involved in homeostatic 
cell shedding in the gut epithelium, or to have an alternate role. During mammalian, 
pathological cell shedding, Piezo1 protein levels were not affected by inflammation 
status and elevated extrusion rates in IECs in both mice and in human colonic 
biopsies of UC patients, suggests that differential Piezo1 translation does not play a 
role during inflammation-induced cell shedding. However, I did determine that in the 
SI Piezo1 is located to the cell membrane in crypt epithelial cells and 
cytoplasmically in cells at the villus tip. Although, the cellular location of Piezo1 
was aligned with its proposed function of sensing cell density, my other findings did 






4.5 Future plans and hypothesis 
4.5.1 Future work on the role of Piezo1 in intestinal cell shedding 
The recently discovered dual role of Piezo1 in epithelial homeostatic turnover, 
suggested this protein as a promising target for further investigation within the IE. 
The authors of the two key publications proposed Piezo1 as a key regulator in 
intestinal homeostasis, but based their findings in non-relevant models for intestinal 
studies i.e. zebrafish dermis, kidney cells, crowding and injury, therefore there was a 
requirement for further tissue-specific investigations. 
Based on my results, it is unlikely that Piezo1 is involved in pathological 
mammalian intestinal cell shedding, however the correlation of cellular localisation 
of the ion channel within sites of cell expansion and extrusion is interesting. The 
applied cell culture stretch and crowding model applied by the authors are elegant 
solutions to mimic homeostatic intestinal turnover in vitro. As previously indicated 
the IE is not expected to be under the same mechanical forces as observed in a 
zebrafish fin, nevertheless applying this model to more relevant intestinal cell lines 
could shed light on the involvement of Piezo1 in the processes within the gut, but 
studies would require the reproduction of the applied cell culture apparatus. The 
wound healing assay may represent an easier system to test, but these studies may 
only generate very preliminary data, due to the physiological differences in relation 
to injury and healing within the IE, when compared to the models previously used in 
this system. 
As I did not quantify cell division rates, this would be the first potential future study 
to investigate the involvement of Piezo1 in modulating intestinal epithelial turnover. 
The ion channel could be involved in sensing cell density in the stem cell 
compartment and influence cell shedding in an indirect manner, based on enterocyte 
migration to the villus tip; homoeostasis - balanced expansion and shedding, injury - 
repair by increased mitosis. Analysing Piezo1 transcript and protein levels in IECs 
isolated from intestinal crypts, and comparing homeostatic conditions with elevated 
shedding rates, may answer this question. To achieve this, I would perform Weisser 
isolations of IECs and split the EDTA incubation into several steps, as villus IECs 





measuring proliferation by staining for Ki67 positive epithelial cells during changes 
to cell extrusion rates induced by LPS. Unfortunately, the difficulty of not being able 
to specifically inhibit Piezo1 in the mouse due to gadolinium toxicity remains, and 
conditional KO mouse models would have to be developed. This was the reasoning 
for my application of the LPS model to modulate shedding rates and investigate 
changes to Piezo1 expression and protein levels, in a relevant in vivo model. 
Inhibition of proliferation and its effect on Piezo1 control of epithelial homeostasis 
would be important as reduction in epithelial turnover within the intestine would be 
akin to the inhibition of Piezo1 by gadolinium in the epidermis. A potential model to 
apply would be administration of chemotherapy drug cytosine arabinoside (ara-C) to 
mice, as it has shown to be successful in temporarily halting cell division in 
intestinal stem cells at non-toxic concentrations [25]. These studies would measure 
Piezo1 translation and transcription rates as a readout, however there may still be an 
issue of correlating protein levels to ion channel function, which can only be solved 
by directly measuring ion flux across cell membranes. This could be achieved by 
path-clamp, a technique measuring ion channel opening and closing which has been 
successfully used in studying neurons in vivo but so far, no model for the IE has been 
developed [347].  
As mentioned, gadolinium has been shown to have serious toxic effects in mice, with 
a single IV injection of 7.89 µg/g (0.05 mmol/kg) resulting in liver and spleen 
necrosis 48 h later. Therefore, a slow perfusion has been suggested to prevent acute 
and severe hypertension, potentially leading to hypertension and cardiovascular 
collapse [313]. The drug has been successfully applied to deplete macrophages in the 
liver and lung, by administration of similar concentrations of 45 µg/g IP for the latter 
(0.9% GdCl with 5 µl/g administered IP) [348, 349]. Mice were dosed immediately 
after birth, and 7 days post delivery, with tissue collection on day 10 [349]. Hence 
the depletion effect was observed long term, most likely due to the requirement of 
gadolinium mineral deposit phagocytosis, leading to macrophage death [313]. 
Additionally, gadolinium has been applied directly to rat lung epithelium, by lavage, 
which resulted in a detection within the epithelial lining fluid at low levels (5 µg at 
100 µg dosage) for 31 days, with a biological half-life of 136 days. It was suggested 





slow metabolism. Effects on the epithelium were not investigated, but a rapid 
infiltration of calcium ion was detected, leading to lung toxicity in severe cases 
[350].  
These results indicate that systemic administration of gadolinium to inhibit Piezo1 
function, may not be a feasible approach, due to off target effects, such as depletion 
of macrophages (which are important in intestinal homeostasis), organ necrosis, with 
systemic effects, and Ca influx potentially affecting intestinal epithelial physiology 
and cytoskeletal structure. Additionally, the utilised models administered gadolinium 
days before tissue collection (to allow for macrophage depletion), with long-term 
exposure of the IE potentially preventing an accurate assessment of Piezo1 inhibition 
on cell shedding. This is due to shedding rates being difficult to quantify under 
homeostatic conditions, as very few cells are extruded without stimulation.  
Therefore, a short-term gadolinium administration model, confined to the intestine, 
such as via an intestinal loop, may prove effective. This ligation of small and large 
intestinal sections has been used to study short term intestinal epithelial specific 
effects of otherwise toxic or harmful compounds (botulinum and C. perfringens 
toxin), with minimal systemic, and off target effects [351, 352]. Hence, gadolinium 
exposure of the IE within the loop system would allow for rapid and specific 
observation of Piezo1 inhibition effects on cell shedding in a mammalian in vivo 
system. 
It should be highlighted that there is sufficient data presented by Eisenhoffer et al. 
and Gudipaty et al. to conclude that Piezo1 plays a central role in controlling 
epidermis homeostasis, as well as potentially also modulating maintenance and 
repair of the kidney and even lung epithelium, by sensing cell density and controlling 
cell extrusion and mitosis. However, with respect to its role within the intestine, my 
studies suggest that Piezo1 does not have a key role in tissue turnover of the 
epithelium. My investigation involving relevant models, including human intestinal 
biopsies, in both homeostatic and increased shedding did not yield supportive results 
for previous hypotheses regarding the role of Piezo1 in IE regulation, thus before 
undertaking further investigation, the success rate of future studies has to be taken 





4.5.2 Investigating the effect of B. breve on the intestinal epithelium 
during homeostasis and disease  
Modulation of cell shedding is essential for intestinal tissue homoeostasis, due to its 
important role in retaining epithelial barrier function [353]. As pathological shedding 
induces intestinal inflammation, due to uncontrolled contact between luminal 
microbes with the host immune system, understanding the processes involved in cell 
shedding and how host and microbial factors may modulate this, gains even further 
importance [30, 354].  
Based on the recent findings that B. breve UCC2003 protects the mammalian IE 
from pathological cell shedding, this represents an important avenue to explore, 
particularly with regards to development of novel therapies [46]. Probing the role of 
B. breve in epithelial crosstalk will allow me to further understand the mechanisms 
of cell extrusion during inflammation, as well as during homeostasis, as 
Bifidobacteria are resident members of the ‘healthy’ human gut microbiota. In 
addition, generated results will also increase our knowledge of the involvement of 
the gut microbiota and in particular Bifidobacteria in cell shedding as a physiological 
process, which is essential for human health.  
As the investigation of a specific candidate of cell shedding, i.e. Piezo1, did not yield 
positive results, I decided to apply an unbiased approach (via RNA-Seq) to generate 
a global data set to allow a holistic analysis of the protective mechanisms of B. breve 
with respect to modulation of epithelial cell function. These studies will be presented 






5 B. breve UCC2003 induces distinct transcriptional responses in 
small intestinal epithelial cells of neonate mice under 
homeostatic condition 
5.1 Introduction 
The genus Bifidobacterium is an important member of the human gut microbiota 
throughout the life course, and various species/strains have been shown to have 
health beneficial effects, including immune modulation, and colonisation resistance 
to pathogens [156]. Importantly, gut-associated diseases such as IBD, where 
breakdown of the intestinal epithelial barrier is a hallmark feature, are associated 
with lower microbiota diversity when compared to ‘healthy’ controls, and 
specifically a lower abundance of bifidobacteria in IBD cohorts [284, 355]. Recently, 
a novel host beneficial effect, mediated by a specific strain of bifidobacteria has been 
described in an IBD experimental model. This publication by Hughes et al. [46], 
utilised a model of pathological small intestinal epithelial cell shedding, which 
mimics increased epithelial barrier gap formation, one of the initial stages of IBD 
pathogenesis. Oral administration of B. breve UCC2003 protected from 
inflammatory-induced apoptotic cell extrusion, however it is currently unclear what 
the exact underlying mechanisms modulating these protective effects are. Thus, this 
chapter describes the studies I carried out to further explore the beneficial effects of 
B. breve on the host epithelium.  
5.1.1 Bifidobacterium breve reduces LPS induced apoptotic cell 
shedding in the small intestine in a EPS capsule, and Myd88-
dependent manner 
As previously described in Chapter 3, the applied pathological cell shedding 
experimental model is an apoptotic response in small intestine IECs, induced by 
systemic delivery of LPS. This targets tissue residing mononuclear cells, where it 
binds to TLR4 and induces TNF-α release. This cytokine binds to TNF-R1 on IECs, 






Summarising the findings by Hughes et al. [46], (where I am second author), for the 
first time we showed that oral administration of B. breve UCC2003 reduces 
pathological IEC shedding in the SI, induced by LPS IP injection. This was assessed 
by casapase-3 staining of intestinal sections during LPS challenge in mice with and 
without B. breve colonisation (Figure 5-1.A,B), and enumeration of apoptotic cells 
along the crypt-villus axis, which showed a significant reduction in B. breve 
colonised mice (Figure 5-1.C). 
 
Figure 5-1  Colonisation of the mouse GI tract by B. breve UCC2003 decreases apoptotic IEC 
shedding in the small intestine induced by systemic LPS administration. 
A Microscopic image of small intestine of mouse with caspase-3 positive (apoptotic) epithelial cells 
visualised by chromogenic staining 90 min post LPS administration, B Image showing small intestine 
of mouse colonised by B. breve 90 min post LPS injection with apoptotic IECs stained by caspase-3 
positivity, C Comparison of caspase-3 positive IECs along crypt-villus axis in small intestine of mice 
injected with LPS with and without B. breve gavage, adapted from Hughes et al., 2017 [46]. 
Notably, B. breve colonisation did not significantly alter protein and/or transcript 
levels of TNF-α in whole small intestinal tissue. Furthermore, there were no 
differences in F4/80+ macrophages within the tissue, or expression of TNF-R1 in 





macrophage independent, and that modulation of other IEC-specific pathways 
downstream of this cytokine are potentially involved. 
Further studies, using Myd88 KO mice, showed that this central adaptor protein was 
crucial to the apoptotic modulatory effects, as B. breve colonised mice did not show 
any significant reduction in caspase-3 positive IECs, when compared to PBS 
controls. We also observed an increase in TLR2, which is upstream of the MyD88 
signalling pathway. As TLR2 may be involved, we next probed the role of the EPS 
capsule of B. breve, as previous studies indicated that Bacillus subtilis EPS can 
signal via a similar mechanism (via TLR4), and protect from intestinal inflammation 
caused by C. rodentium [356]. Importantly, a B. breve EPS mutant did not protect 
mice from pathological cell shedding, and an isogenic strain (expressing a different 
EPS, EPS2) also did not protect from LPS-induced IEC apoptosis, suggesting an 
EPS capsule dependent mechanism.  
Lastly, we investigated the modulation of specific inflammatory and apoptotic 
signals in the whole SI of both B. breve EPS WT and mutant colonised mice after 
LPS-induced cell shedding. Interestingly, we observed increased expression of 
several genes involved in inflammation and apoptosis including IL-6, TNFSR15, 
BAD, CYCS, CASP4, FAS, TRAF5 and TNFRS9 in EPS deletion mutant colonised 









Figure 5-2 B. breve UCC2003 and EPS deletion mutant modulate specific inflammatory and apoptotic signalling in whole small intestine. 
Transcriptional response of whole small intestine of mice colonised by A B. breve UCC2003 EPS deletion mutant and B B. breve-colonised mice for 
both groups 90 min post IP injected with 1.25 mg/kg LPS. Whole small intestine homogenates analysed by qPCR array for transcription of 





In summary, this study highlights that B. breve induces a protective anti-apoptotic 
response in IECs during pathological cell shedding, in a Myd88 and EPS1 capsule 
dependent manner. 
These data give some insights into the potential mechanisms involved in 
bifidobacterial-associated IEC signalling, however they do not provide a global 
overview of cell signalling changes. Thus, in this chapter I sought to investigate the 
intestinal epithelial transcriptome of IECs to capture wide-spread changes induced 
after B. breve colonisation. Importantly, our previous studies were performed in 
LPS-challenged mice, but this model requires pre-colonisation of the GI tract with B. 
breve UCC2003 for 3 days prior to LPS challenge. Therefore, I decided to probe the 
effect of B. breve on IEC transcription under homeostatic conditions, as it could be 
argued that modulation would take place during normal ‘healthy’ conditions. This in 
turn could modulate protection from disease associated stimulus, such as LPS. 
Furthermore, I expanded these studies to include neonatal mice at 2 weeks of age as 
B. breve is a human infant gut isolate, and the genus Bifidobacterium is a prominent 
member of the gut microbiota in early life. Thus, I hypothesised that host IEC 
modulation may be more prominent during earlier stages of microbial, immune and 
epithelial barrier development, than compared to those observed in adulthood. 
Below I discuss and highlight information regarding the use of sequencing 
technology, and germ-free mice, as well as previously identified health beneficial 
effects and mechanisms of B. breve, which are important to this study. 
5.1.2 Bifidobacterium breve and its role and function in the human 
intestinal tract 
The genus Bifidobacterium, and its role in human health across the whole life span 
has been covered in the general introduction. Below I will give specific examples for 
the species B. breve, and in particular the strain B. breve UCC2003. 
B. breve UCC2003 was first isolated from human infant faeces, and was one of the 
earliest Bifidobacterium strains to have its full genome sequenced, significantly 
aiding in the exploration of its health beneficial effects [279]. In addition, a 





determination of specific gene functions and complementary interaction studies 
[357].  
B. breve UCC2003 produces a cell surface associated EPS, which is transcribed from 
a bidirectional gene cluster, allowing for expression of two different EPS capsules 
[358]. The EPS coat has been shown to promote in vivo persistence, while having no 
observable effects on initial colonisation. Through EPS, B. breve UCC2003 is able to 
stay immunologically silent by circumventing adaptive T cell responses by the host. 
In addition, B. breve UCC2003 reduces the intestinal load of the enteric pathogen C. 
rodentium by potentially forming an intestinal biofilm due to EPS capsule 
production. The importance of the EPS capsule in conferring the protective effect 
from apoptotic cell shedding in the mouse SI has been described above. The 
bacterium also expresses pili in vivo, which aids in host colonisation [279]. 
Host immune modulation of DCs by B. breve C50 has been shown to occur via 
TLR2 signalling, which prolongs overall survival and is effect also conferred by 
culture supernatant suggesting cross-talk via secreted bacterial compounds [359]. In 
human disease, B. breve M-16V has been shown to significantly reduce NEC cases 
in preterm infants [360]. One of the potential mechanisms involved in this NEC 
protective effect, as determined in a rat NEC model, may be via improved intestinal 
barrier integrity, by decreasing IL-16 and TNF-α expression. In the context of IBD, 
trials involving B. breve strains include a randomised control trial of patients 
suffering from low or mild UC that were supplemented with B. breve Yakult for a 
year, and which was associated with improvements in disease symptoms, as assessed 
by colonoscopy [361]. 
Taking this information, together with the previously observed protective effect of B. 
breve UCC2003 from apoptotic cells shedding, I decided to utilise sequencing of the 
IEC transcriptome in neonate and adult mice to identify B. breve specific gene 





5.1.3 Utilising RNAseq to assess global transcriptional changes 
The technological basis of NGS have been described in the general introduction, and 
in this section I will discuss utilisation of RNA-Seq for global unbiased 
transcriptional changes in host cells and tissues [362]. 
Similar to other NGS applications, RNA-Seq is high-throughput, highly sensitive, 
and high speed. There are still considerable costs associated with this technology, but 
the price is decreasing over time making this a more viable approach for different 
applications [363]. It can be utilised to quantify transcripts, and also as an 
explorative tool to investigate SNPs, and in contrast to sequencing arrays, does not 
require preselection of probe targets. It allows for the sequencing of the total 
transcriptome including messenger RNA (mRNA), and short RNAs (miRNAs, 
siRNAs, ncRNAs); although specific sample processing techniques have to be used 
to optimally perform these different studies. These include enrichment of specific 
RNAs such as mRNAs by polyA pulldown, as well as size selection, which can 
induce bias, or outright exclusion of certain RNA types [364, 365].  
With RNA-Seq, as with other NGS methods, large data sets are generated that 
require new levels of computational processing power, skills and tools. Following 
the sequencing step, the raw data has to be processed for assembly of transcripts, 
identification of genes, precise quantification, with false positive statistical 
evaluation, and comparison of expression between several samples and conditions. 
These areas are constantly being re-worked and improved, but most developments 
address speed and resource management [362].  
Following this, and which is essential for interpretation of the functional elements, 
and solving the biological interactions of identified differentially expressed genes, is 
pathway analysis. Databases of interactions have been generated and can be overlaid 
on top of transcriptional changes to allow other biologically important information to 
extracted from the generated data. This identification of potentially relevant 
transcriptional modulation would then have to be validated on the gene expression 





5.1.4 The use and limitations of GF mice in microbiota research 
Gnotobiotic mice are animals free of all microorganisms and can greatly aid with 
answering questions relating to specific phenotypes, and the potential involvement of 
singular bacterial species/strains [366]. Fundamentally, GF mice can be used to 
determine if the microbiota is a driving factor in phenotype, i.e. disease pathogenesis 
[367]. More recently, GF mice are also used in sophisticated mono-association 
studies to probe host-microbiota crosstalk, and colonisation of GF mice with a 
defined microbiota, consisting of selected microbes, to study bacteria-bacteria 
interactions, or even xenobiotic models, were for example GF mice are colonised 
with human microbiota, to generate a more translation model [368]. An excellent 
example of a successful mono-colonised study that has greatly aided our 
understanding of host-microbe interactions identified SFB as a key component of the 
intestinal microbiota that promotes the development of Th17 cells [369].  
Importantly, results generated using GF mice should be interpreted carefully as these 
animals have an altered physiology, including an underdeveloped immune system, 
deceased intestinal epithelial turnover, and differences in epithelial gene expression 
[370-372]. In addition, mono-colonisation may also indicate different changes as 
compared to those observed in the presence of a complex microbiota (i.e. in SPF 
mice) [369]. As indicated in the general introduction, and with respect to 
bifidobacteria, several studies have shown cross-feeding with other members of the 
gut microbiota, and therefore this should be considered when discussing GF study 
data. Hence the general rule is that an overall consensus should only be drawn from 
gnotobiotic experiments when the model has also been investigated in the presence 
of a complex microbiota (if possible) [373]. 
Difference in microbiota profiles between human and mouse, as well as between 
laboratory strains/colonies and conditions, should also be taken into consideration, 








Bifidobacteria can positively influence homeostatic intestinal health by specifically 
modulating the transcriptome of IECs. 
5.2.2 Aims 
1. Investigate impact of bifidobacteria colonisation on epithelial transcription 
patterns in vivo during healthy homeostatic conditions, and during 
pathological intestinal inflammation 







5.3.1 Experimental mouse models, and design overview for 
investigation of small intestinal epithelial transcriptional 
response of mice to B. breve UCC2003 colonisation 
We previously observed a protective anti-apoptotic effect of B. breve colonisation on 
the IE during pathological cell shedding in vivo [46]. Initial qPCR analysis identified 
apoptosis-associated genes that were downregulated during acute cell shedding in the 
presence of B. breve.  I hypothesised that the protective effect conferred by B. breve 
is modulated prior to onset of pathological cell shedding, and that this critical 
beneficial IEC ‘programming’ occurs during homeostasis. The potential biological 
reason for this could be that B. breve, as a microbiota member associated with 
health, primes the IE to dampen down responses during inflammatory stimulus e.g. 
LPS, which in turn protects the IEC from damage. I therefore investigated the 
modulation of IEC transcription in vivo without LPS stimulation by RNA-seq 
analysis (Figure 5-3). 
 
Figure 5-3 Overview of experimental design and mouse groups analysed. 
C57B/6 mice were colonised by B. breve UCC2003 by oral gavage (109 cfu) daily on three 
consecutive days, mice groups were conventionally raised (SPF) neonate mice (2 weeks) and their 
mothers, conventionally raised adult mice (12 weeks) and germ free (GF) adult mice (12 weeks), 
tissue was collected on day 4 (24 hours post last gavage) and small intestine collected, small intestinal 
epithelial cells were isolated and RNA extracted from IEC isolations and whole small intestinal tissue, 
transcription was analysed by Illumina HiSeq and data processed for calculations of differentially 





I also expanded the model from adult mice (12 weeks), to include neonatal mice (2 
weeks) as B. breve is a prominent member of the early life gut microbiota. 
To assess the modulation of IECs in vivo, I colonised C57 BL/6 mice with B. breve 
UCC2003 by oral gavage with 109 cfu on three consecutive days, based on the 
established model by Hughes et al [46]. Tissue collection occurred 24 h post last 
gavage (i.e. day 4). Neonate mice were colonised following the same protocol, with 
the exception that the same cfu was administered, but in a 50 μl gavage instead of 
100 μl, due to the size of the neonatal stomach. Mothers were also gavaged, together 
with their pups, and co-housed in the same cage to include vertical transmission as 
neonatal mice are on a milk diet. To differentiate between the potential indirect 
effects on the host of B. breve UCC2003, via modulation of microbiota composition, 
and its direct effect on the IE, I utilised GF mice mono-colonised following the same 
gavage protocol. 
5.3.2 B. breve UCC2003 oral gavage results in stable colonisation of 
conventionally raised neonate and adult mice as well as under 
gnotobiotic conditions, with higher levels in the large intestine 
compared to small intestine 
Our previous work has indicated stable colonisation of B. breve in the GI tract; 
however, it is important to confirm this in my models as presence of B. breve would 
be required for downstream transcriptional responses. Therefore, I monitored 
colonisation via selective plating of faeces on RCA with 50 mg l-1 mupirocin for 
determination of faecal cfu counts. Control mice (and experimental group mice prior 
to first gavage) did not show bifidobacteria colonisation suggesting no (or below 
level of detection) presence of bifidobacteria in the faeces of the utilised mice 
(Figure 5-4.A,C,E). B. breve UCC2003 gavaged mice presented with stable cfu/g 
faeces, starting 24 hours post first administration, and for the duration of the 
experiment, with slightly higher levels in adult mice compared to neonates (Figure 
5-4.A,C). This is in accordance with the observations made by Hughes et al. [46], in 
adult mice (108 cfu/g faeces). GF mice were raised and housed in a sterile 
environment and their gnotobiotic status verified by culture independent faecal cytox 





Supplementary Table 4). To mono-colonise mice with B. breve UCC2003, oral 
administration was performed following the protocol for SPF adult mice, and 
similarly stable colonisation and levels compared to conventionally raised adult was 
observed (Figure 5-4.E). 
Bacterial load along the GI tract differs due to changes in physiological and the 
luminal milieu. Notably, B. breve was present in lower numbers (105 cfu/g faeces) in 
the SI, compared to the LI of neonate and adult SPF mice 24 h post last gavage (108 
and 109 cfu/g faeces respectively, Figure 5-4.B, D). Colonisation levels were similar 
in the GI tract of GF mice at the same time point (Figure 5-4.F). 
These data indicate a stable and high cfu intestinal colonisation of mice, which is 








Figure 5-4  B. breve UCC2003 stably colonises the intestine of neonate and adult conventional 
mice, and adult GF mice with higher levels in the large than in the small intestine. 
Bifidobacteria colonisation by oral gavage in A faeces and B intestinal contents of adult (12-14 
weeks) conventionally raised mice, C faeces and D intestinal contents neonate (2 weeks) 
conventionally raised mice and E faeces and F intestinal content adult (12 weeks) germ free mice, 
oral gavage (109 cfu B. breve UCC2003) on three consecutive days, faecal samples collected on 
indicated days, large and small intestine content collected on day 4 (24 hours post last gavage), 
colonisation (cfu/g faeces) determined by homogenisation of samples in PBS, selective plating on 





detection 2x103 indicated by lowest value on y axis, data shown as mean +/- SD (A n=6, B n=5, C 





5.3.3 16S rRNA sequencing of mouse intestinal microbiota shows B. 
breve UCC2003 colonisation of neonate and adult 
conventionally raised mice by oral gavage and effect on 
community composition 
Previous work has shown that bifidobacteria administration modulates the overall 
microbiota composition. Disturbances of the intestinal bacterial community is 
associated with disease, and in the case of IBD reduced levels of Bifidobacterium is 
associated with active disease, and reduced microbiota diversity. Importantly, these 
changes may have modulatory effects on the host, thus I investigated the effect of B. 
breve UCC2003 administration on the mouse gut microbiota profile via 16S rRNA 
sequencing. 
Adult control mice showed no bifidobacteria in two out of three biological repeats, 
with one mouse having a very low percentage of reads (<1%) mapping (Sample 
contro1, Figure 5-5). In all three control mice, a similar taxonomic ratio at genus 
level was observed, with the most prominent genera detected being Roseburia, 
Alobaculum, Blautia, Lactobacillus and Alistipes. One sample had higher levels of 
Alobaculum and Lactobacillus, which correlated with a reduced presence of other 
taxa. The rarefaction curve of this mouse showed a much lower number of bacterial 
populations detected at the same read counts as the other two samples, with no 
plateau, suggesting a lower capture diversity at the same sequence depth, and which 
could explain the observed intragroup variability (Supplementary Figure 5). 
B. breve UCC2003 oral gavage increased bifidobacteria abundance in the adult 
microbiota to 1.3 - 2.3% after four days of treatment (Figure 5-5). This was 
accompanied in two samples by an increase in Lactobacillus, and decreased 
abundance of Alobacum, Balutia and Alistipes. One sample (UCC2) differed by 
lower Lactobacillus levels, and higher Blautia and Roseburia abundance compared 
to other B. breve gavaged mice, and appeared similar to control mice composition. 
Based on the 16S rRNA data, a Principal Coordinate Analysis (PCoA) was used as 





between the control and B. breve gavaged adult mice, but based on the observed 






Figure 5-5  B. breve UCC2003 colonises the intestinal tract of adult SPF mice with effects on overall microbiota composition analysed by 16S rRNA gene 
sequencing. 
Faecal samples collected from adult (12 weeks) conventionally raised mice colonised by B. breve UCC2003 by oral gavage (109 cfu for three days, sample 





against SILVA database and visualised in MEGAN, data shown as relative abundance normalised to percentage of reads, bar colours corresponding to genus taxa, 






Figure 5-6  B. breve UCC2003 gavage modulates intestinal microbiota profile of adult mice 
analysed by PCoA of genus level composition based on 16S rRNA sequencing. 
Faecal samples collected from adult (12 weeks) mice following oral gavage with 109 cfu B. breve 
UCC2003 on three consecutive days (control received PBS gavage), DNA extracted, V1-V2 of 16S 
rRNA gene amplified and sequenced, reads aligned against SILVA database, PCoA analysis of 





In the intestinal microbiota of control neonate and mother mice no Bifidobacterium 
16S rRNA reads were detected (Figure 5-7). Global composition of control mother 
microbiota is similar to adult mice analysed above, while neonatal controls samples 
had higher abundances of Bacteroides, and potentially Lactobacillus, with a decrease 
in Blautia, Roseburia and Alistipes, and overall decreased diversity. The oral gavage 
with B. breve UCC2003 increases the abundance of bifidobacteria in neonate mice to 
an average of 11.25% (UCC1 14%, UCC2 9%, UCC3 5%), which is accompanied 
by a decrease in Blautia, and an increase in Bacteroides, and potentially 
Lactobacillus. 
PCoA analysis indicates a separation between the control and gavaged neonate 
groups with tighter clustering for the treatment samples compared to control repeats 
(Figure 5-8). The microbiota of mothers was distinctly different from the neonate 
groups, and B. breve administration had a lower modulatory effect on the mothers’ 
microbiota profiles. 
Lower capture diversity of two samples was detected based on rarefaction curve 
analysis showing much lower bacterial population quantity at similar read counts 
without plateau compared to experiment average leading to the exclusion of these 
smaples from the analysis on the basis of insufficient sequencing depth 
(Supplementary Figure 5). 
These results support the B. breve colonisation data generated by plate counts with 
16S rRNA sequencing presenting a higher abundance in neonates, and show a 
distinct modulation of the mouse microbiome by B. breve with effects being stronger 






Figure 5-7 B. breve UCC2003 colonises the intestinal tract of neonate SPF mice and modulates microbiota profile analysed by 16S rRNA gene sequencing. 
Faecal samples collected from neonate (12 weeks) conventionally raised mice and their mothers colonised by B. breve UCC2003 by oral gavage (109 cfu for three 
days, sample collection 24 hours post last administration, control received PBS gavage), DNA extracted, V1-V2 of 16S rRNA gene amplified and sequenced, 
Reads aligned against SILVA database and visualised in MEGAN, data shown as relative abundance normalised to percentage of reads, bar colours corresponding 






Figure 5-8 B. breve UCC2003 gavage modulates intestinal microbiota profile of neonate mice 
analysed by PCoA of genus level composition based on 16S rRNA sequencing. 
Faecal samples collected from neonate (2 weeks) and mother mice following oral gavage with 109 cfu 
B. breve UCC2003 on three consecutive days (control received PBS gavage), DNA extracted, V1-V2 
of 16S rRNA gene amplified and sequenced, reads aligned against SILVA database, PCoA analysis of 





5.3.4 Localisation of B. breve in close proximity with the intestinal 
epithelium using SEM 
In addition to the presence of B. breve in mouse faecal samples following gavage, 
localisation within the GI tract would be expected to be central for host modulatory 
effects. When present in the lumen, B. breve could modulate the IE via bacterial 
products, while localisation in close proximity to IEC could potentially allow direct 
cell surface interactions. 
To observe the localisation of B. breve in realtion to the IE, SEM images were taken 
of the large and small intestine of gnotobiotic (Figure 5-9.A), and conventionally 
raised control, and gavaged mice (Figure 5-9.B). The dehydration processing step 
caused shrinkage, and re-localisation of the mucus layer, but was required due to 
alternative frozen processing retaining the mucus barrier, which would not allow 
visualisation of B. breve in close contact with the IEC. Due to the strong adhesive 
properties of mucus, it is unlikely that bacteria have shifted localisation post tissue 
collection and processing, reducing the potential of artefacts (oral communication 







Figure 5-9  B. breve UCC2003 resides in close proximity of the intestinal epithelium and the 
mucus layer shown by scanning electron microscopy. 
A Germ free (GF) and B conventionally raised (SPF) adult mice were gavaged on three consecutive 





fixed, dried and visualised by scanning electron microscopy (SEM), individual bacteria pseudo 





Images taken of small intestinal mono-colonised IE did not reveal bacteria either on 
top of the mucus or the IE. This could be explained by the small area observed by 
SEM, and the fact that B. breve colonises the SI at lower levels. Notably, when 
imaging the LI, several bacteria can be seen, and are located on top of the mucus 
layer (and potentially within, as revealed by mucus constriction), while single 
bacteria are in direct contact with the epithelium (Figure 5-9.A). SEM visualisation 
of the small and large IE of SPF mice shows bacteria with several different 
morphologies; thus it is difficult to identify B. breve within the SPF microbiota 
(which would require immuno-gold labelling) (Figure 5-9.B).  
In addition, I investigated the localisaiton of B. breve bz staining of small intestinal 
sections with RNAscope, an immunofluorescent in situ hybridisation method 
allowing for visualisation of transcripts by bright field microscopy, using probes 
designed against the Bifidobacterium 16S rRNA sequence. The results were 
inconclusive in part due to the nucleotide length of the probe required for adequate 
binding not allowing for sequence design specific for the B. breve UCC2003 species, 
and will require further optimisation and repetition to ensure reliability. 
In summary, these studies suggest that B. breve UCC2003 could potentially be in 
close contact with the IEC. Notably, this localisation would be expected to have a 
direct impact on interactions with the host. Future experiments will be discussed 
below. 
5.3.5 B. breve UCC2003 intestinal colonisation induces a distinct 
transcriptional response in neonate intestinal epithelial cells, 
with less pronounced effects in adult mice  
Having established and validated the model of B. breve colonisation, I initiated 
holistic investigation of the effect of B. breve UCC2003 on IECs by RNA-Seq, as a 
global assessment of transcriptional changes. 
As previously highlighted, B. breve UCC2003 appears to modulate host responses 
via IEC signalling. Therefore, I the processed collected SI samples for IEC isolation 





FACS of isolated cells, showing high percentage of live cell to be CD45- (marker for 
B, dendritic, NK cells, macrophages, and granulocytes, Supplementary Figure 1.A). 
In addition, histological H&E staining indicated removal of the IE, while leaving the 
LP intact (Supplementary Figure 1.B).  
RNA was isolated from IEC preps, and whole SI from neonate and adult (control and 
B. breve UCC2003 gavaged), and GF and B. breve mono-colonised mice (Figure 
5-3). RNA sequencing was then performed, and data analysed to calculate 
differences between control and B. breve colonised gene expression. This allowed 
me to identify differentially expressed gene patterns induced by B. breve UCC2003 
colonisation in IEC and WSI tissue of neonate and adult mice, and in the presence of 
absence of other microbiota members.  
Starting from the top down, I generated an overview of the number of host genes 
differentially expressed in response to B. breve colonisation by comparing volcano 
plots of DEGs in IECs and WSI, as well neonate and adult SPF mice (Figure 5-10). 
B. breve has the strongest effect on neonatal small intestinal IECs, with 14054 
differentially expressed genes (DEGs, q value < 0.05) ranging from 12 log2 fold 
upregulation to 6 log2 downregulation. A ratio of 1:1.3 comparing down vs up 
regulation favours increase in expression (Figure 5-10).  
In contrast to the pronounced modulation of neonate IECs, the effect of colonisation 
is close to 10-fold lower in IECs of adult mice, with 103 DEGs (p-value < 0.05, log2 
fold change +10 to – 21, Figure 5-10). Analysis of whole SI resulted in even further 
reduced transcriptional regulation with 21 DEGs in neonate WSI and no clear PCA 
clustering observable between groups (Supplementary Figure 7). A total of 47 DEGs 
were identified in adult mouse WSI, with two colonised biological repeats showing 
similarity in expression profile while one sample (UCC3) is more similar to control 
gene expression (Supplementary Figure 8). This mouse had similar colonisation 
levels to other gavaged mice, however these were cfu’s from faecal samples, and it 
cannot be discounted that the bacterial presence within the SI was different, and this 







Figure 5-10  B. breve UCC2003 intestinal colonisation induces a distinct transcriptional 
response in small intestinal epithelial cells of neonate mice. 
Volcano plots of neonate and adult small intestinal epithelial cells (IEC) and whole small intestine 
(WSI) differentially regulated genes (DEGs) compared to control (PBS gavaged), y axis shows q-
value on a log10 scale, x axis presents fold change in log2, statistical significance indicated by red, 
blue line indicating statistical significant cut off of q-value<0.05, generated and calculated with 
DESe2. 
Assessing transcriptional changes in mono-colonised mice compared to GF mice, 
indicates that B. breve colonisation does not significantly modulate IECs (2 DEGs, 
q-value < 0.05, log2 fold change below cut off of 2.5), but this could be skewed by 
one sample within the treatment group (UCC1) showing an expression profile 
different from the tight clustering of the other B. breve colonised samples, and is 





from which this sample was collected showed similar colonisation levels compared 
to group average. Again, a difference in small intestinal colonisation may account for 
this outlier.  
B. breve did induce a very strong effect on monocolonised WSI; with 10052 DEGs 
(q-value < 0.05, log2 fold change +29 to -17) (Supplementary Figure 10). Due to no 
transcriptional differential regulation of IECs the exploration of this dataset is out-
with the scope of this PhD study, but these notable differences between GF and SPF 
IECs profiles will be explored in the discussion. 
Previously we performed an investigation of potential transcriptional targets of B. 
breve UCC2003 during LPS-induced cell shedding, by analysis gene expression by 
qPCR array on whole SI. However, as the focus of my work is on IECs and B. breve, 
I analysed epithelial gene expression of LPS challenged mice, with and without the 
presence of B. breve UCC2003. Interestingly, no DEGs response was observed, with 
most of control and treatment group samples clustering closely (Supplementary 
Figure 11). It could be hypothesised that the strong transcriptional response induced 
by systemic LPS masks the homeostatic modulation of IECs by B. breve. As the 
whole IE is undergoing acute inflammation, and IECs undergo apoptosis in great 
numbers, this may also influence which IECs are collected from the tissue; LPS 
stimulated cells, both in control and B. breve colonised samples removed by the 
Weisser method, leaving non-stimulated IECs for RNA-seq analysis resulting in no 
DEGs. Furthermore, as the cell shedding model is so rapid (1.5h), significant 
modulation of transcriptional responses may not be induced in this short-time frame.  
These data highlight that there are strong IEC transcriptional responses in response 
to B. breve colonisation on the transcriptome of neonate mice during intestinal 
‘health’, but no observable differences during inflammatory cell shedding, as well as 
a strongly reduced effect on adult IECs, and whole small intestinal tissue of adult 
and neonate mice during homeostasis. This emphasises the importance of 
investigating the effect of B. breve on host IECs during homeostasis, which will be 





5.3.5.1 Analysing neonate IEC transcriptional responses by B. breve reveals 
increased expression of TLR2, TLR9, IL17C and integrins 
I used DESeq2 to quality control the dataset of B. breve UCC2003 induced 
differential gene expression in neonate IECs. Due to the overall high number of 
genes analysed for differential expression, and for accurate statistical determination, 
specifically in groups with lower n numbers in relation to genes expressed, DESeq2 
applies a gene-wise dispersion estimate (by maximum likelihood estimation) to each 
DEG, and compares this value to the overall trend in dispersion of the sample set 
through processing, including shrinkage of estimated dispersion. This approach 
allows for the assessment of expected dispersion of the data, and identification of 
potential outliers, as well as the prevention of false positives. Due to biological or 
technical reasons, genes can fall outside of the statistical model, and the applied 
algorithm takes this into account when assessing general statistical certainty of the 
applied DEG calculation [374]. The shrinkage estimation of dispersion for the data 
shows a close association of genes with the line of best fit, with a small number of 






Figure 5-11  Presence of B. breve UCC2003 induces consistent, strong transcriptional changes 
in small intestine epithelial cells of neonate mice 
Overview over transcriptional changes in IECs of neonate mice colonised with B. breve UCC2003 
relative to control (PBS gavaged) A Shrinkage estimation of dispersion, y axis dispersion estimate, x 
axis mean of normalised counts, black dots individual genes, red line maximum likelihood estimation 
(MLE) line of best fit, black dots circled in blue – potential dispersion outliers, blue area around red 
line – genes used for second dispersion estimate (not outliers), B PCA plot of group variability C 
Bland Altman (MA) plot of transcriptional modulation by presence of B. breve UCC2003 relative to 
control, y axis log2 fold change of gene expression, x axis – mean of moralised counts, red dots – 
statistical sig genes (q values 0.05) D Hierarchical clustering of samples based on TOP 50 
differentially regulated genes. 
The PCA analysis (Figure 5-11.B), showed clear separation between control and 
treatment groups, with greater intergroup variability in the control data set. The 
associated Bland Altman (MA) plot gives an overview over changes in gene 
expression in the samples, plotted against the mean read counts, while highlighting 





shows a balanced up and down regulation with read counts correlating with fold 
changes. The majority of upregulated transcripts have higher read counts, while the 
sub-sample of downregulated genes has a similar number of higher expressed genes, 
but a much higher number of DEGs with strong fold changes (less with high read 
counts, more with average read counts). Considering the top 50 differential regulated 
genes (by p-value), the samples cluster hierarchically in accordance with their 
groups, as presented in the heat map (Figure 5-11.D). Most top differentially 
regulated genes in the control group are upregulated, while the opposite is the case 
for the B. breve treatment group. This suggests a dampening effect of B. breve 
colonisation on IECs, by reducing transcription of genes. 
The 25 genes inversely differentially expressed between the control and UCC2003 
gavaged group are based on the Ensemble gene database predicated genes 15487 and 
21988, and ribosomal protein L28 (pseudogene 1), RNase K and ferritin heavy 
polypeptide 1 (Figure 5-11.D). 
To start teasing apart the biological interactions of the substantial number of DEGs 
initially I investigated the genes with strongest fold changes (q value < 0.05). The 







Table 5-1  Transcripts showing highest upregulation in neonate IECs induced by B. breve UCC2003  








Table 5-2  DEGs induced by B. breve UCC2003 in neonate IECs with strongest downregulation  







A large proportion of genes presenting with strongest upregulation in expression by 
B. breve UCC2003 are predicted genes and annotated as non-coding RNAs, but 
without associated function (Table 5-1). Transcripts downregulated by B. breve 
UCC2003 include CD80 (log2 fold change -4.5, expressed in monocytes, dendritic, 
and B cells and essential for T cell activation), which does suggest presence of other 
cell types in this IEC preparation, and could be interpreted as a decreased immune 
cell population in the LP of B. breve colonised mice [375]. A decrease in cytotoxic T 
lymphocyte-associated protein 2 alpha (log2 fold change -4.2, Ctla2a/Ctla2b) could 
further suggest a decreased pro-inflammatory immune response. These results have 
to be validated as the isolation method was targeted at IECs, and no definite 
conclusions about other cell types should be drawn from these data. 
As no clear biological mechanistic modulation could be identified from analysis of 
genes with highest up or downregulation, I continued my search by investigating 
expression of three specific classes relevant in host-microbe interactions and host 













Table 5-4 Small intestinal epithelial caspase expression is affected by B. breve colonisation of the neonate intestine 
 
Expr	Log	Ratio q-value Ensemble	Gene	ID Gene	Symbol Entrez	Gene	Name Location
2.864 0.000525 ENSMUSG00000027995 TLR2 toll	like	receptor	2 Plasma	Membrane
0.907 1.71E-07 ENSMUSG00000031639 TLR3 toll	like	receptor	3 Plasma	Membrane
0.767 7.52E-06 ENSMUSG00000079164 TLR5 toll	like	receptor	5 Plasma	Membrane
3.746 0.0096 ENSMUSG00000045322 TLR9 toll	like	receptor	9 Plasma	Membrane
Expr	Log	Ratio q-value Ensemble	Gene	ID Gene	Symbol Entrez	Gene	Name Location
-0.448 0.0000345 ENSMUSG00000028914 CASP9 caspase	9 Cytoplasm
2.412 6.45E-45 ENSMUSG00000028282 CASP8AP2 caspase	8	associated	protein	2 Nucleus
-1.252 6.24E-17 ENSMUSG00000027997 CASP6 caspase	6 Cytoplasm
-0.607 0.000881 ENSMUSG00000031628 CASP3 caspase	3 Cytoplasm
1.002 6.1E-11 ENSMUSG00000029863 CASP2 caspase	2 Cytoplasm
-0.748 0.0000042 ENSMUSG00000025888 CASP1 caspase	1 Cytoplasm
1.951 0.0272 ENSMUSG00000026928 CARD9 caspase	recruitment	domain	family	member	9 Cytoplasm
-1.433 1.81E-15 ENSMUSG00000037960 CARD19 caspase	recruitment	domain	family	member	19 Cytoplasm





In Table 5-3, differential expression of TLRs by B. breve compared to control mice 
are shown. TLR 2 (which recognises Lipoteichoic acid) was strongly upregulated 
with a log2 fold change of +2.8. TLR9 upregulation (log2 fold change +3.7) carries 
out a dual role in IECs dependent on its cellular localisation [20]. Apical TLR9 
activation prevents NF-κB activation and acts anti-inflammatory, while basal TLR9 
ligand binding has been shown to induce IL-8 secretion, and hence drive pro-
inflammatory responses. The implication of the differential regulation of these two 
TLRs in the host health beneficial effect of B. breve will also be further discussed 
below. 
TLRs 3 and 5 show less pronounced modulation. TLR5 (log2 fold change +0.7)  
recognises flagellin, and IEC specific KO mice present with low grad inflammation 
during homeostatic conditions combined with increased susceptibility to DSS 
induced colitis [376]. TLR3 (log 2 fold change +0.9) surveys viral doubled stranded 
RNA in the intestinal lumen and its expression is significantly downregulated in 
IECs during active CD [377].  
Investigating the effect of B. breve colonisation on caspase expression, revealed both 
up and down regulation (Table 5-4). Interestingly, caspase 3 (marker used for 
identification of apoptotic cell shedding in this study) is downregulated (log2 fold 
change -0.6), together with caspase 9, 6 and 1 (log2 fold change -0.4, -1.2, -0.7).  
Interleukins (ILs) are powerful cytokines produced by immune cells and IECs, which 
play pivotal roles in tissue homoeostasis and disease. Table 5-5 shows all ILs and 
receptors differentially regulated by B. breve relative to control samples. 
Specifically, several IL17 isoform as well as IL-17 receptor classes are differentially 
regulated. IL-17C, which is expressed in IECs, is increased by 5.2 log2 fold (IL-17D 
downregulated by -2.7 log2 fold, expression undefined) (Table 5-5) [378]. IL-17 
receptors are expressed in several cell types, with IL-17RC and IL-17RD present on 
the surface of epithelial cells. Their expression is downregulated slightly (IL-17RC, 
log2 fold change -0.2), as well as upregulated (IL-17RD, log2 fold change 0.9). Two 
other receptor classes are differentially modulated by B. breve, but not expressed on 
IECs (IL-17RB log2 fold change 2.6 T helper cells and fibroblasts, IL-17RA log2 










Table 5-5Interleukins and their receptor transcription in small intestinal epithelial cells is affected by B. breve UCC2003 colonisation. 
 
Expr	Log	Ratio q-value Ensemble	Gene	ID Gene	Symbol Entrez	Gene	Name Location
-0.367 0.0179 ENSMUSG00000030748 IL4R interleukin	4	receptor Plasma	Membrane
-1.978 0.0000493 ENSMUSG00000068758 IL3RA interleukin	3	receptor	subunit	alpha Plasma	Membrane
-0.389 0.00271 ENSMUSG00000024810 IL33 interleukin	33 Extracellular	Space
3.587 2.16E-15 ENSMUSG00000050377 IL31RA interleukin	31	receptor	A Plasma	Membrane
4.515 0.00846 ENSMUSG00000025383 IL23A interleukin	23	subunit	alpha Extracellular	Space
1.12 2.2E-24 ENSMUSG00000037157 IL22RA1 interleukin	22	receptor	subunit	alpha	1 Plasma	Membrane
1.371 0.000325 ENSMUSG00000044244 IL20RB interleukin	20	receptor	subunit	beta Plasma	Membrane
-1.371 0.00219 ENSMUSG00000027720 IL2 interleukin	2 Extracellular	Space
0.871 0.0109 ENSMUSG00000022514 IL1RAP interleukin	1	receptor	accessory	protein Plasma	Membrane
1.759 0.000000206 ENSMUSG00000070427 IL18BP interleukin	18	binding	protein Extracellular	Space
-0.719 0.00106 ENSMUSG00000039217 IL18 interleukin	18 Extracellular	Space
0.935 0.00197 ENSMUSG00000040717 IL17RD interleukin	17	receptor	D Cytoplasm
-0.273 0.0409 ENSMUSG00000030281 IL17RC interleukin	17	receptor	C Plasma	Membrane
2.06 0.000243 ENSMUSG00000015966 IL17RB interleukin	17	receptor	B Plasma	Membrane
-0.324 0.0203 ENSMUSG00000002897 IL17RA interleukin	17	receptor	A Plasma	Membrane
-2.72 2.96E-27 ENSMUSG00000050222 IL17D interleukin	17D Extracellular	Space
5.219 0.000514 ENSMUSG00000046108 IL17C interleukin	17C Extracellular	Space
2.602 0.0000199 ENSMUSG00000001741 IL16 interleukin	16 Extracellular	Space
1.32 2.13E-08 ENSMUSG00000023206 IL15RA interleukin	15	receptor	subunit	alpha Plasma	Membrane
0.664 0.00828 ENSMUSG00000031712 IL15 interleukin	15 Extracellular	Space
4.814 7.38E-15 ENSMUSG00000018341 IL12RB2 interleukin	12	receptor	subunit	beta	2 Plasma	Membrane
-0.368 0.0318 ENSMUSG00000073889 IL11RA interleukin	11	receptor	subunit	alpha Plasma	Membrane





5.3.5.2 Pathway analysis of genes differentially regulated by B. breve 
UCC2003 in neonate IECs shows expression upregulation of 
integrin, and downstream signalling components 
In addition to the manual curation of the DEGs modulated by B. breve, I utilised 
downstream pathway analysis to explore wider biological functions. 
As RNA-Seq gives global gene expression data, it is important to use additional 
pathway modelling to infer important mechanistic associations. Based on DEG lists, 
pathway analysis, utilising gene and protein databases greatly aids in interpretation 
of RNA-Seq data, as weighting of fold expression changes of specific genes are 
taken into account, together with the total modulation of all DEGs [379]. This allows 
small expression changes, such as in transcription factors, which otherwise would 
potentially have been overlooked to be analysed, and if present may suggest 
modulation of other transcripts in a wider pathway, which could have important 
biological function [362]. If the analysis considers direction of fold changes, this 
allows for an even more specific and detailed analysis. However, as with all large 
datasets, the number of pathways containing DEGs increases and with this the rate of 
false positives. This has been addressed by statistical models, but the problem 
remains that with RNA-Seq data identifying all true biological responses is 
sometimes problematic, and which is why downstream validation of targets increases 
the robustness of conclusions drawn.  
Pathway analysis tools are under constant development, and I tested Innate DB and 
Cytoscape (both open source), and in addition I also used Ingenuity Pathway 
Analysis (IPA) by Qiagen. Based on the number of DEGs mapped to pathways, IPA 
had the highest resolution, and was thus taken forward for analysing the data sets 
(data not shown). Notably, IPA includes regular manually curated additions of 
experimentally validated biological interactions, together with automatic searching, 
while open source tools are usually reliant on only computational databases, 
although they have the significant added benefit of being freely available to the 





When analysing the IEC neonate data set pathways, the DEG cut-off was set at a 
relatively stringent q value < 0.05 to ensure statistical accuracy, while fold change 
integration barrier was kept low log2 > +/-0.8. 
In the neonate dataset, integrin signalling showed very strong mapping of DEGs to 
this pathway (92 out of 219), a z-score of 2.157 (IPA mathematical model of 
correlation between predicted direction of regulation of transcripts in pathway and 
experimental DEG fold changes) and a p-value taking fold change direction and gene 
mapping to pathway into account of 2.69x10-5 (Figure 5-13, Table 5-6).  
Integrin subunit α 1, 2 and 2b, 4, 6, 9, 10, E, M, V, and subunit β 6 and 7 were all 
increased in IECs of neonatal mice colonised by B. breve UCC2003. The 
upregulation ranged from 1 log2 fold of integrin subunit β6 to 3.8 log2 fold of 
subunit α10 (Table 5-6 andTable 5-7). These regulations were consistent between 







Figure 5-12 Integrin and downstream signalling component expression is upregulated by B. breve colonisation in neonate intestinal epithelial cells. 
Pathway analysis of total differentially regulated small intestinal epithelial cell genes modulated by B. breve UCC2003 gavage utilising IPA shows integrin and 






Table 5-6  B. breve UCC2003 intestinal colonisation of neonate mice increases expression of integrins and downstream signalling network 
components in IECs  






Table 5-7  B. breve UCC2003 intestinal colonisation of neonate mice increases expression of integrins and downstream signalling network 
components in IECs  
Symbol Entrez Gene Name Ensembl Expr Log Ratio
Expected regulation 
(based on pathway activation)
Location Type(s)
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase ENSMUSG00000026842 0.834 Up Nucleus kinase
AKT1 AKT serine/threonine kinase 1 ENSMUSG00000001729 -0.886 Up Cytoplasm kinase
ARF1 ADP ribosylation factor 1 ENSMUSG00000048076 -0.995 Down Cytoplasm enzyme
ARF3 ADP ribosylation factor 3 ENSMUSG00000051853 -0.959 Down Cytoplasm enzyme
ARF5 ADP ribosylation factor 5 ENSMUSG00000020440 -1.356 Down Cytoplasm enzyme
ARHGAP5 Rho GTPase activating protein 5 ENSMUSG00000035133 2.814 Up Cytoplasm enzyme
ARHGAP26 Rho GTPase activating protein 26 ENSMUSG00000036452 1.058 Down Cytoplasm other
ARPC2 actin related protein 2/3 complex subunit 2 ENSMUSG00000006304 -0.992 Up Cytoplasm other
ARPC3 actin related protein 2/3 complex subunit 3 ENSMUSG00000029465 -1.313 Up Cytoplasm other
ARPC4 actin related protein 2/3 complex subunit 4 ENSMUSG00000079426 -1.2 Up Cytoplasm other
ARPC5 actin related protein 2/3 complex subunit 5 ENSMUSG00000008475 -0.842 Up Cytoplasm other
ARPC1A actin related protein 2/3 complex subunit 1A ENSMUSG00000029621 -1.062 Up Extracellular Space other
ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 ENSMUSG00000022377 1.421 Up Plasma Membrane other
ATM ATM serine/threonine kinase ENSMUSG00000034218 3.713 Up Nucleus kinase
BRAF B-Raf proto-oncogene, serine/threonine kinase ENSMUSG00000002413 1.671 Up Cytoplasm kinase
CAPN7 calpain 7 ENSMUSG00000021893 1.018 Up Cytoplasm peptidase
CAPN8 calpain 8 ENSMUSG00000038599 2.238 Up Cytoplasm peptidase
CAPNS1 calpain small subunit 1 ENSMUSG00000001794 -1.776 Up Cytoplasm peptidase
DOCK1 dedicator of cytokinesis 1 ENSMUSG00000058325 1.545 Up Cytoplasm other
FGFR2 fibroblast growth factor receptor 2 ENSMUSG00000030849 1.473 Up Plasma Membrane kinase
FGFR3 fibroblast growth factor receptor 3 ENSMUSG00000054252 1.822 Up Plasma Membrane kinase
FNBP1 formin binding protein 1 ENSMUSG00000075415 0.93 Up Nucleus enzyme
FRS2 fibroblast growth factor receptor substrate 2 ENSMUSG00000020170 0.837 Up Plasma Membrane kinase
GRB2 growth factor receptor bound protein 2 ENSMUSG00000059923 -0.842 Up Cytoplasm kinase
GRB7 growth factor receptor bound protein 7 ENSMUSG00000019312 -1.176 Up Plasma Membrane other
GSK3B glycogen synthase kinase 3 beta ENSMUSG00000022812 1.156 Down Nucleus kinase
HRAS HRas proto-oncogene, GTPase ENSMUSG00000025499 -1.276 Up Plasma Membrane enzyme
ILK integrin linked kinase ENSMUSG00000030890 -0.935 Up Plasma Membrane kinase
IRS1 insulin receptor substrate 1 ENSMUSG00000055980 2.92 Up Cytoplasm enzyme
IRS2 insulin receptor substrate 2 ENSMUSG00000038894 1.847 Up Cytoplasm enzyme
ITGA1 integrin subunit alpha 1 ENSMUSG00000042284 2.315 Up Plasma Membrane other
ITGA2 integrin subunit alpha 2 ENSMUSG00000015533 2.881 Up Plasma Membrane transmembrane receptor
ITGA4 integrin subunit alpha 4 ENSMUSG00000027009 2.896 Up Plasma Membrane transmembrane receptor
ITGA6 integrin subunit alpha 6 ENSMUSG00000027111 1.29 Up Plasma Membrane transmembrane receptor
ITGA9 integrin subunit alpha 9 ENSMUSG00000039115 2.434 Up Plasma Membrane other
ITGA10 integrin subunit alpha 10 ENSMUSG00000090210 3.801 Up Plasma Membrane other
ITGA2B integrin subunit alpha 2b ENSMUSG00000034664 1.632 Up Plasma Membrane transmembrane receptor
ITGAE integrin subunit alpha E ENSMUSG00000005947 2.448 Up Plasma Membrane other
ITGAM integrin subunit alpha M ENSMUSG00000030786 1.154 Up Plasma Membrane transmembrane receptor
ITGAV integrin subunit alpha V ENSMUSG00000027087 1.532 Up Plasma Membrane transmembrane receptor
ITGB6 integrin subunit beta 6 ENSMUSG00000026971 1.064 Up Plasma Membrane other
ITGB7 integrin subunit beta 7 ENSMUSG00000001281 1.502 Up Plasma Membrane transmembrane receptor
KL klotho ENSMUSG00000058488 4.003 Up Extracellular Space enzyme





(continued from previous page) 
Symbol Entrez Gene Name Ensembl Expr Log Ratio
Expected regulation 
(based on pathway activation)
Location Type(s)
MAP3K11 mitogen-activated protein kinase kinase kinase 11 ENSMUSG00000004054 -0.886 Up Cytoplasm kinase
MAPK3 mitogen-activated protein kinase 3 ENSMUSG00000063065 -1.809 Up Cytoplasm kinase
MAPK8 mitogen-activated protein kinase 8 ENSMUSG00000021936 1.018 Up Cytoplasm kinase
MPRIP myosin phosphatase Rho interacting protein ENSMUSG00000005417 1.852  Cytoplasm other
MYL12A myosin light chain 12A ENSMUSG00000034868 -0.98 Up Cytoplasm other
MYL12B myosin light chain 12B ENSMUSG00000024048 -1.466 Up Cytoplasm other
MYLK3 myosin light chain kinase 3 ENSMUSG00000031698 -1.235 Up Cytoplasm kinase
NCK2 NCK adaptor protein 2 ENSMUSG00000066877 0.844 Up Cytoplasm kinase
PAK3 p21 (RAC1) activated kinase 3 ENSMUSG00000031284 2.687 Up Cytoplasm kinase
PDGFB platelet derived growth factor subunit B ENSMUSG00000000489 -1.028 Up Extracellular Space growth factor
PFN1 profilin 1 ENSMUSG00000018293 -1.317 Up Cytoplasm other
PFN2 profilin 2 ENSMUSG00000027805 -0.871 Up Cytoplasm enzyme
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha ENSMUSG00000030660 1.756 Up Cytoplasm kinase
PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta ENSMUSG00000026447 1.98 Up Cytoplasm kinase
PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma ENSMUSG00000030228 4.569 Up Cytoplasm kinase
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ENSMUSG00000027665 1.409 Up Cytoplasm kinase
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma ENSMUSG00000020573 1.118 Up Cytoplasm kinase
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 ENSMUSG00000041417 1.59 Up Cytoplasm kinase
PIK3R3 phosphoinositide-3-kinase regulatory subunit 3 ENSMUSG00000028698 1.182 Up Cytoplasm kinase
PIK3R5 phosphoinositide-3-kinase regulatory subunit 5 ENSMUSG00000020901 1.375 Up Cytoplasm kinase
PIKFYVE phosphoinositide kinase, FYVE-type zinc finger containing ENSMUSG00000025949 2.237 Up Cytoplasm kinase
PLCG2 phospholipase C gamma 2 ENSMUSG00000034330 0.892 Up Cytoplasm enzyme
PPP1R12A protein phosphatase 1 regulatory subunit 12A ENSMUSG00000019907 2.276  Cytoplasm phosphatase
Ppp1r12b protein phosphatase 1, regulatory (inhibitor) subunit 12B ENSMUSG00000073557 2.485  Cytoplasm other
PTEN phosphatase and tensin homolog ENSMUSG00000013663 1.054 Down Cytoplasm phosphatase
PTK2 protein tyrosine kinase 2 ENSMUSG00000022607 0.954 Up Cytoplasm kinase
RAC1 ras-related C3 botulinum toxin substrate 1 ENSMUSG00000001847 -0.995 Up Plasma Membrane enzyme
RAC3 ras-related C3 botulinum toxin substrate 3 ENSMUSG00000018012 -0.912 Up Cytoplasm enzyme
RHOC ras homolog family member C ENSMUSG00000002233 -1.682 Up Plasma Membrane enzyme
RHOD ras homolog family member D ENSMUSG00000041845 -1.074 Up Cytoplasm enzyme
RHOG ras homolog family member G ENSMUSG00000073982 -2.262 Up Cytoplasm enzyme
RHOT2 ras homolog family member T2 ENSMUSG00000025733 -0.908 Up Cytoplasm enzyme
RHOV ras homolog family member V ENSMUSG00000034226 -0.939 Up Plasma Membrane enzyme
RND2 Rho family GTPase 2 ENSMUSG00000001313 -1.392 Up Cytoplasm enzyme
RND3 Rho family GTPase 3 ENSMUSG00000017144 0.961 Up Cytoplasm enzyme
ROCK1 Rho associated coiled-coil containing protein kinase 1 ENSMUSG00000024290 1.775 Up Cytoplasm kinase
RRAS related RAS viral (r-ras) oncogene homolog ENSMUSG00000038387 -2.432 Up Cytoplasm enzyme
SOS1 SOS Ras/Rac guanine nucleotide exchange factor 1 ENSMUSG00000024241 1.702 Up Cytoplasm other
SOS2 SOS Ras/Rho guanine nucleotide exchange factor 2 ENSMUSG00000034801 1.14 Up Cytoplasm other
TLN1 talin 1 ENSMUSG00000028465 1.096 Up Plasma Membrane other
TLN2 talin 2 ENSMUSG00000052698 2.582 Up Nucleus other
TLR9 toll like receptor 9 ENSMUSG00000045322 3.746 Up Plasma Membrane transmembrane receptor
TSPAN5 tetraspanin 5 ENSMUSG00000028152 0.995  Plasma Membrane other
TSPAN6 tetraspanin 6 ENSMUSG00000067377 -0.957  Plasma Membrane other
TSPAN7 tetraspanin 7 ENSMUSG00000058254 -1.134  Plasma Membrane other
TTN titin ENSMUSG00000051747 6.038 Up Cytoplasm kinase
VCL vinculin ENSMUSG00000021823 0.861 Up Plasma Membrane enzyme





Within the integrin signalling pathway, I observed elevated fold changes of direct 
downstream adapter and signal transducers of integrins including protein tyrosine 
kinase 2 (log2 fold change +0.9, also known as focal adhesion kinase, FAK), Talin 1 
and Talin 2 (log 2-fold change +1 and +2.5) and Vinculin (log 2 fold change +0.8). 
While Talin and Vinculin link integrins to the cytoskeleton, FAK signals from 
integrins via phosphorylation [380]. FAK KO intestinal epithelial cells undergo 
increased apoptosis due to loss of survival signals mediated by cell adhesion contacts 
in vitro, while upregulation protects from apoptosis via NF-κB signalling in vitro 
[381-383]. Some downstream partners show decreased transcription such as integrin 
linked kinase (log2 fold change -0.9). 
It should be noted that not all DEGs mapped to the pathway agree with activation of 
signalling based on the direction of their expression modulation by B. breve 
UCC2003. For example, Ras homolog family members C, D, G, T2 and V are 
downregulated (log2 fold change -0.9 to -2.2) which are involved in cytoskeletal 
reorganisation and transcriptional regulation.  
This pathways analysis indicates that B. breve UCC2003 upregulates IEC integrin 
expression and signalling in neonatal IECs. I also observed other pathways that were 
differentially modulated, and additionally, as is often the case with global 
transcriptional pathway analysis; some pathways had both up- and down-regulated 
genes making conclusions difficult. It should be mentioned that my applied model 
utilises conventionally raised mice, which have been exposed to microbial stimuli for 
the duration of their life span, and thus the introduction of a single commensal 
bacterial species to the established microbiota, which may also explain the low 





5.3.6 Small intestinal epithelial cells of adult mice show discrete 
transcriptional changes induced by B. breve compared to 
neonate mice 
Quality control of the adult dataset by Shrinkage Estimation of Dispersion shows 
most genes closely associate with the line of best fit, and most genes used for second 
dispersion estimation (Figure 5-13.A).  
 
Figure 5-13  B. breve UCC2003 colonisation of adult mice induces small changes to intestinal 
epithelial transcriptome 
Overview over transcriptional changes in IECs of adult mice colonised with B. breve UCC2003 
relative to control (PBS gavaged) A Shrinkage estimation of dispersion, y axis dispersion estimate, x 
axis mean of normalised counts, black dots individual genes, red line maximum likelihood estimation 
(MLE) line of best fit, black dots circled in blue – potential dispersion outliers, blue area around red 
line – genes used for second dispersion estimate (not outliers), B PCA plot of group variability C 





control, y axis log2 fold change of gene expression, x axis – mean of moralised counts, red dots – 
statistical sig genes (q values 0.05) D Hierarchical clustering of samples based on TOP 50 
differentially regulated genes. 
The biological repeats present with clear separation between groups based on a PCA 
(Figure 5-13.B), except for one sample in the B. breve colonised group (UCC1), 
which is more similar to control group gene expression, but colonisation level 
analysis by plate counts showed similar cfu counts compared to biological repeats. 
Based on the MA plot (Figure 5-13.C), 87 DEGs are upregulated, while 16 are 
downregulated. 
The samples based on hierarchical clustering (Figure 5-13.D) associate within their 
groups based on analysis of the top 50 DEGs (p-value < 0.05), with this data set 
showing a more heterogonous gene expression between groups (compared to neonate 
samples).  
As with the analysis of the neonate dataset, initially genes with highest fold changes 
were investigated to understand the biological process of B. breve UCC2003 







Table 5-8 Differentially expressed genes with strongest positive fold change induced by B. breve UCC2003 in adult IECs 
Mapping pipeline alterations identified transcripts ID which were translated to gene IDs, duplicate transcripts with identical expression and q-values are 









Table 5-9 Intestinal epithelial transcripts with strongest downregulation in adult mice induced by B. breve UCC2003 colonisation 
Mapping pipeline alterations identified transcripts ID which were translated to gene IDs, duplicate transcripts with identical expression and q-values are 







The most upregulated gene is leukocyte immunoglobulin like receptor B3 (log2 fold 
change 8.2), which are expressed exclusively in immune cells highlighting, together 
with strong upregulation of immunoglobulin kappa variable (log2 fold change 8.1), a 
potential contamination of the IEC isolations by other cell types (Table 5-8). Nuclear 
antigen SP100 is part of the nuclear body that regulates gene transcription 
(potentially in response to leukaemia and viral infections), and a regulator of g-
protein signalling 1, are both upregulated (fold2 change 8 and 7.1) [384]. However, 
these genes are involved in various cellular processes, and without identification of 
specific up or downstream interactors, no definite biological mechanism can be 
identified for the increased transcription levels. 
The list of downregulated genes in adult IECs by B. breve (Table 5-9) contains 4 
unique genes. Phospholipase group A2 is a digestive enzyme involved in digestion 
of fatty acid glycerol, while gasdermin C belongs to a family of proteins exclusively 
expressed in the skin and the GI tract, with its upregulation suggested in colon rectal 
cancer [385, 386]. RegIII-γ is an anti-microbial peptide that convers its function 
through cell wall destruction via binding to peptidoglycans [387]. 
Overall, I was not able to identify specific targets or pathways potentially involved in 
the protective effect of B. breve analysing adult IEC transcription. This potentially 
supports the suggestion that bifidobacteria intestinal colonisation conveys a stronger 
host modulatory effect in early life, due to the not yet fully trained host immune 
system, as well as stronger modulatory effects on microbiota composition. The 
mechanism for LPS induced apoptotic cells shedding observed in adult mice remains 





5.3.7 miRNA21 expression predicted to be downregulated by B. 
breve UCC2003 in neonate IECs 
The utilised RNA-Seq approach involved isolation of RNA from tissues using a 
protocol that excludes transcripts with a length < 200 nt, which excludes small 
RNAs (18-24 nt) from the sequencing step. In addition, samples were processed by 
polyA pulldown, in addition to paired end sequencing generating reads > 200 
nucleotides, which is optimised to enrich for mRNA, and generate long reads that 
aids assembly and gene mapping, but is not suitable for profiling of small RNAs.  
More recently, it has become clear that small RNA types (18-24 nucleotides), 
including miRNA and siRNAs, play important biological roles. However, for such 
additional analysis, alongside mRNA RNA-Seq, I would have needed to perform 
additional sequencing runs, which was out with the scope of this PhD project.  
Within my datasets I did observe a small number of mRNA read counts, but previous 
studies have indicated that the applied protocol does not allow for accurate 
quantification, as read counts do not always correlate with an actual abundance, due 
to the bias introduced during sample processing. Therefore, I did not take these 
results forward for additional analysis [388].  
However, to potentially still investigate involvement of small RNAs in the observed 
transcriptional response to B. breve, I took an approach that used the DEG datasets 
from host mRNA to predict potential regulation of sRNAs, based on the expression 
of their known and predicted targets utilising IPA “upstream regulator” calculation. 
My analysis suggested miR21 to be downregulated, which appeared to be a 
promising target as it has previously been shown to be overexpressed in IECs of 
patients with UC, while in vitro overexpression decreases TEER, due to impaired TJ 
integrity [389].  
The neonate IEC dataset was used to make this prediction and was based on 60 out 
of 87 DEGs that are known targets of miR21 and expressed to match with their 
expression response (upregulation) with the predicted decrease in miR21 expression 





was the fact that miR21 reads counts were also present in the RNA-Seq sequencing 
data with a decrease in B. breve UCC2003 gavaged neonate IEC samples. 
 
Figure 5-14  B. breve UCC2003 colonisation does not modulate miR21 and its downstream 
target PDCD4 expression in whole small intestine and epithelial cells. 
(A) miR21and (B) PDCD4 expression in small intestinal tissue (whole small intestine and IECs) of 
conventionally (SPF) raised adult (12 weeks), neonate (2 weeks), SPF adult mice with elevated small 
intestine apoptotic cell shedding and germ free (GF) mice with and without B. breve UCC2003 
colonisation, mice were colonised with B. breve UCC2003 by oral gavage (109 cfu) on three 
consecutive days and tissue collected on day 4, intestinal cell shedding induced by IP injection of 1.25 
mg/kg LPS on day 4 and tissue collection 90 min post administration, IEC isolated from small 
intestinal tissue, RNA extracted from IEC isolations and whole small intestine samples, miR21 and 
PDCD4 expression assessed by qPCR, expression normalised to housekeeper and presented as fold 
change compared to age, colonisation status and treatment matched control group, data shown as 
mean +/- SD (SPF adult n=5, SPF neo n=5, GF adult n=6, DSS n=6). 
To validate this prediction, I subsequently analysed miR21 expression changes in 
mouse tissue in response to B. breve colonisation utilising a miR specific qPCR 
amplification and qPCR protocol. Contradictory to what the pathway analysis had 
predicted, I observed that expression was not altered during homeostatic conditions 
in IEC and WSI of neonatal mice, as well as adult and GF mice (Figure 5-14.A). As 
this miRNA has been implicated to play a role in UC, I also analysed intestinal tissue 
from LPS challenged mice, and observed that pre-colonisation with UCC2003 
induced a potential increase in miR21 expression, with a stronger response in IECs 





programmed cell death 4 (PDCD4), has previously been implicated to be protective 
in progression and metastasis of colon cancers [390]. A reduction in miR21 
expression would theoretically increase PDCD4 expression as the miRNA targets 
PDCD4 transcripts for degradation [391]. However, expression of PDCD4 was not 
altered in any of the analysed samples (Figure 5-14.B), but it should be noted that 
miR21 has a large variety of targets, and the approach, inferring miRNA regulation 
via mRNA pathway analysis, may not cleanly dissect true biological differences, 
which is why further validation and investigation is required. 
In addition to examining miR21 in the SI, I also analysed expression in the LI, and 
intriguing noted that miR21 expression was significantly downregulated in B. breve 
colonised mice in both adult and neonates. Additionally, in large intestinal samples 
collected from mice with DSS-induced colitis, miR21 transcription was also 
significantly decreased by presence of B. breve UCC2003. However, PDCD4 was 
also downregulated in these samples, and a decrease in miR21 would be expected to 
increase PDCD4 transcript levels due to reduced levels of degradation 
(Supplementary Figure 12). 
To summarise, B. breve appears to induce distinct transcriptional responses in IECs 
of neonatal mice. The investigation of signalling networks suggests an upregulation 
of integrin signalling, as well as the induction of TLR2 and TLR9, as well as IL17C. 
Importantly, these targets have been shown to play critical functions within the IE, 
and these data highlight B. breve-associated beneficial traits with respect to host-







The integrity of the IE is essential for human health, and a break down in this barrier 
has been associated with uncontrolled inflammation and disease. The microbiota 
plays a key role in positively regulating this barrier, but currently our knowledge on 
how specific bacterial members modulate IEC function is unclear. Whilst previous 
studies, including Hughes et al, have shed light on how beneficial microbes, such as 
B. breve UCC2003 may interact with the host via specific factors, i.e. via MyD88 
signalling during intestinal inflammation, it has yet to be determined, at a more 
global level, what genes and pathways are modulated during homeostasis. Thus, in 
this chapter I sought to probe B. breve-IEC transcriptional cross talk by performing 
unbiased RNA-Seq on isolated small IECs from both adult and neonatal mice, and 
downstream DEG and pathway analysis. The aim was to pinpoint key IEC pathways 
that B. breve may modulate to promote improved barrier integrity during 
homeostasis, which may allow development of improved targeted microbiota 
therapies for both health and disease. 
An important trait for any potentially beneficial microbiota therapy, such as B. breve, 
is the ability to colonise the GI tract, and also its specific localisation within the 
intestine e.g. within the mucus layer, or in direct contact with IECs. Faecal and 
intestinal cfu’s revealed that B. breve UCC2003 was able to colonise the murine GI 
tract, and therefore would be expected to interact with the host. B. breve may interact 
with the host via secretion of metabolites, as previous studies using Caco-2 cells 
have shown that supernatants from other bifidobacterial species were able to prevent 
TNF-α induced epithelial disruption, and increased wound healing, which the 
authors postulated was via the SCFA acetate [281]. Furthermore, the presence of B. 
breve was shown to modulate the wider microbiota, including increases in 
Lactobacillus and Bacteroides, and decreases in Balutia and Alistipes in both adult 
and neonatal mice, which would also be expected to modulate available metabolites 
for IECs (e.g. butyrate). Indeed, previous studies have highlighted the cross-feeding 
activities of bifidobacteria, and these microbe-microbe interactions will be probed in 





Previous studies have also indicated that a more direct interaction of Bifidobacterium 
on host cells, via contact-dependent mechanisms, may play a key role in modulating 
host functions.  In porcine IECs, co-culture with B. breve MCC-117 reduced the 
induction of pro-inflammatory cytokines in response to challenge by E. coli PAMPS 
[393]. Furthermore, previous studies with UCC2003 have shown that surface 
associated molecules such as the EPS capsule, appear to be critical for persistence 
within the GI tract, and that EPS negative B. breve UCC2003 mutant failed to induce 
protection of IECs during LPS-induced cell shedding [358, 394]. 
To reach the IE, microbes must first penetrate the mucus barrier. Interestingly, 
previous studies have suggested certain Bifidobacterium species have enzymes that 
can digest components on the mucus layer i.e. mucins, which may facilitate their GI 
localisation [395]. The SEM images suggest that B. breve is in close proximity with 
the IE, and therefore it is expected that this strain may be capable of directly 
modulating IEC responses. However, there are some limitations of these studies, 
particularly the fact that the methods for tissue collection do not preserve the mucus 
barrier completely, which hinders visualisation of B. breve. This could be addressed 
by colonising mice with a fluorescently labelled microbe, which would allow 
accurate visualisation within the lumen, and additionally could be used for 
longitudinal imaging of colonisation via ‘live’ imaging [396]. This clone is present 
within the lab, and will be utilised in future experiments to address the question of 
direct interaction of B. breve with the IE.  
After confirmation of colonisation and localisation within the GI tract, the next step 
was to perform global unbiased transcriptional analysis of IECs by B. breve 
UCC2003 through an RNA-Seq approach during homeostatic or ‘healthy’ 
conditions. The SI was chosen as B. breve had been shown by Hughes et al. to have 
a protective effect at this site from LPS-induced cell shedding, and importantly I 
confirmed colonisation of the SI, albeit at lower densities than observed in the colon, 
and observed close contact of B. breve with the small IECs.  
My analysis indicated a strong and distinct transcriptional IEC response in neonate 
mice, with the effect on IECs in adult being much weaker, with 10-fold lower 
number of DEGs. This could be attributed to several factors. The neonatal mouse 





more plastic to change, such as the introduction of a new species at very high levels 
by oral supplementation. This is confirmed by the high abundance of B. breve 
UCC2003 in the neonatal group microbiota 16S rRNA profiles when compared to 
the adult group, which may indicate a higher abundance within the microbial 
community is directly attributable to greater transcriptional changes. These high 
levels could be further supported by the fact that B. breve UCC2003 is a human 
infant isolate, and able to metabolise HMO lacto-N-tetraose and lacto-N-neo-
tetratose [397]. Although, mouse breast milk has a reduced number of milk 
oligosaccharides, when compared to HMO diversity, this diet would still be expected 
to selectively support the growth and colonisation of the neonatal mouse intestinal 
tract [398]. However, it may not just be an ‘abundance game’. Previous studies have 
established that the early life microbiota has a stronger effect on the host, which is 
based on new bacterial-host interactions in an immunologically ‘naïve’ host, and in 
later life these responses have already been primed. This is in part shown by the fact 
that neonatal innate immune cells, expressing TLR ligands, respond to microbial 
ligands distinctively differently than adult immune cells, which is characterised by 
reduced production of inflammatory compounds, and an increase in regulatory 
cytokines (i.e. IL-10) [399]. Nevertheless, I was still able to detect modulation by B. 
breve on adult IECs, which could in part be explained by the low levels of 
Bifidobacterium present in these mice, and hence the ability to induce specific 
pathways. As highlighted, I also probed WSI (which includes immune, and various 
other cells types, alongside IECs) transcriptional responses to B. breve, and observed 
low number of DEGs in both neonate and adult mice. The training of the immune 
system by the commensal microbiota in SPF mice could explain the low levels of 
DEGs observed in WSI of adult and neonate mice, which may also correlate with the 
strong induction of DEGs in WSI of mono-colonised mice in response to B. breve 
colonisation. 
Although there was a reduced transcription response in adult IECs to B. breve, 
downregulation of RegIIIγ was observed. Mice deficient for this antimicrobial 
compound present with increased contact between small intestinal villus tip IEC, and 
luminal bacteria, due to mucus alterations, and increased immune responses to 





previous studies in GF mice have indicated that another B. breve strain, B. breve 
NC29950 induced RegIIIγ, while exposure to other single commensal bacteria such 
as E. coli JM83 did not [401]. Furthermore, the induction by B. breve required whole 
cells (live and dead), as exposure of Caco-2 cells lines to culture supernatant failed 
to increase RegIIIγ expression. In contrast to this mono-colonisation system, B. 
breve UCC2003, as part of a complete microbiota in a conventionally raised mice, 
with a developed immune system, may induce downregulation of RegIIIγ to improve 
colonisation, and aid interaction with the host, by allowing contact with the IECs.  
Examining the neonatal DEGs in more detail revealed several interesting B. breve-
induced targets were observed; upregulation of TLR2 and TLR9, and IL17C. 
TLR2, which is expressed apically, is an important receptor for Gram positive 
MAMPs, including lipoproteins and peptidoglycan, which is present in cell walls. 
Notably, our previous work reported an increase in TLR2 expression in response to 
UCC2003 colonisation (potentially via EPS-capsule interactions), and which was 
suggested to signal via MyD88. Interestingly, TLR2 (and TLR4) are expressed at 
low levels on IECs, and in these neonatal mice, B. breve may upregulate this TLR to 
increase signalling via surface-associated factors to promote tissue homeostasis. 
Indeed, previous studies have shown, that TLR2 activation via protein kinase C, 
caused ZO-1 translocation, and increased intestinal barrier function, and MyD88 
signalling via TLR2/4 was determined to be crucial for limiting mucosal adherence 
and penetration of microbiota members through production of Paneth cell α-
defensins and RegIIIγ [402]. Collectively, these studies suggest that TLR2 plays a 
key role in protection of the IE, and may be one of the key targets for B. breve that 
drives beneficial IEC responses. 
Another gene target of interest that is upregulated in neonatal IECs is TLR9. TLR9 is 
expressed in IECs and recognises unmethylated CpG sequences in DNA, and is 
located at the apical and basolateral side of specialised M cells (IECs associated with 
PP). Notably, GF mice do not apically express TLR9, and IBD patients have 
downregulation of TLR9 in intestinal biopsies. The consequences of TLR9 
activation differs depending on the site of binding [20]. Exposure to ligands apically 
prevents NF-κB activation by ubiquitination, while binding at the basolateral 





Furthermore, apical stimulation of TLR9 can inhibit inflammatory IEC responses to 
basolateral binding, which suggests a level of tolerance induction, and a role for 
TLR9 in mediating host tolerance to luminal commensal bacterial. Mice deficient in 
TLR9 have low IECs NF-κB thresholds, and are more susceptible to DSS colitis, and 
in neonatal NEC models TLR9 deficient mice also present with increased symptoms 
of NEC, while activation of TLR9 signalling via bacterial DNA binding reduced the 
severity of NEC. Finally, the authors suggest that previous studies that observed 
attenuation of DSS colitis and NEC by probiotic bacteria, including B. longum, B. 
breve, B. infantis, may be mediated via the TLR9 receptor signalling cascade, and 
further suggests the utility of B. breve in possibly modulating IEC functions [403]. 
TLR3, while showing a less pronounced upregulation, nevertheless could have a 
strong biological effect, as its presence in IECs is inversely correlated with 
susceptibility to rotavirus infection. High levels are detected in adult mice, which are 
resistant to infection, while adult TLR3 IEC KO mice show higher colonisation 
[404]. Furthermore, TLR3 expression is low in suckling neonate mice, and human 
infants, and expression increases during the first 3 weeks of life. Interestingly, in 
neonates TLR3 IEC KO did not affect or worsen susceptibility to infection 
suggesting an essential role of TLR3 in adults, while responses in neonates are TLR3 
independent [404]. It could be hypothesised that B. breve is involved in the observed 
increase in expression as mice mature, and hence is important for the host defence 
against viruses.  
The IL-17 cytokine family are strong inducers of inflammation, and are critical for 
pathogen protection. Within this family there are several isoforms (IL-17A-F), which 
have been shown to have distinctive roles. In response to B. breve colonisation, IL-
17C was found to be significantly upregulated in IECs, and previous studies have 
indicated this isoform is important for modulating cytokine production, and 
stimulation of anti-microbial peptides in the GI tract. IL17C signalling, via IL-
17RA/IL17RE receptor complex, reacts to pathogen colonisation by modulating 
innate immune response and barrier function [405]. In response to C. rodentium 
infection, IL-17C was upregulated in colonic IECs, and in synergy with IL-22, 
increased anti-bacterial peptides, pro-inflammatory cytokines and chemokines (e.g. 





rodentium load in the GI tract, which was postulated to occur via direct colonisation 
resistance mechanisms (i.e. biofilm formation), but may also be linked to IL-17C 
modulation, and which would be of interest to pursue in future studies [358]. Studies 
using IL-17C KO mice, indicated greater susceptible to DSS-induced colitis, which 
was linked to increased IL-17A production, and reduced barrier integrity. These 
authors also showed that IL-17C directly regulated expression of occludin in colonic 
IECs, and another study using human tracheobronchial epithelial cells, indicated that 
IL-17 (together with IL-6) increases mucus glycoprotein genes MUC5AC and 
MUC5B expression, which could also be involved in enhancing barrier function 
[406]. These studies, together with my RNA-seq data, indicate IL17C as a promising 
B. breve-modulated target, which could be targeted to promote host defence against 
pathogens, and priming of the IE, via TJs, and potentially mucins.  
While the observed increase in IL-23 expression in neonate IECs by B. breve may be 
associated with a negative role in intestinal inflammation and in IBD, recently IL-23 
has been attributed health beneficial and protective effects, specifically in IECs 
[407]. IEC can produce IL-23 when stimulated by lymphotoxin beta receptor 
signalling, which aids in colonic wound repair, and offers protection from DSS-
induced colitis [407]. This effect is IL-22 dependent, which mediates the observed 
increased IEC survival and mucus production. Interestingly, IL-22 receptor unit 
alpha expression was also upregulated in the presence of B. breve. Hence, it could be 
proposed that under homeostatic conditions, B. breve increases IL-23 signalling as 
mean of modulating intestinal homeostasis, which when an inflammatory stimulus 
occurs (such as LPS) this keeps the immune system response in check. 
Use of pathway analysis, to expand the investigation into broader intestinal processes 
modulated by B. breve, revealed integrin signalling upregulation in neonate IECs. 
Integrins are a large family of transmembrane spanning proteins, which can induce 
cellular signalling and connect the extracellular matrix to the intracellular 
cytoskeleton, and are essential for intestinal epithelial barrier maintenance to 
macromolecules [408, 409]. Importantly, ITAG4 and ITAGV, which are upregulated 
in response to B. breve colonisation in neonate IECs, have recently been identified as 
IBD related SNP targets [410]. These mutations in B and T cells, resulted in 





responses in these immune cells, but highlighted that this hypothesis requires 
investigation in biological samples. Integrin signalling also play a critical role in 
maintenance of the epithelial barrier as previous studies have indicated with integrin 
αvβ6 maintaining IE integrity in T84 monolayers measured by trans epithelial 
resistant (ion flux) and permeability to macromolecule ovalbumin. Knockdown of 
this integrin increased macromolecule permeability, but not transepithelial crossing 
of ions [409]. In combination with cell matrix interactions and transmembrane 
signalling, one of the central roles of integrins is as a key regulator of cell 
differentiation, which has been well studied in the epidermis [411, 412]. As the IE is 
one of the fastest regenerating tissues of the human body, constant cell 
differentiation and migration is taking place. Integrins are expressed and involved in 
IE differentiation, but their role is this process is not well understood. Interestingly, 
the separation of IECs from the LP triggers anoikis (specific form of apoptosis) 
including signalling cascades, which are part of the integrin signalling pathway. 
Based on this knowledge, the effect of overexpression of integrin α5β1 in rat small 
intestinal cell lines RIE1 protected these cells from apoptosis when exposed to 
cytotoxic agents (aspirin, staurosporinem, etoposide). However, overexpression of 
subunit α2 did not induce protection [413].  
As the integrin family is diverse in structure and composition (two subunits form one 
functional dimer), it could be argued that even though one major subunit (i.e. α5β1) 
involved in apoptosis protection is not differentially regulated, the overall increase in 
expression, as well as upregulation of one subunit (i.e. β6 involved in improved IE 
barrier function), provides strong evidence for further exploration of the involvement 
of these complex integrin mechanisms in B. breve IEC modulation and potential 
protection [414]. Additionally, colonisation of B. breve UCC2003 three days prior to 
tissue collection could have already induced cytoskeletal and transcriptional changes, 
with integrin signalling having returned to baseline levels, while cytoskeletal and 
protein level modulation, are retained, but not measured by RNA-seq. Furthermore, 
mitogen activated kinases were both up and downregulated; myosin light chains and 
myosin light chain kinase decreased in transcription, while myosin phosphatase Rho 





reorganisation. It remains a possibility that changes to FA, and TJs are not only 
expression dependent, but also occur post translationally. 
miRNAs play a critical role in global transcriptional responses and downstream 
functions, therefore my first validation experiment from the RNA-Seq datasets was 
further investigation of miR21, as overexpression of miRNA has previously been 
linked to both mouse and human IBD studies. Although, pathway analysis predicted 
downregulation of miR21 within small IECs in B. breve colonised mice, and 
downstream targets, this was not supported by further qPCR studies. Previous 
studies have indicated that in vitro, miR21 expression was increased in response to 
TNF-α mediated intestinal epithelial TJ breakdown [415]. In the same polarised 
Caco-2 cell line, miR21 expression correlated inversely with epithelial barrier 
permeability. Comparing between GF and conventionally raised mice, Nakata et al., 
observed microbiota colonisation to induce miR21 expression, and regulate epithelial 
barrier function via upregulation of ADP ribosylation factor 4 transcription (ARF4). 
This small GTPase was found to be upregulated when miR21 targets programmed 
cell death 4 (PDCD4) and phosphate and tensin homolog PTEN were suppressed 
[416]. Notably, I did not observe major changes in miR21 expression in the SI 
induced by B. breve UCC2993 colonisation (except for the slight increase in in IECs 
and WSI during LPS induced cell shedding, but there was great intergroup 
variability), which may indicate B. breve does not have a significant role to play in 
miR21 regulation in the SI. However, I did observe a significant decrease in miR21 
in B. breve UCC2003 colonised whole colonic tissue. This reduction during DSS-
induced colitis suggests miR21 as a potential target for health beneficial effects 
specifically within the colon. However, PDCD4 (shown by Nakata et al. to be 
supressed by miR21) also showed decreased expression in the same samples. 
PDCD4 has been shown to have a beneficial role in colorectal cancer, while its 
suppression in Caco-2 cells caused a decrease in epithelial barrier function via 
GTPase ARF4, and its apparent downregulation by B. breve requires further 
investigation [416]. 
In summary, this study generated global transcriptional datasets of host responses to 
B. breve intestinal colonisation in neonatal and adult mice. A distinct response by 





the host health beneficial effect of B. breve. These targets include TLR2, TLR9, IL-
17C, and integrin signalling, and which will be explored further in subsequent 





5.5 Future plans 
The results generated so far are the first steps in understanding the host health 
beneficial effects of B. breve. Fundamental to confirm these data, is validation of the 
identified targets by qPCR. Following this analysis, tissue staining of TLR9, to 
observe its location relative to IEC baso-apical axis, would be performed. These 
further studies should be performed on both neonatal samples, as well as adult tissue 
samples, as translocation can occur within the intestinal cell membrane, which could 
change numbers of TLR9 receptors present at the apical surface. Previous studies 
have indicated expression of TLR9 in jejunal and colonic biopsies, as well as Caco-
2- cell lines, and TLR9 expression within the human jejunum is promising as it 
suggests that human small intestinal cells could be used for in vitro co-culture with 
B. breve.  
Integrin upregulation would also be of significant interest to pursue further as it is 
induced in both neonate and adult samples. Preliminary experiments would involve 
validation of RNA-Seq results, followed by integrin staining to assess location 
within the IE. Measurements of TEER, in presence and absence of B. breve in 
combination with different integrin inhibitors, would be a potential avenue to 
explore. An alternative approach would be the use of cell type specific integrin KO 
mice, which would allow for observation of B. breve UCC2003 modulation of 
integrins in a translational model. 
Additional, the observed upregulation of IL-17C transcription by B. breve poses a 
promising target to investigate further, particularly with respect to its role in 
pathogen defence (i.e. C. rodentium), which also correlates with previous B. breve 
pathogen protection studies [358, 405]. Following preliminary experiments in vitro, 
observing IL-17C induction in intestinal cell lines co-cultured with B. breve, KO 
mice for IL-17C (commercially available) could be utilised for C. rodentium 
infection studies, which would allow generation of more translational results. As B. 
infantis reduces NEC incidence in neonate rats, potentially by preventing overgrowth 
of pathogenic or opportunistic pathogenic bacteria, and bifidobacteria being a 
prominent member of the “normal” infant gut microbiota, bifidobacterial-induced 
IL-17C could potentially confer health beneficial effects against pathogen invasion at 





The downregulation of miR21 in large intestinal samples colonised by B. breve is an 
interesting observation, and although out with the focus of this investigation, is a 
potentially promising avenue to explore. Initially, expression of other downstream 
targets of miR21 could be investigated, as one important downstream target, 
PDCD4, was observed to be downregulated in samples with decreased miR21 
expression, while an increase was expected. Recently comparing GF with 
conventionally raised mice, an increase in miR21 in the presence of the microbiota 
was observed, with accompanying decrease in PDCD4, and increase in ADP 
ribosylation factor 4 (ARF4), which in vitro has been shown to increase epithelial 
permeability [416]. Hence ARF4 expression would be a high priority target to 
investigate in vivo, in combination with measurements of B. breve UCC2003 
modulation of epithelial permeability. 
As mentioned above, understanding how B. breve modulates IEC function, either via 
direct interactions with the host, and/or indirect effects modulated via metabolites or 
bacteria-bacteria interactions is central to developing novel therapies. This requires a 
meta-functional analysis of the microbiota as well as B. breve itself. An overlay of 
host and bacterial functional data in form of RNA-Seq has been coined dual RNA-
Seq or paired RNA-Seq and has been applied successfully in shedding light on host-
microbe interactions [419]. The initial results generated using this approach will be 






6 B. breve UC2003 transcription shows distinct modulation during 
colonisation of gnotobiotic and conventionally raised mice, and 
affects wider microbiota function  
6.1 Introduction 
In the previous chapter, I have shown that B. breve is able to induce distinct 
transcriptional responses in adult and neonatal mouse IECs. This modulation could 
potentially play an important role in host wellbeing, and thus help define B. breve-
associated beneficial effects that could be harnessed to promote homeostasis, and/or 
modulate disease pathogenesis. Probing the role of B. breve on host responses is key 
to defining pathways that are modulated by this bacterium, however to more 
comprehensively determine what microbial factors may modulate these host changes 
it is important to explore B. breve transcriptional responses in vivo, and also 
determine how introduction of B. breve into the wider microbiota may modulate the 
metatranscriptome, and intestinal metabolome. The aim is to identify specific 
changes induced by B. breve colonisation, and identify microbial genes/pathways 
that could potentially be targeted for further development of more ‘personalised’ 
probiotics.  
6.1.1 Bifidobacteria metabolism: impact on the host, and wider 
microbiota via cross-feeding  
Carbohydrates represent the main energy source within the human diet, and are 
essential for host and microbiota metabolism Their bio-availability depends strongly 
on their structure, and this influences their uptake along the GI tract. Simple 
carbohydrates, such as sugars (e.g. lactose and sucrose), are absorbed in the upper 
part of the intestinal tract by the host, and residing members of the microbiota such 
as Lactobacillus [251]. In the colon, the main site of bifidobacterial intestinal 
colonisation, available carbohydrates are more complex, and as such they avoid 
digestion and uptake by the host, and thus represent an important dietary source for 
microbial fermentation [420]. Plant derived complex carbohydrates include pectin, 





CHs [420]. Furthermore, microbial associated carbohydrates, such as EPS capsules, 
also contribute to the wide variety of available carbohydrates in the gut [421].  
Bifidobacteria have been shown to be able to metabolise a wide range of these 
carbohydrates found in the mammalian diet (defined as heterofermentative), 
particularly within the colon. This carbohydrate degrading ability is due to a series of 
carbohydrate-degrading enzymes encoded in the genome, which allow for 
breakdown of polymeric carbohydrates to monosaccharides; processed by fructose-
6-phosphate phosphoketolase (hexose fermentation pathway). This enzyme is a key 
part of the “bifid” shunt, as bifidobacteria lack the ability to ferment glucose by 
aldolase (part of glycolysis), or glucose-6 dehydrogenase (hexose monophosphate 
pathway) [422]. This fermentation pathway process yields glucose, lactate and 
acetate, and distinguishes bifidobacteria from other gut-associated microbiota 
members e.g. Lactobacillus.  
Other enzymatic pathways essential for bifidobacteria are GHs, which help cleave 
complexes into smaller fragments. GHs in the human genome do not process the 
main complex carbohydrates found in diet (e.g. fructo- and galacto-oligosacharides, 
inulin, etc.) [253]. However, these components can be fermented by bifidobacteria, 
making metabolites available to the host, and also other microbiota members lacking 
GHs. Analysing the overall distribution of GHs in the microbiota, bifidobacteria 
contain more than half, giving the genus an essential role in complex carbohydrate 
fermentation in the human intestine [253]. 
As these carbohydrates have specific growth promoting effects on bifidobacteria 
they have been widely used as prebiotics, defined as ‘a substrate that is selectively 
utilised by host microorganisms conferring a health benefit’ [423]. Notably, 
previous studies have indicated a beneficial role for prebiotic supplementation in 
rodent models; administration of resistant starch and fructooligosacharides to rats, 
increased Bifidobacterium and Lactobacillus cfu, which was correlated with 
increased barrier function, via MUC-2 upregulation, and an increase in the mucus 
barrier [424]. 
The fermentation of CHs is involved in cross feeding between bifidobacterial 





molecules produced by breakdown, or production of lactate and acetate, both 
compounds produced via bifidobacterial metabolism. This interaction has been 
demonstrated both for plant and host derived CH sources. For example, lactate and 
acetate produced by two B. adolescentis strains, via fermentation of either starch or 
fructo-oligosaccharides, was processed by E. hallii to butyrate, a SCFA essential for 
IEC metabolism [132]. Host derived CHs, such as mucins, also play a key role in 
intra-genus ecosystems, as B. breve UCC2003, whilst lacking the ability to digest 
mucus independently, and is able to grow by feeding on mono- saccharides, when 
co-cultured with B. bifidum PRL2010, via this strains ability to breakdown mucins. 
During infancy, HMOs are a major component of the diet, and reach the colon 
undigested, in contrast to simple sugars, which are absorbed by the host directly. 
Various bifidobacteria possess the ability to metabolise HMOs, which gives them a 
competitive advantage, and preferentially selects these strains as early colonisers. B. 
bifidum and B. longum subsp. infantis possess the genetic machinery to completely 
process a wide variety of HMOs, while B. breve can only digest certain HMOs, 
however it does utilise downstream HMO metabolites produced by other 
bifidobacterial strains [259].  
Iron is an essential micronutrient, which is critical for growth and persistence of 
bacteria within the intestine. Pathogens express iron-sequestering mechanisms to 
improve their colonisation success [425]. Bifidobacteria also encode iron uptake 
systems, and previous studies have indicated that B. breve UCC2003 has two 
putative systems; sifABCDE, which is involved in ferrous iron transport, and the 
bfeUO-encoded transport system, which imports both ferrous and ferric iron [426]. 
Vitamins can be produced and utilised by microbiota member, and are essential for 
overall health of the host and the wider microbiota. Folate production has been 
identified in several strains of Bifidobacterium, including B. adolescentis MB239 
[427]. Notably, folate is linked to increased IEC turnover, with potential negative 
effects on colon rectal cancers, but additive folate supplementation is often suggested 
to patients with IBD, to reduce symptoms and relapse [428, 429]. 
Bifidobacteria produce a vast array of metabolites in response to dietary 





Efficient colonisation of these bacteria within the GI tract is also important for these 
downstream metabolic activities, and in this respect EPS capsules and pili may be 
expected to play a key role as discussed in section 1.4.4. Thus, this microbiota genus 
represents a key player to probe transcriptional changes in vivo, examining both 
intra-strain responses (i.e. B. breve UCC2003), and also inter-microbiota responses.  
6.1.2 Differences in the microbiota between mouse models and 
humans  
The use of mouse models to study human physiology has been discussed with 
regards to genetic, immunological, and intestinal epithelial differences in the general 
introduction. In this section, I will give a brief overview of the mouse microbiota in 
comparison to the human intestinal bacterial community (summarised in Figure 6-1). 
 
Figure 6-1 Overview over the bacterial composition and abundance of human and mouse 
microbiota at genus level  
based on the published mouse catalogued and human microbiota studies, amended from 
Hugenholtz & de Vos, 2017 [430]. 
Human and mouse microbiota’s share similarities when compared at the phyla level, 
with Bacteroidetes and Firmicutes being the most abundant [216]. Notably, a recent 





including different strains, providers, and different mouse facilities [431]. This study 
is the most holistic to date, and is an excellent reference for future mouse studies. 
The analysis showed 541 total species in the mouse microbiota, with 26 ‘core’ 
species. Interestingly, the mouse microbiota shows functional similarity with the 
human microbiota, as 95.2% of KEGG orthologous groups are shared, but only 4% 
of the mouse gut bacterial genes are present in the human microbiota. Crucially, the 
main driver of differences in microbiota composition between mice is supplier, 
followed by facility. This highlights the importance of consistency when performing 
mouse microbiota experiments, as it has been shown that even within the same 
facility changes occur to the intestinal bacterial community. Hence, it has been 
suggested to co-house mice for as long as possible to account for inter-animal 
variation, and potentially retain samples or animals with the “original” microbiota 






6.2 Hypothesis and aims 
6.2.1 Hypothesis 
B. breve transcriptional profiles differ when in an in vivo environment, and in the 
presence of a diverse microbiota, which may link to modulation of wider microbiota 
profiles, and host IEC responses.  
6.2.2 Aims 
1. Analyse the B. breve UCC2003 transcriptome in vivo (both SPF and GF models), 
and compare to in vitro 
2. Assess changes to the overall microbiota metatranscriptome to identify modulation 
by B. breve UCC2003 colonisation 
3. Investigate the effect of B. breve UCC2003 on the metabolome of the intestinal tract 
4. Observe potential direct interactions between host and B. breve via membrane 







6.3.1 B. breve UCC2003 transcription is distinctly different 
comparing in vitro with in vivo gnotobiotic, and conventionally 
raised intestinal conditions 
Here, I present an investigation into the global transcriptome of B. breve UCC2003 
in vitro, and in vivo, both in gnotobiotic and conventionally raised mice, to assess 
specific genes/pathways that may be involved in colonisation process, modulation of 
the wider microbiota, and IEC modulation (as presented in chapter 6.3). 
6.3.1.1 Overview of experimental design to investigate changes to 
microbiota transcription, taxonomy and metabolomic profile in 
response to B. breve UCC2003 colonisation 
To analyse the intestinal microbiota metatranscriptome, the colonisation model 
previously applied (chapter 5.3) was used. In brief, SPF and GF mice were colonised 
by oral gavage with 109 cfu on three consecutive days. Following 24 hours post the 







Figure 6-2 Analysing metatranscriptome and metabolome in vitro and in vivo in response to 
B. breve UCC2003 colonisation 
C57B/6 adult (12 weeks) SPF and GF mice were colonised by oral gavage (109 cfu) with B. breve 
UCC2003 on three consecutive days, large intestinal contents were collected 24 hours post last 
gavage (day 4), assessment of in vivo samples by RNA extracted and sequenced using Illumina HiSeq 
and processed for identification of differential gene expression of UCC2003 transcripts (Bowtie2 
alignment to B. breve UCC2003 reference genome, HTseq read counts, differential expression 
DeSeq2), microbial taxonomy and SEED functions of metatranscriptome (SUPER-FOCUS), 
metabolomic analysis of large intestinal contents by NMR and of isolated bile acid fraction by MS, 
assessment of in vitro B breve UCC2003 gene expression and metabolomic profile by culturing in 
MRS for 18 h, RNA extracted, transcripts sequenced and analysed following in vivo workflow, 
supernatant collected and analysed by NMR, in vitro samples generated by Jennifer Ketskemety, 
NMR performed by Gwenaelle Le Gall, bile acid fractionation and MS analysis carried out by Mark 
Philo. 
For RNA extraction from intestinal contents, I trialled three extraction protocols. The 
first one was a modified RNAsnap method, which included a Percoll gradient to 
allow for concentration and purification of the bacterial cells prior to RNA 
processing [432]. The second method had been published by Illot et al. for extraction 
of transcripts from colonic contents, while the third method was a modified 
commercial protocol using the QiagenRNeasy RNA isolation kit, with the 






With bacterial load being lower in mono-colonised, compared to SPF mice, it was 
essential that the utilised protocol enabled reliable extraction of high quality (RIN>8) 
and quantity of RNA (>1ug required for sequencing) from small samples (average 
pellet weight <35 mg). The modified Qiagen kit protocol was determined to be the 
most successful, based on these criteria, and was therefore taken forward.  
RNA extraction from contents of the SI and colon of SPF and GF mice were trialled, 
however I did not successful obtain enough high-quality RNA from small intestinal 
contents of mono-colonised mice, most likely due to lower bacterial abundance 
(Figure 5-4 in chapter 4). Processing small intestinal samples of SPF mice did yield 
RNA, but of poor quality (RIN<6), potentially caused by the higher concentration of 
digestive enzymes leading to greater degradation. Therefore, I progressed with RNA 
extraction from colonic content and faeces from GF mono-colonised mice and SPF 
mice, and obtained reproducible and high-quality RNA suitable for downstream 
processing. After optimisation experiments, the large intestinal contents of mono-
colonised mice had all been processed, therefore faecal samples for this group were 
used for sequencing. Samples were depleted of ribosomal RNA by 
immunoprecipitation as bacterial mRNA only makes up 1-5% of total RNA. 
Samples were sequenced by Illumina HiSeq 75 bp paired end protocol.  
Following raw data generation, processing was performed for identification of B. 
breve UCC2003 genes, as well as overall metatranscriptome function of the total 
bacterial community with bioinformatic support and guidance by Shabhonam Caim 
(QIB).  
6.3.1.2 Probing B. breve UCC2003 transcription for distinct patterns during 
in vivo and gnotobiotic as well as colonisation as part of a complex 
microbiota 
To identify differential gene expression of B. breve UCC2003 in vivo, as a member 
of the wider microbiota community, and as a mono-coloniser, read fragments 
generated by RNA-seq were mapped against the B. breve UCC2003 genome, using 
Bowtie 2, followed by read count extraction with HTSeq, and differential gene 





In addition to the described experimental groups, RNA extracted from B. breve 
UCC2003 in vitro (MRS media at stationary growth phase, performed by Jennifer 
Ketskemety, was also analysed and compared to allow comparison of in vivo vs. in 
vivo transcription. 
Alignment of RNA fragments to reference genomes is essential for accurate gene 
count determination. The utilised pipeline has been successfully applied to in vitro 
samples of single bacterial species, and in this study produced adequate outputs 
(based on quality control) for B. breve UCC2003 in vitro, and mono-colonised 
samples [433]. The alignment of raw reads of metatranscriptome samples requires a 
different approach to ensure high quality alignment and capture resolution. In this 
study I utilised Bowtie 2, which has also been previously used by other groups, but 
there are some limitations of this approach, which will be discussed further within 
the discussion and future work section [434]. 
6.3.1.3 Comparing B. breve UCC2003 transcription in vitro and in vivo as 
part of complex microbiota, and in a gnotobiotic mouse model, 
reveals distinct gene expression profiles for each condition 
Based on detected B. breve UCC2003 transcriptome, initially an overview of all 
three data sets was generated. The PCA plot in Figure 6-3.A shows a clear clustering 
of groups, suggesting a distinct gene expression profile of B. breve UCC2003 in 







Figure 6-3 B. breve UCC2003 RNAseq in vitro and in vivo in the intestine of GF and SPF mice reveals distinct transcriptional patterns in each 
condition 
In vitro – B. breve UCC2003 culture in MRS, Mono – GF mice colonised by B. breve UCC2003, SPF+UCC – conventionally raised mice colonised by B. breve 
UCC2003 A PCA plot of group variability, B Bland Altman (MA) plot, y axis log2 fold change of gene expression, x axis – mean of moralised counts, red dots – 





Visualising the top 50 genes (Figure 6-3.B), based on p-value, presents hierarchical 
clustering of individual in vitro samples, separate from in vivo repeats, which may 
link to the artificial environment of culturing in MRS media, compared to the 
environment within the mouse intestine. A stronger intergroup similarity between 
mono-colonised, and samples extracted from SPF mice colonised by B. breve 
(SPF+UCC) can be observed. More than 75% of genes are strongly upregulated (red 
in heatmap) under in vitro condition, with the remaining functional units being 
strongly downregulated (blue). There is general consensus between direction of fold 
change between in vivo samples, with SPF+UCC repeats presenting very low 
expression of specific genes. To understand this, as well as clustering further, gene 
overlap of expressed genes between groups is shown in Figure 6-3.C. The total 1984 
transcripts present in the B. breve UCC2003 reference genome are expressed in the 
sum of the data set. Mono-colonised samples share their entire expression profile 
with the SPF group, with 32 genes only expressed when cultured in MRS, while all 
396 genes expressed by B. breve UCC2003 in vivo, as part of the wider microbiota, 
are also transcribed under gnotobiotic and in vitro conditions. 
Of these uniquely expressed genes in vitro (Table 6-1), three were hypothetical 
proteins, for which no homologues sequences were found (NCBI BLAST [435], 
75% coverage, 75% identity). In total, 25 of these transcripts were identified as 
transposases, which are located at different parts of the genome, but share sequence 
identity between each other. Three unique sequences were found and are indicated 
by letters under “Sequence Identity” in Table 1. Homology analysis of sequence C 
(shared between genes Bbr_0159 and Bbr_0302) did not yield similar proteins with 
known functions. Interestingly, transposases with sequence A (11 in total uniquely 
expressed under in vitro conditions) mapped with 49% identity and 90% coverage to 
gene BL105A_0419 in B. longum 105-A [436]. This transcript is labelled as a 
putative transposase in the organism, and suggested to be part of an EPS cluster. 
Two other transposases, Bbr_0433 and Bbr_463 only expressed in vitro, are part of 
the EPS cluster in B. breve UCC2003, with an additional 10 other transposases 
sharing their sequence (indicated by letter B in Table 6-1), while also unique to in 
vitro conditions, but present at other sites within the genome [280]. In addition, 





vitro culture. Expression of all genes within the EPS cluster will be shown and 
discussed below. It should be mentioned though that gene Bbr_0462, a transposase 
in B. breve UCC2003 EPS cluster, shares sequence homology with the identified 
transposase BL105A_0419, involved in EPS production in B. longum, and is again is 
only transcribed in vitro.  
Table 6-1 Uniquely expressed B. breve UCC2003 genes under in vitro conditions compared 








This great overlap of genes expressed between groups emphasis that the distinct 
transcriptional profiles observable by PCA and heatmap, are largely based on 
expression values. Regarding SPF+UCC samples, the very low number of genes 
detected could be a potential artefact of using Bowtie 2 as metatranscriptome 
alignment software, and will be discussed further in the future work section of this 
chapter. 
6.3.1.4 In the intestinal tract of gnotobiotic mice, B. breve UCC2003 
increases expression of pathways involved in HMO metabolism, and 
iron uptake, while decreasing EPS production compared to in vitro 
transcription 
To assess genes required for in vivo colonisation, adaptation to the nutrients present 
in the intestinal tract, and potentially identify genes with host beneficial effects, I 
analysed DEG expression in the B. breve UCC2003 in vitro vs. the mono-colonised 
GF transcriptome. 
Figure 6-4.A shows a PCA analysis, with both groups clustering distinctively, with 
stronger intergroup differences between the two in vitro repeats. Assessing 
hierarchical clustering based on top 50 differentially expressed genes (Figure 6-4.B), 
a clear separation between in vitro and mono-colonised samples is observed, with all 
genes upregulated in vivo. Calculation of DEGs shows 701 transcripts upregulated in 
B. breve when present in the intestinal tract of GF mice, while 669 are decreased in 







Figure 6-4 B. breve UCC2003 colonisation of gnotobiotic mice induces distinct bacterial transcriptional responses compared to in vitro gene 
expression 
A PCA plot of group variability B hierarchical clustering of samples based on TOP 50 differentially regulated genes C Bland Altman (MA) plot, y axis log2 fold 





Table 6-2 presents the top 25 upregulated genes in mono-colonised samples, based 
on log2 fold changes. Interestingly, four genes involved in metabolism of HMOs 
lacto-N-tetraose (LNT) and lacto-N-neotetraose are present in this list [397]. This 
includes gene 1599 (Bbr_1558, NahP1) and gene1600 (Bbr_1559, nahP2), both 
permease proteins of ABC transporter systems, and gene1601 (Bbr_1560, nahT), a 
ATP binding protein of permease transporter systems. The proposed metabolomics 
pathway is shown in Figure 6-5, with the corresponding expression values in my 
dataset presented in Table 3. Out of 20 involved proteins (Table 6-3), 10 shows 
transcriptional upregulation, while 9 are present, but not modulated, in contrast to 
downregulation of gene1628 (Bbr_1586, nahK), a phosphotransferase family 
protein. Particularly striking is a 5-fold increase in β-galactosidase gene540 
(Bbr_529, lntA), which is a key enzyme in the pathway, as it processes LNT to 





Table 6-2 B. breve UCC2003 top 25 upregulated DEGs under in vivo mono-colonised conditions compared to in vitro transcription  








Figure 6-5 Representation of human milk oligosaccharide metabolism by B. breve UCC2003  
Proposed by James et al., overview over HMO metabolism by B. breve UCC2003 of lacto-N-tetraose 
(LNT), lacto-N-neotetraose (LNnT), and lacto-N-biose (LNB), gene names corresponding Table 3.: 
LntA (beta-galatosidase), LacZS (galactoside symporter), LacZ6 (beta-galactosidase), NahA (beta-N-
acetylhexosaminidase), LntA (beta -galatosidase), LnbP (lacto-N-biose phorylase), (adapted from 
James et al, 2016 ). 
Another candidate gene found in the top 25 upregulated transcript list (Table 6-2) is 
gene226 (Bbr_0222, bfeO); a conserved hypothetical secreted protein, with an iron 
binding domain (Table 6-4) [437]. It belongs to an iron starvation induced cluster, 
that has previously been shown, in B. breve UCC2003, to be induced by iron-
starvation conditions (in vitro). This cluster is under the transcriptional control of 
interspecies signalling molecule autoinducer-2 (AI-2), which is the by-product of 
methylthioadenosine/S-adenosyl-homocystine nucleosidase (luxS) [438]. This gene 
(Bbr_0541 [gene552]), is non-significantly upregulated (2.7 log2 fold, q-value 0.08), 







Table 6-3 B. breve UCC2003 genes involved in HMO metabolism are upregulated under monocolonise in vivo conditions relative to in vitro 








Table 6-4 Genes involved in iron uptake differentially upregulated in B. breve UCC2003 during intestinal colonisation of germ free mice relative to in 
vitro conditions 







Table 6-5 B. breve UCC2003 top 25 downregulated DEGs under in vivo mono-colonised conditions compared to in vitro transcription 







Table 6-6 Gene cluster required for B. breve UCC2003 surface exopolysaccharide production present transcriptional downregulation under in vivo 
gnotobiotic conditions compared to in vitro 







Table 6-5 shows the top 25 downregulated DEGs based on log2 fold2 change, 
comparing in vitro conditions, with colonisation of the GF mouse gut. Of those hits, 
12 belong to the bidirectional EPS-encoding gene cluster in B. breve UCC2003, 
shown in Figure 6-6 [358]. As mentioned in subchapter 1.4.4, this cluster is 
responsible for production of an EPS capsule that facilitates colonisation, and also 
provides bile, and acid resistance [439]. The gene cluster can generate two different 
EPS structures based on the orientation of promotor orientation. EPS polymers are 
produced by enzymatic chain reactions carried out by glycosyl transferases (GT) 
with both EPS (EPS1, EPS2) sharing one priming glycosylase (gene453/Bbr_0441 
and gene454/Bbr_0442). Analysis of total DEGs revealed 20 transcripts in the 
pathway to be downregulated with fold changes ranging from -1 to -9, while the 
remaining involved genes are not statistically altered (Table 6-6). Downregulation of 
priming GT occurs for EPS1 (gene453/Bbr_0441), while unaltered for EPS2 
(gene453/Bbr_0441).  
 
Figure 6-6 Overview over gene cluster involved in surface exopolysaccharide production in B. 
breve UCC2003 
Corresponding gene expression fold changes shown in Table 6, adapted from Fanning et al, 2012 
Hypothetical proteins contained within the list of downregulated DEGs under mono-
colonised conditions Table 6-5, were analysed for sequence homology, and gene466 
(Bbr_0454) shared 99% sequence and 100% coverage identity with insertion 





identified in eight other bifidobacterial strains [440]. Other identified IS were shown 
to be active during growth in vitro, and were suggested to cause genome reduction 
and rapid adaptation to new growth conditions [441]. In addition, the identical 
sequence overlap was found in an integrase of B. breve MCC114 (NCBI reference 
sequence KOA65106.1), further supporting the function of this transcript as a 
transposase. 
6.3.1.5 Colonisation of intestinal tract harbouring complex microbiota 
induces differential expression of B. breve genes involved in 
metabolism, stress response, and transformation resistance, relative 
to gnotobiotic conditions 
The RNA-seq analysis of the bacterial metatranscriptomic data differs significantly 
from single species samples as indicated above. For this analysis, I used Bowtie 2 (as 
the raw read aligner), due to the feasibility of implementation, and utilisation of 
bacterial RNA-seq in single species populations [298]. Distinct clustering can be 
observed for mono-colonised samples, while SPF+UCC has greater intragroup 
variability, based on the PCA plot (Figure 6-7.A). Hierarchical clustering, assessing 
expression ratios, separates samples of both groups, as shown by heatmap analysis 
(Figure 6-7.B). A total of 49 genes are differentially expressed, with 48 upregulated, 
and one downregulated (30A ribosomal protein, log2 -1.6-fold change, Figure 6-7.C). 
It should be noted that out of 1972 genes in the B. breve UCC2003 reference genome 
(NCBI ID 1273), 397 unique genes were mapped in SPF+UCC compared to 1953 in 
mono-colonised. In addition, expression counts are lower in SPF+UCC (max. 399 to 






Figure 6-7 Colonising of conventionally raised mice induces upregulation of a distinct gene profile compared to gnotobiotic mice 
A PCA plot of group variability B hierarchical clustering of samples based on TOP 49 differentially regulated genes C Bland Altman (MA) plot, y axis log2 fold 






Table 6-7 B. breve UCC2003 top upregulated genes based on fold change comparing presence in complete microbiota with mono-colonised conditions  










Table 6-7 highlights the top downregulated genes, based on log2 fold change. 
Hypothetical proteins were analysed by BLAST for sequence homology, with above 
mentioned parameters, and three hits were returned. Gene1521 (Bbr_1487) showed 
homology with a transcriptional regulator of the MarR family in B. breve ACS-071 
(Ref Seq: WP_003830074.1). Genome wide studies in B. longum have shown 
bifidobacteria to harbour relatively few transcriptional regulators of this type, 
compared to other bacteria [248]. The exact function of the gene in B. breve is 
unknown.  
The anti-restriction protein ArdA, found in the NCBI reference sequence for B. breve 
(WP_015439154.1), overlapped with upregulated hypothetical gene1578 
(Bbr_1539), and could suggest an increase in transformation in the presence of other 
gut bacteria favouring horizontal gene transfer. Contrastingly, gene217 (Bbr_0214), 
a type II restriction-modification system subunit, also presents with increased 
expression in the presence of the wider microbiota, which could be interpreted as a 
defence mechanism against foreign DNA. 
Hypothetical protein gene1398 (Bbr_1366) shares 100% sequence, and 99% 
coverage, with cell wall integrity and stress response protein 1, which was again 
found within the NCBI B. breve reference (WP_065465773.1). Studies of this 
protein in other microbes (e.g. Saccharomyces cerevisiae) have located it to the cell 
surface, with a function of reacting to stress, such as heat shock, or cell division, 
with induction of cell wall remodelling [442, 443]. Interestingly, gene1270 
(Bbr_1241), a cell wall biosynthesis associated protein, is upregulated by log2 6.7-
fold, which further suggests that B. breve UCC2003 is adapting to the presence of 
other gut microbiota, specifically with cell wall modulation. 
Calcineurin-like phosphoesterase (Gene1383, Bbr_1351) expression is increased 
when B. breve UCC2003 is part of a complex microbiota, relative to mono-
colonisation. The exact function of calcineurin-like phosphoesterase is not yet 
understood, but the gene has been shown to have increased expression in B. longum 
BBM68, when exposed to bile acids in vitro.  
The Sugar ABC transporter permease (gene1700) gene was upregulated by 6.8 log2 





nutrients within the gut of GF, compared to SPF mice [444]. Other genes showing 
increased expression, potentially involved in adaptation to the available nutrient pool 
in SPF mice, are a glycoprotease (gene1154, Bbr_1125), a branched chain amino 
acid transport system II carrier protein (gene1022, Bbr_1001), and gene1965 
(Bbr_1908), which functions as a serine/threonine protein kinase. 
Lastly, gene55 (Bbr_0055), a conserved hypothetical protein, had strongest 
upregulation, which has previous been suggested to be  non-essential, due to higher 
insertion frequency in this gene in a high-resolution transposon directed insertion 
sequencing (TraDIS) approach [357]. This highlights the potential difference in 
transcription encountered between in vitro and in vivo conditions.  
For the previously highlighted EPS cluster genes (Figure 6-6), there were no read 
counts observed within the SPF+UCC sample set, while some genes transcripts 
involved in HMO metabolism, and iron assimilation pathways were present but with 
q-values < 0.05, due to intergroup variation. These findings are potentially skewed 
by the applied read garment mapping, and gene count quantification approach, 
producing lower read counts for B. breve UCC2003 gene expression in the 
metatranscriptome samples. Additional analysis will further tease apart other genes 






6.3.2 Assessing the effect of B. breve colonisation on wider microbiota 
composition and function 
The benefits of metatranscriptome sequencing of the gut microbiome include the 
ability to determine pan-transcriptional changes that are potentially induced by B. 
breve UCC2003 colonisation.  
As touched upon earlier, the challenge of metatranscriptome data processing lies in 
identification of genes within the raw reads. For the gut microbiota, this includes 
more than 9,000,000 unique genes from 125,000 bacterial genomes, which is 
computationally challenging [435, 445]. For this analysis SUPER-FOCUS 
(SUbsystems Profile by databasE Reduction using FOCUS, SF) was utilised (Figure 
6-2), which is a homolog-based approach that sorts each generated sequence into a 
subset (proteins families with similar function), by comparison to a pre-clustered 
SEED database [300, 446]. This method allows for rapid identification, without loss 
of sensitivity, coupled with greater functional coverage of reference databases 
queried. In addition, this software contains FOCUS, a profiler that constructs 
taxonomic compositions based on oligonucleotide sequences to reference genomes 
sourced from SEED servers [301, 447]. This allowed me to investigate the effect of 
B. breve UCC2003 colonisation on the gut microbiota composition. 
6.3.2.1 Introduction of B. breve UCC2003 shifts the overall microbiota 
function to increased protein production, and decreased 
carbohydrate metabolism 
The supplementation of bifidobacterial species has been shown to induce various 
changes in the intestinal microbiota. This may in part be due to cross-feeding 
mechanisms between bifidobacteria species, and other microbiota members, such as 
butyrate producing anaerobes (e.g. Firmicutes, Eubacteria) [132]. As these 
modulations are associated with health beneficial effects I analysed the effect of B. 
breve UCC2003 colonisation on the overall function of the microbiota, which will be 
presented below.  
Analysing sample similarity, based on their SEED classification, by PCA is shown 





mice, with and without B. breve colonisation, while the overall differences between 
groups, and individual samples are small, as indicated by the axis range. This agrees 
with previous studies supplementing mice with UCC2003, and also the small 
taxonomic changes investigated by 16S rRNA sequencing in this model (Figure 5-5 
in Chapter 2) [46]. 
Figure 6-9 shows functional SEED classification on sublevel 2, of the total 
microbiota in groups SPF and SPF+UCC. Figure 6-9.A highlights the top 20 
enriched pathways based on relative abundance. Mice supplemented with B. breve 
had significantly (p < 0.05) decreased abundance of the subgroup assigned to central 
carbohydrate metabolism, as well genes associated with lysine, threonine, 
methionine and cysteine metabolism, and polysaccharide production. A statistically 
significant increase (p < 0.05) was observed for protein synthesis, with a slight trend 
in upregulation for capsular and extracellular polysaccharides.  
 
Figure 6-8 Colonisation by B. breve UCC2003 has small effects on the overall function profile 





PCA plot based on SEED classification by SUPER_FOCUS of the metatranscriptome, comparison 
between functional profile conventionally raised mice (SPF1, SPF2, SPF3) and mice colonised by B. 






Figure 6-9 B. breve UCC2003 colonisation induces distinct changes to overall intestinal microbiota function at high and low abundance levels 
A Top 20 sublevel 2 functional pathways identified in metatranscriptome of conventionally raised mice with (SPF+UCC) and without (SPF) B. breve UCC2003 
colonisation based on relative abundance, n=3, statistical analysis by two-way ANOVA with Bonferroni post-test, * = p-value < 0.05 B Unique functional 





Table 6-8 Unique SEED functions expressed in metatranscriptome of conventionally raised 
mice colonised by B. breve UCC2003 compared to control mice 
based on relative abundance of sublevel 2 classifications by SUPER-FOCUS 
 
Having assessed changes to functional readouts with highest enrichment, Figure 
6-9.B presents overlap, and distinct differences at sublevel 2 groups, present in either 
SPF or SPF+UCC, to identify modulation with small overall abundance.  
Interestingly, lactate racemization appears unique to SPF control mice, while B. 
breve UCC2003 induces 12 different pathways. These include; protein secretion 
system II and III, sugar phosphotransferase system, and sulfatases, as well as a 
general stress and stationary phase response pathway, and heat shock, cell division 
protease, and methyltransferase classes (Table 6-8) [448]. 
B. breve UCC203 has been shown to express a fructose phosphotransferase system, 
including a membrane transporter, but as this analysis is of total microbiota function, 
it cannot be distinguished whether B. breve, or another gut microbe, is responsible 
for the induction of this pathway in UCC2003 colonised mice. Nevertheless, this 
highlights a potentially unique fructose metabolic pathway associated with B. breve 






6.3.2.2 Colonisation by B. breve induces small but distinct shifts in intestinal 
microbiota taxonomy 
In Chapter 5, I presented data that indicated that B. breve UCC2003 modulates the 
mouse intestinal microbiota (via 16S rRNA profiling, Figure 5-6 in chapter 5); with 
most striking differences including an increase in Lactobacillus, and a decrease in 
Blautia and Alobacum. For metatranscriptomic data, reads can be specifically 
assigned to unique bacterial reference genomes, allowing profiling of bacterial 
taxonomy. These two technologies have been compared and found to be similar in 
sensitivity, and ability to correctly assess community composition, with the caveat 
that these studies used different bioinformatic approaches [449, 450]. The FOCUS 
profiler, as part of SF, has been referenced by 15 primary research publications, 
which applied this pipeline in their analysis, and this was used to analyse the 
taxonomy of groups SPF and SPF+UCC, and the composition at family levels 
(Figure 6-10).  
Both groups harbour similar abundance of Lachnospiracea (data set average 16%) 
and Ruminococcaceae (data set average 4%). B. breve UCC2003 colonisation 
appeared to increase Prevotellaceae (average abundance 6.8+ SPF to 8.7% 
SPF+UCC), with the gavaged group containing two samples with higher levels 
(SPF+UCC2, SPF+UCC3), and one (SPF+UCC1) with levels similar to control. An 
increase was also observed for Spirochaetaceae (average abundance 0.6% control to 
2.8% B. breve colonised), and Leptospiraceae, with no detection in SPF to an 
average abundance of 1.4% in SPF+UCC (no detection in SPF+UCC3).  
A decrease in abundance after B. breve colonisation was observed for 
Eubacteriaceae (average abundance 165 control to 8% SPF+UCC), and potentially 
Clostridiaceae, with average abundance decreasing from 10% in SPF mice to 7% in 
gavaged samples. Intergroup variability is high, as Clostridiaceae was only detected 
in two control samples (SPF1, SPF2), while in the gavaged group two colonised 
mice (SPF+UCC2, SPF+UCC3) present with low levels, but in SPF+UCC1 





Bifidobacteriaceae was detected in all three mice in SPF+UCC at an average of 
0.8% relative abundance (which correlates with results from 16S metataxonomic 
profiling, Figure 5-5 in chapter 5), compared to no detection in SPF samples. 
Results generated by selective plating of faeces showed presence of Bifidobacterium 
at 108 cfu/mg faeces in all SPF+UCC mice (Figure 5-4, chapter 5), while no colonies 
were detected from plating of control group samples, and confirms these mice were 
colonised with B. breve. 
In contrast to RNA-seq, 16S rDNA sequencing amplifies the ribosomal sequences 
which increases detection, while RNA-seq performs unbiased replication (with the 
exception of ribo depletion), leading to a proportionally representation of reads from 
different bacterial species within the raw data. When analysing metatranscriptome 
taxonomy by SF, a minimum relative abundance cut-off is applied to ensure 
acceptable false positive rates. This minimum limit of detection could lead to low 
levels of Bifidobacterium assigned reads to be discarded, and explain the levels 






Figure 6-10 B. breve colonisation induces small shifts in microbiota abundance at family level 
Data shown as relative abundance normalised to percentage of reads generated from meta-transcriptome, lengths representative of relative abundance, taxa with 
average abundance < 0.5% collated as “Other”, taxonomic assignment by FASTA sequence alignment to SEED server reference genomes with FOCUS, data 





6.3.3 Assessment of B. breve UCC2003 effect on intestinal 
metabolomic and bile acid profile does not reveal clear 
modulation in germ free and conventionally raised mice 
Building on transcriptional profiling of B. breve in vivo, and its effect on the 
microbiota metatranscriptome, metabolomics analysis of intestinal contents was 
performed to potentially correlate transcriptional modulation, with metabolomics 
modulation. This was achieved by processing colonic contents for identification of 
bile acids (via HPLC), and other metabolites by NMR.  
The PCA plots in Figure 6-11 compare similarity between GF, B. breve mono-
colonised, conventionally raised (SPF) and SPF B. breve UCC2003 colonised mice, 
based on their metabolomic (Figure 6-11.A), and bile acid (BA, Figure 6-11.B) 
composition.  
Metabolically, GF and B. breve UCC2003 mono-colonised groups cluster together 
(with the exception of sample GF1), and show a small, but distinct, separation 
(Fig11.A). Statistical analysis of individual metabolite differences recapitulates this, 
with Dimethylamine and Raffinose being significantly downregulated in mono-
colonised samples (p<0.05, Figure 6-12.). Due to intergroup variability, these 
findings, together with other trends (shown in Figure 12 and discussed further 
below), will need to be investigated further, by initially increasing sample size to 
ensure biological significance and relevance (complete data set in Supplementary 
Figure 13 to Supplementary Figure 15).  
Based on their metabolomic profile, SPF and SPF+UCC groups overlap (Figure 
6-11.A), and no statistically significant modulation of individual compounds was 
identified (Supplementary Figure 16 to Supplementary Figure 18).  
Investigating the BA composition in intestinal contents of these groups (Figure 
6-11.B), GF and mono-colonised samples overlap when compared by PCA (Figure 
6-11.B), with only Tauro-beta-muricholic acid (T-β-MA) significantly upregulated 
in B. breve colonised samples (p<0.05, Supplementary Figure 19). Intergroup 
variability is high and will require an increased number of replicates to determine 





BA profile of SPF and SPF+UCC groups overlap strongly with no clear intergroup 
clustering (Figure 6-11.B) and no statistically significant modulation was observed. 
Interestingly, T-β-MA shows a slight trend of increased concentration in B. breve 
colonised SPF mice (Supplementary Figure 20).  
Figure 6-12 shows metabolites with significant differences, or non-significant trends, 
comparing between intestinal contents of GF and B. breve UCC2003 colonised 
samples. Butyrate, methyl- and hydroxybutyrate was detected in both groups, with a 
very slight increase in mono-colonised samples for butyrate. Bifidobacteria cannot 
produce butyrate, just like the host, and presence within the intestine is usually 
associated with butyrate producing bacteria. As this metabolite and its breakdown 
products are also detected in the GF group, and gnotobiotic status has been 
confirmed by culture dependent and independent methods (Supplementary Figure 3 
and Supplementary Table 4), it could be hypothesised that it is present within the 
feed.  
Significantly reduced dimethylamine (with intergroup differences between GF 
samples, p<0.05), and raffinose identified at 5.44 parts per million (ppm), was found 
in mono-colonised samples when compared to GF. Methylamine can be produced by 
gut microbes through the conversion of dietary choline [451]. Therefore, the 
decreased concentration in B. breve mono-colonised samples is surprising, as is the 
increased levels in choline, compared to control. Methylamines are absorbed by the 
intestinal mucosa, so it could be suggested that the B. breve is not involved in the 
production of this compound, and may alternatively be inducing increased 







Figure 6-11 B. breve colonisation on intestinal metabolome in GF and SPF mice 
(A) PCA plot of metabolomic data of germ free (GF), B. breve UCC2003 mono-colonised (Mono), conventionally raised (SPF) and SPF mice 





As previously mentioned, bifidobacteria are acetate producers, and intestinal 
enterocytes absorb this SCFA as a nutrient substrate. However, no significant 
difference was observed for acetate in GF, compared to mono-colonised mice, which 
may indicate that the acetate produced by B. breve has been absorbed by the host. 
However, an increase in formate concentration was detected in both the B. breve 
mono-colonised intestine, and in vitro, when compared to controls.  
This data set was supplemented with metabolomics generated from B. breve 
UCC2003 in vitro cultures (stationary growth phase, performed by Jennifer 
Ketskemety, complete data set in Supplementary Figure 21 to Supplementary Figure 
22). A statistical comparison or direct comparative visualisation to in vivo 
metabolites was not possible due to the analysis of one pooled in vitro sample, as 
well as differences in presented concentrations (in vitro – mM, in vivo – NMR 
insistently/mg intestinal content). Figure 6-13. shows a selection of biologically 
relevant metabolites comparing concentration levels in B. breve supernatant to non-
inoculated MRS control (complete data in Supplementary 5). Strong increases in the 
concentration of lactate (26-fold), formate (1.29-fold), and glutamate (1.8-fold), was 
observed in B. breve cultures, while dimethylamine, choline and hydroxybuturate 
were detected at low levels in both conditions, but were not different between B. 
breve compared to control. A decrease in concentration was measured for lactose (-1 






Figure 6-12 B. breve UCC2003 colonisation of germ free mice does not induce a clear 
profile in intestinal metabolome 
Overview over metabolite concentration in large intestinal content of germ free mice (GF) and mice 
colonised by B. breve UCC2003 (Mono), Data presented as NMR intensity per mg intestinal content, 
individual values plotted (n=3 mice), mean and SD indicated, statistical significance analysed by 
Two-way ANOVA with Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to 







Figure 6-13 Under in vitro conditions B. breve UCC2003 shows clear metabolic activity 
including sugar consumption and lactate production 
Data presented as mM concentration in supernatant, single values plotted, B. breve cultured in MRS 
and samples collected at 18 h, samples generated by Jennifer Ketskemety, NMR performed by 






6.3.4 B. breve may produce member vesicles, which may play a role 
in host interactions 
As discussed above, microbial metabolites play a key role in modulating host 
physiology, including IECs. Much of the previous work in this area has focused on 
the roles of diffusible, small-molecule hormones and nutrients; however recent 
studies suggest that microbiota-derived metabolites may interact with the host via 
transport in bacterial membrane vesicles (MVs). Previous work has studied this 
interaction pathway in Gram positive pathogens; where, MVs are used to deliver 
toxins, or immune response dampening metabolites, which facilitate bacterial 
colonisation and invasion [453, 454]. Notably previous studies have suggested that 
Bifidobacterium species may produce MVs, in the case of B. bifidum LMG13195, 
which has the ability to induce polarisation of naïve T cells to Treg cells [455]. 
Therefore, I hypothesised that B. breve UCC2003 may influent host physiology (i.e. 
IECs) via MVs. 
6.3.4.1 Extraction method of potential B. breve UCC2003 membrane 
vesicles 
Supernatant from B. breve UCC2003 stationary cultures was processed for MVs 
enrichment (with 100 kDa MW cut-off), and concentrated by ultracentrifugation 
following an established protocol [456]. The sample was then separated by SDS 
page, and mass spectrometry (MS), for qualitative assessment of proteins present 
(Figure 6-14). 
 






6.3.4.2 Proteomic profile of potential B. breve membrane vesicle isolation 
could suggest host interaction potential 
Amino acid sequences detected by MS were mapped against B. breve UCC2003 
Swissprot database, and quality controlled (peptide score >2, protein match 
significance <0.05). A total of 625 proteins were detected with Table 6-9 presenting 
top 25 entries based on mascot score. Out of these, seven are involved in ABC sugar 
transporter systems, and nine contribute to sugar metabolism. The fact that an 
enolase was detected is intriguing as this putative human plasminogen receptor has 
been shown to locate to the cell surface of certain bifidobacterial strains, giving them 
the ability to bind and enzymatically process host plasminogen. This could play a 
role in host colonisation, and additionally facilitate host interaction, as this has been 
shown to allow migration across physical and molecular barriers [457].  
Table 6-9 Top 25 identified proteins in potential MV isolation from B. breve UCC2003 
from vitro culture supernatant  






6.3.5 Bacterial host interaction via short RNAs resulted in no clear 
identification of involved mechanisms 
Additional bacterial components that could be transported in MVs, and allow 
interspecies crosstalk with the host and IECs, are miRNAs. A recent study in silico 
predicted that various bacterial transcripts might generate putative miRNA structures 
that could interact with the host genome. In vitro, these bacterial sequences were 
shown to regulate target gene expression in human embryonic kidney cells 
(KEK293), thus mimicking host miRNAs [458]. In another study, a Mycobacterium 
marinum nucleotide sequence was shown in vitro, when overexpressed during 
infection of HeLa cells, to be processed as a host pre-microRNA, and decrease 
expression of its eukaryotic gene target [459]. Furthermore, vesicles isolated from 
Pseudomonas aeruginosa contained shortRNAs, which in vivo reduced lung 
epithelial cell immune responses (decreased cytokine release and neutrophil 
infiltration), which facilitated colonisation [460]. 
6.3.5.1 No RNA detected in potential B. breve membrane vesicle isolations 
I performed a preliminary analysis for the presence of RNAs in the isolated B. breve 
UCC2003 in vitro MV fraction, by detecting transcripts though Bioanalyser. No 
RNA was detected, with a sensitivity threshold of >5ng. Due to the short length of 
miRNAs, analysis by other means such as RNA-seq, miRNA targeted qPCR, or 
Agilent small RNA analysis kits would have to be performed. The proteomic data 
contained 33 entries related to RNAs processing, including ligases, 
methyltransferases, and polymerases, which might suggest transcript presence, but 
further studies would have to be performed to confirm this.  
6.3.5.2 Host miR 21 has predicted binding sites within B. breve genome, but 
does not affect growth in vitro 
Recently, it has also been determined that host transcripts (i.e. miRNAs) may 
modulate bacterial transcription, thus providing a two-way dialogue between 
microbe and host. The authors detected host miRNAs in the intestinal lumen, and 





deficient in miRNAs in IECs showed abnormal gut microbiota composition, and 
reconstitution of these mice with faecal miRNAs restored microbiota profiles [461].  
As described in chapter 5.3.7 (Supplementary Figure 12), I observed a decrease in 
host miR21 expression in whole large intestinal homogenates of neonate and adult 
mice colonised by B. breve UCC2003. I hypothesised that this effect could allow B. 
breve to either (i) facilitate its own colonisation (e.g. growth promoting effects), or 
(ii) by modulate the overall microbiota composition. In collaboration with 
Padhmanand Sudhakar (EI), in silico binding sites of miR-21-3p (NCBI gene ID 
406991) were identified by miRbase in the bacterial genomes of B. breve UCC2003 
and S. Typhimurium SL1344 (NCBI GenBank ID: FQ312003.1) [462]. This analysis 
yielded 263 miR21 targets within the B. breve genome, and 370 when using S. 
Typhimurium SL1344 (Supplementary Table 7 and Supplementary Table 8 
respectively). 
To address the first hypothesis, I performed growth kinetics of B. breve in the 
presence of miR21. No effect by the transcript was detected (Figure 6-15.A). To 
perform preliminary experiments on the second hypothesis, the effect of miR21 on S. 
Typhimurium SL1344 growth was assessed, but no modulation in growth was 
detected (Figure 6-15.B).  
These generated data, including proteome of potential B. breve MVs, and bindings 
sites of host miR21 in bacterial genomes, lays the foundation for future 
investigations into B. breve host modulation via MVs, which will be outlined in the 






Figure 6-15 miR21does not affect growth kinetics of B. breve UCC2003 and S. 
Typhimurium SL1344 in vitro 
Growth kinetics presented in cfu/ml over time of (A) B. breve UCC2003 and (B) S. Typhimurium 
SL1344 grown in MRS/LB with 10 µg/ml miR21, or scrambled control, data shown as mean +/- SD, 
limit of detection 2x101 cfu/ml. 
6.4 Discussion 
Understanding how specific microbes, and the wider microbiota, changes at a 
transcriptional and metabolite level, in response to different environments (i.e. in 
vitro vs in vivo), is important for enhancing our understanding of what key microbial 
factors may promote host health, and thus aid in the design and development of new 
targeted therapies. In this chapter, I determined that B. breve UCC2003 has a distinct 
transcriptional profile in vivo, when part of the wider gut microbiota, and as a single 
species within the host (i.e. in gnotobiotic mice). Furthermore, B. breve appears to 
‘switch-on’ specific GH, as well as iron scavenging pathways, and decreases EPS 
cluster gene expression in the GF gut, relative to in vitro levels. Assessment of the 
impact of B. breve UCC2003 colonisation on overall microbiota function indicates 
decreases in carbohydrate metabolism, as well as increases in overall protein 
synthesis. Intestinal metabolomic profiling did not suggest a clear modulation by B. 
breve UCC2003 in GF, or conventionally raised mice. 
It is currently unclear what specific pathways B. breve UCC2003 utilises in vivo for 
metabolism of host-derived dietary components, and how this may link to 
colonisation of the GI tract, and modulation of the wider microbiota via cross-
feeding. Notably, I identified upregulation of gene clusters previously shown to be 
involved in HMO utilisation in mono-colonised GF mice. HMOs in human breast 
milk cannot be metabolised by the infant, and are believed to directly shape the early 
life microbiota by acting as a prebiotic [463]. The described pathway has been 
characterised in B. breve UCC2003, but several other species, including B. bifidum 
and B. longum possess gene clusters with similar function [397, 464]. It is interesting 
to observe upregulation of key enzymes in this process when B. breve is present in 
the intestinal tract of adult mice, which feed on a chow rather than milk-based diet. 





studies have indicated that these pathways can be utilised for both HMO and mucin 
degradation, which may indicate that B. breve is directly utilising these host-derived 
carbohydrates, or other similarly structured chow-based carbohydrates [395]. These 
findings, may lead to the identification of additional compounds able to feed 
bifidobacteria in vivo, in cases where HMO delivery via breast milk is not possible 
e.g. via supplementation of formulas.  
Interestingly, when I compared expression profiles of mono-colonised mice to SPF 
mice colonised with UCC2003, there was significant upregulation of specific genes 
involved in metabolism, which may link to the availability of nutrients in a complex 
microbiota ecosystem. Within the adult microbiota, there is an intricate network of 
microbes that each utilise different dietary components, and in turn cross feed other 
microbial neighbours. I observed upregulation of an ABC sugar transporter permease 
in SPF mice, when compared to GF, which has been shown to facilitate transport of 
various oligosaccharides from simple maltose and lactose, to more complex fructo-
oligosaccharides and xylose [465]. An upregulation of this permease in the presence 
of the wider microbiota, in comparison to gnotobiotic conditions, might be because 
of the availability of different sugars due to breakdown of complex carbohydrates 
otherwise unavailable to B. breve by intestinal bacteria. Indeed, other complex 
carbohydrate digesting bacteria, such cellulolytic Eubacterium spp and Bacteroides 
spp may increase the availability of carbohydrates available for uptake by B. breve, 
and hence warrant an increase in specific transport systems [466]. Interestingly, 
metabolomics data indicated a decrease in raffinose in mono-colonised mice, in 
comparison to GF, and previous studies have indicated that different bifidobacterial 
strains show preferential utilisation for this sugar in vitro, over glucose [467]. 
Therefore, these data suggest that B. breve UCC2003 also prefers this sugar in vivo.   
Regarding cross-feeding, the converse is also true, i.e. the introduction of B. breve 
into the wider microbiota would also be expected to impact overall metabolic 
function. As mentioned above, bifidobacteria can utilise a wide range of 
carbohydrate sources, with at least 10% of its genome encoding proteins related to 
transport and metabolism of carbohydrates, indeed this genus represents one of the 
most efficient microbiota members at metabolising diverse dietary components [258, 





availability. This effect is more pronounced in early life with bifidobacteria being 
one of the earliest colonisers, degrading specific HMOs, and host mucins (as 
discussed above), and producing breakdown products that are available to the wider 
microbiota (e.g. lactate and acetate). No changes were detected in either lactate or 
acetate comparing SPF with SPF B. breve colonised mice, as well as GF with B. 
breve mono-colonised mice. However, this could be due to absorption of these 
metabolites by IECs, which are known to act as energy sources, and also modulate 
anti-inflammatory effects [469]. Notably, the SCFA formate was increased in the 
presence of B. breve (in vitro and in vivo). Relatively little is known about its 
biological function, but a recent publication determined that overgrowth of 
Proteobacteria, such as E. coli, during intestinal inflammation, was associated with 
formate oxidation, and aerobic respiration [394, 470]. This was accompanied by an 
increase in formate concentrations in the gut, and interestingly the authors did not 
observe formate in GF mice, indicating it is bacterial derived. Bifidobacteria are able 
to also produce formate, as part of their carbohydrate metabolism, with the ratio 
between formate, lactate, and acetate dependent on substrate types available [471]. 
Generally high levels of formate production correlated with low levels of acetate and 
vice versa, which may indicate that B. breve UCC2003 is also a major formate 
producer, and would be of interest to follow-up in subsequent studies.  
Regarding carbohydrate metabolism, I observed a decrease in overall microbiota 
functional abundance in this SEED class, which could suggest that the presence of B. 
breve, with its arsenal of carbohydrate digestive capabilities, allows other microbiota 
members to decrease their own carbohydrate breakdown systems and cross-feed in 
the presence B. breve. This could in turn allow for these members to have a more 
efficient metabolism, due to decreased effort in nutrient acquisition, and lead to the 
observed increase in protein synthesis SEED class abundance. It would be interesting 
to relate these functional changes to modulation of taxonomy, to investigate which 
specific members might cross-feed, but due to classification at family level no clear 
function can be associated with the modulated taxa. Taken together, it could be 
suggested that B. breve UCC2003 colonisation increases overall nutrient availability 
for microbiota members, causing an increase in overall metabolomic functionality. 





modulation levels as observed in these data i.e. <1%), as a previous supplementation 
study in humans indicated that stable engraftment of B. longum AH1206 was 
associated with low abundance of resident B. longum, and underrepresentation of 
specific carbohydrate utilisation genes in the pre-treatment microbiota. This suggests 
that bifidobacteria may promote resource availability, which allows more efficient 
colonisation, which may prove central for development of long-term, and 
personalised microbiota reconstitution strategies [472].  
Although there is a steady supply of dietary carbohydrates in the GI tract, the host 
directly limits the availability of certain nutrients e.g. iron, to reduce the colonisation 
of pathogenic microbes. To overcome this restricted availability, many microbes 
have evolved iron scavenging systems, including Bifidobacterium. Notably in GF 
mono-colonised mice (when compared to iron-rich in vitro conditions), I observed 
significant upregulation of an iron scavenging pathway previously shown to be under 
the control of auto-inducer AI-2. The transcription of the enzyme producing AI-2 as 
a by-product (encoded on luxS, BBr_0541, gene552) was slightly, but not 
statistically significantly upregulated [473]. AI-2 expression regulation has been 
related to population density (quorum sensing) by secretion and sensing of AI-2 in 
the environment [474]. It was found that conditions with high glucose and acidic pH, 
such as found in in vitro culture in MRS, has strong inhibitory effects on AI-2 
activity. Hence, it is possible that B. breve UCC2003 does not produce AI-2 via luxS 
in vitro, due to growth conditions, while during mono-colonisation does upregulate 
its expression, which in turn could induce the iron scavenging pathway. Previous 
studies have shown that this cluster is upregulated in vivo; in conventionally raised 
Balb/C mice gavaged with B. breve UCC2003, relative to in vitro data (analysed by 
microarray). In the same study, using the model organism C. elegans, the genes bfeU 
and bfeB were identified to be critical for iron uptake, and GI tract colonisation, and 
interestingly each mutant exhibited a significantly decreased ability to confer 
protection to Salmonella-infected nematodes, as compared to the WT B. breve 
UCC2003. In my data, the corresponding gene to bfeU (gene225, BBr_0221, 
membrane spanning protein with iron permease) was not differentially regulated, 
while bfeB (gene227, Bbr_0223, hypothetical membrane spanning protein) was 





in gut pathogen protection, and may be important targets for subsequent colonisation 
resistance studies 
An additional bifidobacterial component that has previous been shown to play a role 
in resistance to enteric infections, including the pathogen C. rodentium (a mouse 
model pathogen for human-associated Enteropathogenic E. coli), is the EPS capsule. 
Surprisingly, in mono-colonised GF mice, I observed downregulation of genes 
involved in EPS production in B. breve, relative to in vitro. Alongside, its potential 
anti-infection role, the EPS capsule has also been shown to play a role in bile and 
acid resistance, facilitating colonisation of the GI tract, however GF mice had high 
colonisation levels after gavage suggesting that EPS may not be required for optimal 
colonisation in the ‘naïve’ murine GI tract. Previous studies have indicated the GF 
mice have an altered pH and bile acid profile (which is directly linked to microbiota 
processes, and discussed in more detail below), thus may also be linked to reduced 
expression of EPS in these conditions; i.e. B. breve can downregulate EPS 
expression (and thus reduce its overall metabolic burden) in this environmental niche 
[475, 476]. Comparing this result to SPF mice, the overall microbiota functional 
abundance showed a significant decrease in polysaccharide production in the 
presence of B. breve, but a slight elevation of EPSs, which may indicate other 
microbes are inducing this expression. As the metatranscriptomics data did not map 
any EPS gene reads to the B. breve genome, we cannot determine if EPS expression 
is induced in this complex microbiota environment, when compared to mono-
colonisation. 
Within the artificial environment of in vitro culture, EPS expression may be high due 
to the largely unlimited availability of nutrients. Indeed, previous work on 
bifidobacterial EPS capsules has suggested that sugar precursors may be involved in 
modulation of expression and production; B. longum subsp. longum CRC 002 was 
found to have enhanced EPS production on lactose compared to glucose, which 
directly impacted cell wall polysaccharide biosynthesis [477]. Interestingly, and as 
highlighted previously (chapter 1.4.4), the EPS capsule also plays a key role in 
immune-modulation, serving as an immune ‘silencer’ to avoid recognition by the 
host, and thus promote long-term persistence. As GF mice have an immature 





system, and it would be of significant interest to explore this further by performing 
additional immune assays [478]. 
Bifidobacteria are bile tolerant, which aids colonisation of the intestinal tract, and 
several factors, such as bile efflux transport systems and bile salt hydrolases, are 
involved in this process. Notably, calcineurin-like phosphoesterase, which convers 
bile resistance to B. breve UCC2003, is upregulated in the presence of other bacteria. 
While BA concentrations are higher in the ileum of GF mice compared to 
conventionally raised mice, the faecal excretion is 63% lower [479, 480]. 
Correspondingly, I observed more diverse and higher concentrations of BAs in SPF 
mice compared to gnotobiotic mice, suggesting the requirement of B. breve to 
increase its BA resistance mechanisms. This has been attributed to the microbiota 
modulating the BA pool within the LI by deconjugation, dehydrogenation and 
dihydroxylation, making it chemically more diverse. This metabolism of BA offers 
bacteria a source of carbon and nitrogen, as well as sulphur, in addition to giving bile 
resistance, and capabilities to grow within the presence of BAs. Indeed, gene800 
(Bbr_0780), a hydrolase of the haloacid dehydrogenase super family, was 
upregulated, but is has not yet shown been shown if this family is involved in bile 
salt deconjugation. Bifidobacteria such as B. longum SBT2928 do harbour bile salt 
specific hydrolases, and can utilise these enzymes for human and animal BA 
modification [481]. Recently, a feedback pathway has been identified that links bile 
acid concentration in the intestine, to production in the liver [482]. T-β-MA is 
present in high concentrations in the intestine of GF mice, as is it not being 
deconjugated by microbes, and acts as an antagonist to farnesoid X receptor in 
enterocytes, which in turn reduces levels of fibroblast growth factor 15 (FGF15) 
release. FGF15 acts as a suppressor of T-β-MA production in the liver, closing the 
feedback loop. In conventionally raised mice, T-β-MA is deconjugated and hence 
more FGF15 is released to reduce production of the BA. However, I observed higher 
concentrations of T-β-MA in B breve mono-colonised samples, and previous 
publications indicate that B. longum can deconjugate this BA, as well as taurocholic 
acid. Furthermore, an publication from 1987 indicated that B. longum was able to 
process taurocholic acid, but not tauro-beta-muricholic acid [483]. As deconjugation 





the liver to decrease bile acid production, and as no decrease in T-β-MA was 
observed in my samples, this might explain the higher BA concentration in SPF 
samples, compared to GF or mono-colonised groups.  
Within the datasets, I also observed a significant number of hypothetical genes that 
were differentially regulated. Some shared sequence homology with other bacterial 
genes, while others did not. Although Bifidobacterium represent an important 
beneficial genus, mechanistic phenotypic studies into specific genes has proved 
difficult due to issues with molecular manipulation; particularly due to the high 
number of R/M systems, and the EPS capsule, which limits uptake and integration of 
‘foreign’ DNA.  These issues have somewhat limited large-scale annotation of genes 
to function, and thus it is not surprising I observed so many hypothetical genes in 
this dataset. It would be of significant interest to probe the function of these 
hypothetical genes, particularly the ones that are highly differentially regulated (e.g. 
gene55, Bbr_0055), and recently a genome wide mutagenesis library in B. breve 
UCC2003 has been generated which would allow these studies [484]. While 
screening of all mutants in vivo is not feasible (preliminary in vitro experiments have 
been performed), the generated data set could allow for better informed selection of 
genes for further study.  
The approach used to analyse these large RNA-Seq datasets was DESeq2, which was 
used to detect differential gene expression between groups [374]. This software 
package is optimised for small samples sizes, and large dynamic range between 
replicates. This pipeline improves regulation analysis, via the previously mentioned 
shrinkage estimation (subsection 5.3.5), to ensure stable and reliable calling of 
differential expression, as well as accurate quantification of fold changes. It has been 
utilised in more than 3500 published RNA-seq studies since its release in, including 
several bacterial transcriptome studies (NCBI, accessed on the 24.1.2017). However, 
the numbers of biological repeats analysed for differential gene expression can 
greatly impact accuracy and precision, with lower replicates increasing false positive 
discovery rates [485]. The group of B. breve UCC2003 transcription in vitro 
contained two biological replicates, which is the suggested minimum threshold for 
DESeq2. Low replicate numbers have been shown to affect correct identification of 





packages [485, 486]. This is because of the requirement to account for inter-replicate 
variability of biological samples. To support the results presented, either sample size 
would have to be increased or validation by different analysis software to be 
performed. With regards to the metatranscriptomic datasets, there are some 
additional limitations of DESeq2; there is a requirement of minimum splicing 
distances, which in bacterial transcription discards any genes mapped to gene 
boundaries. As bacterial genomes lack introns, this setting causes a proportion of 
genes to be filtered out. In a single species sample with high expression, these 
changes can be disregarded as they are normalised between repeats, while in 
metatranscriptome samples, with typically low expression, this can significantly 
reduce detected gene expression. As B. breve colonises the adult mouse gut at low 
abundance, and metagenomic abundance can at least in part be correlated to 
metatranscriptional abundance in the gut microbiome, the limitations of this method 
should be considered [130]. Recently a new mapping tool, HISAT2, has been 
developed which allows for enumeration of mapping data based on unique reads 
which circumvents the Bowtie2 intron problem [487]. This tool will be applied in 
future analysis of the data sets to validate and ensure robust B. breve UCC2003 
transcriptional quantification. 
The potential of B. breve to crosstalk with the host via MV is an intriguing avenue of 
scientific exploration. Host modulation via MVs has been extensively studied in 
pathogens, but recently their role in commensal bacteria is being explored. An 
important finding showed extracellular vesicles from B. breve NutRes200 inhibited 
TLR2/6 induction, while enhancing TLR2/1 and TLR4 responses, and also 
enhancing phagocytosis by DCs in vitro [488]. The isolated fraction of B. breve 
culture medium could potentially include MVs, as the applied purification method 
enriches for molecular weight of MVs identified in Bacteroides spp. [489]. In 
addition, the generated proteomic data provides a platform for further analysis, as 
published proteomic analysis of MVs from P. aeruginosa categorised 57% of 
detected proteins to be cytoplasmic, 25% as extracellular, and 16% membrane bound 
[490]. This was performed by assignment of GO classes, which also allowed 





generated data, which could then form the basis for future investigations of potential 
bifidobacterial MVs. 
The preliminary investigation of RNA presence within the potential MV isolation 
was based on previous studies that suggested host transcriptional regulation by 
bacterial non-coding RNAs. A study in C. elegans revealed two E. coli transcripts to 
downregulate gene expression in the host, while in M. marinum a short bacterial 
RNA was found associated with host RNA processing machinery (RISC complex) 
during in vitro cell infection, and when overexpressed resulted in host target 
transcriptional repression [491, 492]. Even though I was not able to detect RNA in 
the MV isolation, the applied method for RNA detection by Bioanalyser has a 
detection limit of 5 ng. 
The observation that host miRNAs modulate intestinal microbiota composition, and 
specifically affect growth of certain species was a unique finding by Liu et al. [461]. 
However, to my knowledge no other primary research has been published on this 
mechanism. My preliminary growth kinetic experiments indicated that miR21 did 
not modulate B. breve or Salmonella growth.  However, it cannot be discounted that 
miR21 may affect different physiological aspects of bacterial physiology, such as 
EPS or pili synthesis, which have implications for host bacterial interactions. To 
investigate this, the preliminary bindings site identification of miR21 in B. breve and 
S. Typhimurium genome may allow identification of specific genes that might be 
regulated. It should be noted that the applied method relies on sequence homology 
alignment, while a more precise analysis would involve bindings site prediction, 
taking into account secondary structure, and mismatches within mRNA seed 
sequences. 
In summary, I have shown distinct B. breve transcriptional profiles in vivo, 
comparing between gnotobiotic colonisation, and presence within a complex 
microbiota. This includes genes involved in metabolism of differing nutrient sources, 
as well as bile acid resistance, and increased stress responses. In addition, relative to 
in vitro conditions, B. breve increases expression of iron scavenging and GH 
clusters, while downregulating EPS production in gnotobiotic conditions. The 
generated metabolomic data yielded no distinct differences due to the presence of B. 





modulated by B. breve colonisation, with increases in protein production and 
decreased carbohydrate metabolism. These data provide new insights into the 
adaption of B. breve UCC2003 to each environment, and indicates key factors to be 






6.5 Future plans 
The presented data implies distinct transcriptional responses of B. breve to differing 
in vitro and in vivo conditions, based on the applied bioinformatic pipeline including, 
Bowtie2 mapping of reads to the B. breve genome, followed by transcript 
enumeration by HTSeq and differential gene expression calculation by DESeq2 
[298, 299, 374]. To improve on this approach several measures will be applied in the 
future.  
DESeq2, as mentioned in the previous section. was optimised for small sample sizes 
common in next generation sequencing experiments, but an increase of biological 
repeats for the in vitro sample group (currently 2 biological replicates) will greatly 
improve the accuracy of DEG calculation. Similar, the comparison of B. breve 
UCC2003 transcripts between GF and SPF colonised mice can be improved upon 
due to the current low B. breve UCC2003 gene count in the SPF samples, which 
could interfere with the applied shrinkage estimation of gene expression dispersion 
and impact precision and verified calling of differential expression. This will be 
approached by utilising SAMSA2, a bioinformatic tool specifically designed for 
met-data annotation based upon MG-RAST, a public meta-data annotation service 
which uses DIAMOND as high throughput aligner and automated pre-processing of 
raw reads [493-495]. In addition, the previously mentioned difficulty in quantifying 
bacterial transcripts with conventionally tools (chapter 6.3.1.5), due to lack of introns 
in bacterial genomes, will be addressed by utilisation of HISAT2 [487]. This will 
allow for more accurate transcript enumeration for both the UCC2003 genome, as 
well as the metatranscriptome data set.  
These changes will allow for increased information extraction from the 
metatranscriptome data, and could allow for identification of differential gene 
expression of other bacterial microbiota members in the presence and absence of B. 
breve UCC2003. This could lead to the identification of specific cross-feeding 
relationships as suggested by my presented data. 
With the advent of meta-transcriptional data, instead of analysing gene expression of 
host and bacteria independently, “dual RNA-seq” has emerged, allowing for 





successfully applied by Illot et al. to profile host responses during colitis induced by 
H. hepaticus infection, while integrating these results with changes to microbial 
transcription (normalised to modulation of DNA abundance changes induced by 
pathogen colonisation) [140]. Compared to this approach, my data would allow me 
for a “paired RNA-seq” analysis as host and bacterial transcripts are not identified 
from the same sequencing samples. This would still potentially identify overlapping 
responses between IEC DEGs, and bacterial DEGs, to integrate host effect with 
bacterial physiology. 
An essential step for all next generation sequencing data is validation. Technical 
replication by qPCR should be the first approach with the additional benefit of 
potentially increasing samples size, resulting in increased certainty in the observed 
modulation and its biological significance. This would then be followed by probing 
the identified mechanism in biological systems in vitro or in vivo. Due to the 
difficulties in genetic manipulation of B. breve UCC2003, this could be 
circumvented by assessments of physiological changes, such as in the case of 
downregulation of EPS production in vivo, via SEM visualisation. Fortunately, the 
lab has access to a Transposon Directed Insertion Sequencing (TraDIS) library, 
which after full characterisation of the generated mutants, could allow for testing of 
the generated hypothesis in the different models. A potential first experiment would 
include the investigation of the identified HMO metabolomic cluster, showing 
upregulation in gnotobiotic mice, to assess its essentiality for colonisation, and going 
further by comparing its role in GF, and also the SPF intestine of adult and neonate 
mice. It could be hypothesised that this cluster is involved in processing of 
carbohydrates other than HMOs, as these were not present in the GF mouse. Hence 
an investigation into other substrates could be started in vitro, with a potential 
candidate being host derived mucus, with potential results being taken forward in 
vivo. 
Lastly, future experiments regarding host bacterial crosstalk via MVs, and non-
coding RNAs will also form part of potential future work, but some initial key 
studies need to be completed to indicate if these are worthwhile avenues to explore. 











7 Conclusion and perspectives 
Bifidobacteria are early, and abundant, gut microbiota colonisers, that remain in the 
human intestinal tract throughout life [156]. The genus is generally associated with 
host health, and in particular lower abundance has been observed in IBD patients, 
with supplementation reducing incidence of relapse [284, 321]. Several studies have 
investigated potential health beneficial effects, including immune modulation, 
promoting intestinal homeostasis, and IEC specific actions, such as strengthening of 
TJs during homeostasis, and pathological disruption, but our understanding of the 
underlying mechanism is still incomplete [201, 246, 281, 282] 
Therefore, I sought to determine how B. breve UCC2003 affects IECs, either 
directly, by modulating specific host functions, or in concert with the intestinal 
microbiota, to deliberate its health benefits. 
7.1 Summary of results and future research directions 
The aim of this study was to investigate the role of B. breve; both on the host, 
focussing on the ion channel Piezo1, and then more globally via the IEC 
transcriptome, and additionally probe B. breve in vivo transcription, and exploring 
how B. breve colonisation modulated the wider microbiota. The overarching goal 
was to identify host factors modulated by B. breve, and pinpoint bifidobacterial 
components that may regulate these effects. 
Initially, using relevant mammalian intestinal in vivo, in vitro, and ex vivo models, I 
assessed the role of Piezo1 in mammalian cell shedding. However, no changes to 
protein levels during elevated shedding rates were observed. Additionally, no 
transcriptional modulation in UC patient biopsies was detected, compared to 
controls. This suggests that differential translation of Piezo1 does not play a role in 
inflammation-induced cell shedding in the mammalian intestine. However, I did 
observe Piezo1 cellular positions along the IE, aligning with its proposed role of 
sensing cell crowding at sights of cell extrusion (villus), and cell stretch at sights of 
division (crypt) is intriguing. This finding will be further investigated with 





can fully answer the involvement of the ion channel Piezo1 in shedding. Hence, 
application of the Piezo1 inhibitor gadolinium in an intestinal loop model will 
conclude this avenue of questioning. The generated data are a direct measurement of 
Piezo1 function on cell extrusion in the mammalian intestine, not only during 
pathological extrusion, but also in heath and homeostasis, which will significantly 
add to the research field and pose interestingly questions as to the requirements of 
this protein, in more physiologically relevant models than tested previously.  
Although studies into Piezo1 did not indicate that B. breve colonisation altered this 
ion channel, my previous studies in the LPS cell shedding model indicated a direct 
modulatory role for B. breve on IECs.  Thus, I utilised global RNA-seq of IECs as an 
unbiased approach to assess transcriptional changes induced by B. breve UCC2003. 
I observed a strong, and distinct, profile in neonatal mice, with the effect reduced, in 
number of regulated genes and amplitude of regulation, in adult IECs. This is 
particularly interesting as early colonisation of B. breve has been linked to health 
beneficial effects, such as reduced incidence in asthma [496]. With strong immune 
modulatory effects on naïve hosts, and a more plastic infant microbiota, the observed 
stronger effects in neonates support the notion of bifidobacteria as an important early 
life coloniser, and could suggest that it is required for a healthy ‘status quo’ [154, 
497].  
Particularly promising targets identified in neonate IECs included; TLR2, TLR9 and 
IL-17C. Transcriptional upregulation of these genes could potentially improve 
epithelial barrier function, and induce anti-inflammatory stimuli, resulting in 
intestinal homeostasis. Intriguingly, these modulations occurred during homeostasis, 
without inflammatory insult, further supporting the pivotal role of B. breve in health. 
These findings suggest bifidobacterial effects may offer protection from disease 
initiation, and therefore highlight the use of this microbe as a prevention strategy. 
The increase in specific integrin expression, and overall integrin signalling, could be 
the most promising effect observed, due to their important role in intestinal epithelial 
integrity, barrier functions, and protection from insult [411, 413]. Future work will 
investigate these targets individually to observe the biological effects of their 





Analysing B. breve transcriptional responses in vivo, comparing between gnotobiotic 
colonisation, and in the presence of a complex microbiota, I observed a distinct 
profile, including upregulation of stress responses, bile acid resistance, and 
utilisation of different metabolism pathways. Compared to in vitro conditions, B. 
breve increased expression of iron scavenging, and carbohydrate metabolism 
clusters, while downregulating EPS production. While colonisation did not modulate 
the metabolome in GF and SPF mice, B. breve did increase overall microbiome gene 
expression with respect to protein production, while decreasing carbohydrate 
metabolism. These results indicate that B. breve colonisation alters both the 
taxonomy, and function of a complex, established community during intestinal 
homeostasis. This is an impressive finding, and supports the use of bifidobacteria in 
modulating the intestinal microbiota, with the aim to improve host health or treat 
disease. Exploring this effect further, by improved metatranscriptome analysis, could 
reveal transcriptional regulation of specific members and functions, significantly 
adding to our current knowledge of bifidobacteria crosstalk [258] 
The B. breve specific upregulation of carbohydrate metabolism, and iron scavenging 
during monocolonisation, supports our knowledge of in vitro experiments and in 
vivo observations of bifidobacteria offering protection from pathogen colonisation, 
and as a cross feeder, through complex carbohydrate metabolism in early life and 
adulthood [156, 358, 498]. These in vivo functional observations have given insight 
into B. breve intestinal adaptation, and indicate target factors to be investigated for 
host and microbiota modulatory effects, with potential health beneficial effects as 
probiotics. 
Overall, my work has generated a comprehensive overview of B. breve effects on the 
host epithelium, and intestinal microbiota transcription. These data lay the 
groundwork for further investigation on host-bacterial cross talk. Additional analysis 
of the metatranscriptome data to identify specific functional microbiota modulation 
by B. breve, as well as the integration of host and bacterial transcriptomics, will 
generate a holistic network furthering our understanding of microbiota intestinal 
epithelial interaction. Crucially, the identified bacterial and host IEC targets, are 






7.2 Impact of findings and translational aspect of research 
The intestinal epithelial barrier is crucial for health, whilst its breakdown, leading to 
a ‘leaky’ barrier, is linked to numerous diseases, therefore understanding the 
underlying mechanisms involved in its maintenance are essential [94]. 
To my knowledge, this study is the first to investigate Piezo1 as a regulator of 
epithelial cell shedding in the mammalian intestine, with previous studies utilising in 
vitro and zebrafish models [499]. Hence, this investigation, with the proposed 
additional intestinal loop study, is contributing knowledge to an important field of 
research for human health, which may have direct relevance for development (or 
not) of drugs targeting Piezo1.  
Additionally, as there is a significant unmet need for new IBD treatments, which will 
induce, and retain remission, or even prevent onset; therapies that may induce these 
responses are in high demand. Bifidobacteria, which are reduced in abundance in 
IBD patients, and previous probiotic human trials, which suggest they may provide 
beneficial responses in both CD and UC patients, represent a promising cost-
effective and non-toxic avenue to further explore, with the aim of improving human 
and intestinal health [102, 361, 500, 501].  
The generated global datasets of B. breve-induced host, bifidobacterial, and 
microbiota transcription in vivo responses contributes substantial knowledge on host-
microbe interactions to the scientific community, with future data mining, and 
integration of multi ‘omic data, aiding in hypothesis generation and validation. 
Furthermore, identified host target could generate leads for drug development, while 
bacterial transcription patterns could aid in targeted probiotic selection and 
development. This could improve treatment of a wide variety of intestinal 
pathologies involving the IE, and inflammation, such as IBD and NEC, together with 
developing our understanding of how probiotics confer their effects. 
Particularly modulation of IEC integrins by B. breve, in recent light of IBD SNP 
identification in these genes, and drug treatment targeting immune homing via this 
mechanism, offers an intriguing insight into the potential future of personalised 





Additionally, this study has shed light on the homeostatic modulatory effects of 
bifidobacteria during different life stages, including early and later life, which 
significantly increases the scientific knowledge of “lifelong” gut health, as a public 
health target. As bifidobacteria are an important member of the gut microbiota, this 
is a particularly important area of research [67, 236, 502].  
Lastly, this study has given scientific support to the notion that specific bacteria, and 
their modulation of the intestinal microbiota, can affect host health. This is 
particularly important, as changes observed during homeostasis, when this signature 
is lost, could indicate heightening risk of disease development, offering biomarkers, 
and targets for prevention or cure. Hence, administration of beneficial or probiotic 
bacteria, and modulation of the microbiota, could support the healthy host state, and 








Supplementary Table 1 Clinical data including assessment of inflammation severity at time of biopsy collection from Ulcerative Colitis patients and 
histological grading of biopsies to be used transcriptional analysis during acute inflamed colitis. 
Biopsies were collected from the sigmoidal colon from patients being assessed for a suspected flare of UC or for investigation of another possible bowel condition 
(found macroscopically and microscopically normal). Inflammation of each patient was categorised as normal or inflamed based on grading of separate clinical 






Supplementary Table 2 Summary and additional information on sequencing and 
immunoprecipitation of samples analysed by RNAseq 
RNAseq was performed at the Welcome Trust Sanger Institute, Legend: WSI – whole small intestine, 
IEC – intestinal epithelial cells, LI content – large intestinal content, SPF – single pathogen free 
(conventionally raised), GF – germ free, adult – 12 weeks of age, neonate – 2 weeks of age, control – 
PBS sham gavage and/or PBS sham IP injection, + UCC2003 – oral gavage with 109 cfu B. breve 
UCC2003 on three consecutive days with tissue collection on day 4, LPS = IP injection of 1.25 mg/kg 










Supplementary Table 3 Summary and additional information on sequencing and 
immunoprecipitation of samples analysed by RNAseq 











Supplementary Figure 1 Analysis of IEC isolation purity by FACS and histology pf striped 
tissue 
A FACS of isolated IECs using PI dead/alive stain and anti-CD45 as general leucocyte marker, main 
live cell population CD-45 negative (gated left), representative sample shown B H&E stain of 
intestinal epithelium post IEC stripping using modified Weisser method, representative microscopic 








Supplementary Figure 2 Assessment of acute colonic colitis induced by DSS administration 
A total colon weight normalised to length at day 7 of DSS administration in control and treatment 
group (DSS acute) B disease activity index (DAI) at day 7 of DSS administration comparing control 
croup to treatment group, n=5, mean +/- SD, Mann-Whitney test, ** p<0.005, **** p<0.0001. 
 
 






Faeces of germ free control (A) and B. breve UCC2003 gavaged mice (B) collected at day 4, cytox 
stain labelling DNA showing no microbial presence in gnotobiotic faeces while in gavaged mice 
bacterial presence was observed, representative images shown. 
 
Supplementary Table 4 Supplementary Figure 4 Verification of germ free status of mice by 
expansion culture 
Faeces collected from germ free control mice (A) and B. breve UCC2003 (B) at indicated days were 
cultured in RCM under anaerobic conditions, - indicated no observed growth, + indicates growth after 




Supplementary Figure 4 Assessing IEC proliferation of GF and SPF animals and the effect of 
B. breve UCC2003 colonisation on both conditions 
Comparing proliferation rates between germ free (GF) and conventionally raised mince (SPF) (A) and 
assessing the effect of B. breve colonisation in SPF animals (B) and GF conditions (C), Ki67 stain of 
SI tissue, data presented as ratio of Ki67 positive intestinal epithelial cells per total number of 







Supplementary Figure 5 Rarefaction curves of 16S rRNA gene sequencing data. 











Supplementary Figure 6 Rarefaction curves of 16S rRNA gene sequencing data. 












Variation between 16S rRNA gene sequencing data of neonate microbiota samples based on abundance of species at genus level 








B. breve is localised in close contact with the small intestinal epithelium shown by staining of family specific 16s rRNA transcripts. 
Conventionally raised adult (12 weeks) mice were colonised with B. breve UCC2003 by oral gavage (109 cfu on three consecutive days, tissue collection on day 4), 
small intestinal tissue sections were processed and Bifidobacteria 16S transcripts visualised by RNAscope (brown chromogenic staining), counter stained with 






Supplementary Figure 7 DEGS induced by B. breve UCC2003 in neonate WSI. 
Overview over transcriptional changes in whole small intestine (WSI) of neonate mice colonised with 
B. breve UCC2003 relative to control (PBS gavaged) A Shrinkage estimation of dispersion, y axis 
dispersion estimate, x axis mean of normalised counts, black dots individual genes, red line maximum 
likelihood estimation (MLE) line of best fit, black dots circled in blue – potential dispersion outliers, 
blue area around red line – genes used for second dispersion estimate (not outliers), B PCA plot of 
group variability C Bland Altman (MA) plot of transcriptional modulation by presence of B. breve 
UCC2003 relative to control, y axis log2 fold change of gene expression, x axis – mean of moralised 
counts, red dots – statistical sig genes (q values 0.05) D Hierarchical clustering of samples based on 







Supplementary Figure 8 DEGS induced by B. breve UCC2003 in adult WSI. 
Overview over transcriptional changes in whole small intestine (WSI) of adult mice colonised with B. 
breve UCC2003 relative to control (PBS gavaged) A Shrinkage estimation of dispersion, y axis 
dispersion estimate, x axis mean of normalised counts, black dots individual genes, red line maximum 
likelihood estimation (MLE) line of best fit, black dots circled in blue – potential dispersion outliers, 
blue area around red line – genes used for second dispersion estimate (not outliers), B PCA plot of 
group variability C Bland Altman (MA) plot of transcriptional modulation by presence of B. breve 
UCC2003 relative to control, y axis log2 fold change of gene expression, x axis – mean of moralised 
counts, red dots – statistical sig genes (q values 0.05) D Hierarchical clustering of samples based on 







Supplementary Figure 9 DEGS induced by B. breve UCC2003 in GF IEC. 
Overview over transcriptional changes in intestinal epithelial cells (IEC) of germ free (GF), adult 
mice colonised with B. breve UCC2003 relative to control (PBS gavaged) A Shrinkage estimation of 
dispersion, y axis dispersion estimate, x axis mean of normalised counts, black dots individual genes, 
red line maximum likelihood estimation (MLE) line of best fit, black dots circled in blue – potential 
dispersion outliers, blue area around red line – genes used for second dispersion estimate (not 
outliers), B PCA plot of group variability C Bland Altman (MA) plot of transcriptional modulation by 
presence of B. breve UCC2003 relative to control, y axis log2 fold change of gene expression, x axis 
– mean of moralised counts, red dots – statistical sig genes (q values 0.05) D Hierarchical clustering 







Supplementary Figure 10 DEGS induced by B. breve UCC2003 in GF WSI. 
Overview over transcriptional changes in whole small intestine (WSI) of germ free (GF), adult mice 
colonised with B. breve UCC2003 relative to control (PBS gavaged) A Shrinkage estimation of 
dispersion, y axis dispersion estimate, x axis mean of normalised counts, black dots individual genes, 
red line maximum likelihood estimation (MLE) line of best fit, black dots circled in blue – potential 
dispersion outliers, blue area around red line – genes used for second dispersion estimate (not 
outliers), B PCA plot of group variability C Bland Altman (MA) plot of transcriptional modulation by 
presence of B. breve UCC2003 relative to control, y axis log2 fold change of gene expression, x axis 
– mean of moralised counts, red dots – statistical sig genes (q values 0.05) D Hierarchical clustering 








Supplementary Figure 11 DEGS induced by B. breve UCC2003 in adult IECs stimulated by 
systemic LPS. 
Overview over transcriptional changes in intestinal epithelial cells (IEC) of adult mice colonised with 
B. breve UCC2003 relative to control (PBS gavaged) at 90 min post 1.25 mg/kg LPS IP injection 
inducing SI apoptotic IEC shedding with B. breve colonisation conferring protection from the LPS 
effect, A Shrinkage estimation of dispersion, y axis dispersion estimate, x axis mean of normalised 
counts, black dots individual genes, red line maximum likelihood estimation (MLE) line of best fit, 
black dots circled in blue – potential dispersion outliers, blue area around red line – genes used for 
second dispersion estimate (not outliers), B PCA plot of group variability C Bland Altman (MA) plot 
of transcriptional modulation by presence of B. breve UCC2003 relative to control, y axis log2 fold 
change of gene expression, x axis – mean of moralised counts, red dots – statistical sig genes (q 







Supplementary Table 5 DEGs in neonate IECs induced by B. breve UCC2003 colonisation that 
are known targets of miR21 with their predicted regulation by miR21 and their fold change 









Supplementary Figure 12 B. breve UCC2003 colonisation decreases miR21 and its downstream 
target PDCD4 expression in the large intestine of conventionally raised adult and neonate mice 
as well as during DSS induced colitis. 
A miR21 and B PCDC4 expression in large intestine of conventionally (SPF) raised adult (12 weeks), 
neonate (2 weeks), SPF adult mice with acute colonic colitis (DSS) and GF mice with and without B. 
breve UCC2003 colonisation, mice were colonised with B. breve UCC2003 by oral gavage (109 cfu) 
on three consecutive days and tissue collected on day 4 (days 7 for DSS groups), acute colonic colitis 
was induced by administration of 1.5% DSS in drinking water until tissue collection at day 7, miR2 
and PDCD4 expression assessed by qPCR, expression normalised to housekeeper and presented as 
fold change compared to age, colonisation status and treatment matched control group (with the 
exception of DSS samples normalised to SPF adult), data shown as mean +/- SD (SPF adult n=5, SPF 








Supplementary Figure 13 Overview over metabolite concentration in large intestinal 
content of germ free mice (GF) and mice colonised by B. breve UCC2003 (Mono) 
Data presented as NMR intensity per mg intestinal content, individual values plotted (n=3 mice), 
mean and SD indicated by lines, statistical significance analysed by Two-way ANOVA with 
Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to peak location in parts per 






Supplementary Figure 14 Overview over metabolite concentration in large intestinal 
content of germ free mice (GF) and mice colonised by B. breve UCC2003 (Mono) 
Data presented as NMR intensity per mg intestinal content, individual values plotted (n=3 mice), 
mean and SD indicated by lines, statistical significance analysed by Two-way ANOVA with 
Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to peak location in parts per 






Supplementary Figure 15 Overview over metabolite concentration in large intestinal 
content of germ free mice (GF) and mice colonised by B. breve UCC2003 (Mono) 
Data presented as NMR intensity per mg intestinal content, individual values plotted (n=3 mice), 
mean and SD indicated by lines, statistical significance analysed by Two-way ANOVA with 
Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to peak location in parts per 







Supplementary Figure 16 Overview over metabolite concentration in large intestinal 
content of conventionally raised mice with (SPF+UCC) and without (SPF) B. breve UCC2003 
colonisation 
Data presented as NMR intensity per mg intestinal content, individual values plotted (n=3 mice), 
mean and SD indicated by lines, statistical significance analysed by Two-way ANOVA with 
Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to peak location in parts per 






Supplementary Figure 17 Overview over metabolite concentration in large intestinal 
content of conventionally raised mice with (SPF+UCC) and without (SPF) B. breve UCC2003 
colonisation 
Data presented as NMR intensity per mg intestinal content, individual values plotted (n=3 mice), 
mean and SD indicated by lines, statistical significance analysed by Two-way ANOVA with 
Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to peak location in parts per 











Supplementary Figure 18 Overview over metabolite concentration in large intestinal 
content of conventionally raised mice with (SPF+UCC) and without (SPF) B. breve UCC2003 
colonisation 
Data presented as NMR intensity per mg intestinal content, individual values plotted (n=3 mice), 
mean and SD indicated by lines, statistical significance analysed by Two-way ANOVA with 
Bonferroni post-test (* p-value < 0.05), values in metabolite name relate to peak location in parts per 






Supplementary Figure 19 Overview over bile acid concentrations in large intestinal 
content of germ free mice (GF) and mice colonised by B. breve UCC2003 (Mono) 
Data presented as ng of bile acid per mg intestinal content, individual values plotted (n=3 mice), mean 
and SD indicated by lines, statistical significance analysed by Two-way ANOVA with Bonferroni 







Supplementary Figure 20 Overview over bile acid concentration in large intestinal 
content of conventionally raised mice with (SPF+UCC) and without (SPF) B. breve UCC2003 
colonisation 
Data presented as ng of bile acid per mg intestinal content, individual values plotted (n=3 mice), mean 
and SD indicated by lines, statistical significance analysed by Two-way ANOVA with Bonferroni 







Supplementary Figure 21 Overview over metabolite concentration in supernatant of B. 
breve UCC2003 in vitro culture during stationary growth (UCC) compared to media control 
(control) 
Data presented as mM concentration in supernatant, single values plotted, B. breve grown in MRS and 








Supplementary Figure 22 Overview over metabolite concentration in supernatant of B. 
breve UCC2003 in vitro culture during stationary growth (UCC) compared to media control 
(control) 
Data presented as mM concentration in supernatant, single values plotted, B. breve grown in MRS and 
samples collected at 18 h, Samples generated by Jennifer Ketskemety, NMR performed by Gwenaelle 












Supplementary Table 7 Predicated top 25 miR21 binding sites in B. breve UCC2003 genome 







Supplementary Table 8 Predicated top 25 miR21 binding sites in S. Typhimurium SL1344 
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